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The present studies were performed to investigate the effects of endotoxemia on 
glucose and insulin dynamics, and to examine their relationship to laminitis in horses.  
The frequently sampled intravenous glucose tolerance test was evaluated and refined for 
use in horses.  A new FSIGTT was developed, consisting of 100 mg/kg dextrose followed 
by 20 mU/kg insulin 20 min later.  This new test was used in subsequent experiments to 
assess glucose and insulin dynamics while minimizing urine glucose spillover.  Serum C-
peptide concentrations were measured in horses to investigate pancreatic function and 
this work revealed a decrease in C-peptide-to-insulin ratio after dextrose challenge, 
suggesting reduced hepatic insulin extraction.  Administration of endotoxin both as an 
intravenous bolus and 8-hour continuous rate infusion significantly lowered insulin 
sensitivity and increased the acute insulin response to glucose.  The effects of resting 
insulin sensitivity on the magnitude of insulin resistance induced by endotoxin 
administration were subsequently investigated.  Resting insulin sensitivity was 
successfully reduced by oral administration of 20 mg dexamethasone, but levothyroxine 
sodium failed to improve insulin sensitivity.  However, endotoxemia-induced insulin 
resistance was ameliorated by pretreatment with levothyroxine sodium.  Administration 
of endotoxin alone, oligofructose alone, or endotoxin followed by oligofructose resulted 
in the development of Obel grade ≥ 2 laminitis in 0/8, 1/8 and 5/8 horses, respectively, 
indicating a significant association between endotoxemia and laminitis.  In summary, 
results show that endotoxemia exerts an adverse effect on glucose and insulin dynamics 
and plays an important role in the development of laminitis in horses.  Pretreatment with 
levothyroxine sodium prevented insulin resistance associated with endotoxemia, so this 
treatment warrants further investigation. 
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CHAPTER 1  
Literature review 
 
1.1 Carbohydrate metabolism – the role of insulin 
 
1.1.1 Carbohydrate digestion: 
 
Carbohydrate (CHO) provides the majority of dietary energy for horses, with 
cereal grains, grain by products, and forage being the primary sources (Geor 2006).  
Generally, the carbohydrate content of the feed is divided into nonstructural 
carbohydrates (NSC) and neutral detergent fiber (NDF; Hoffman et al. 2001).  The NSC 
content can be calculated using the following equation: 
NSC = 100 - (water + ash + fat + crude protein + NDF) 
Alternatively, NSC content can be divided into ethanol- and water-soluble CHOs, with 
the former containing mono- and di-saccharides and some low molecular weight 
oligosaccharides, and the latter comprising mostly fructans and some high molecular 
weight oligosaccharides (Virgona and Barlow 1991).  Nevertheless, these groups relate 
better to ruminant than equine digestive physiology.  Based on the primary site of 
digestion in the equine gastrointestinal tract Hoffman et al. (2001) divided the dietary 
CHO content into three groups: hydrolysable, rapidly fermented, and slowly fermented 
CHOs.  Hydrolysable CHOs, including hexoses, disaccharides, oligosaccharides, and 
non-resistant starches are digested in the small intestine yielding glucose.  If hydrolysable 
CHOs are delivered to the hindgut, they undergo rapid fermentation.  Digestion of slowly 
and rapidly fermented CHOs occurs in the equine hind gut by enzymes secreted by 
resident microbes.  Rapidly fermented CHOs, comprising resistant starches of galacto- 
and fructo-oligosaccharides, are readily fermented in the large intestine.  Hemicellulose, 
cellulose and ligno-cellulose form the fraction of slowly fermented CHOs which 
primarily produce the volatile fatty acid acetate when fermented in the large intestine 
(Geor 2006; Hoffman et al. 2001). 
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Digestion of the hydrolysable CHO content of the feed is catalyzed by enzymes 
either acting within the lumen of the gastrointestinal tract or on the surface of mucosal 
epithelial cells (Herdt 2002).  During the luminal phase of digestion, polysaccharides 
leaving the stomach are further metabolized by pancreatic α-amylase in the duodenum 
and proximal jejunum.  Intraluminal digestion of carbohydrates yields polysaccharides of 
intermediate chain length, known as dextrines, which are then further broken down into 
maltose and maltotriose.  Intraluminal digestion of amylopectin yields α-limit-dextrines 
containing α[1-6] linkages that are not hydrolyzed by α-amylase (Herdt 2002).  During 
the membraneous phase of digestion, substrate-specific enzymes bound to the brush 
border of the enterocytes hydrolyze di- and tri-saccharides into monosaccharides 
(glucose, galactose, and fructose).  Enteral absorption of monosaccharides occurs in two 
steps via secondary active transport.  The first step involves the sodium-glucose 
transporter (SGLT) 1, which facilitates glucose uptake on the luminal side of the 
enterocyte (Bell et al. 1993).  The second step occurs at the basolateral membrane where 
glucose exits the enterocyte through glucose transporter (GLUT) 2 proteins (Gould and 
Bell 1990).  The abundance of SGLT1 in the equine small intestine is highest in the 
duodenum and then decreases towards the ileum, indicating that the majority of glucose 
absorption occurs in the proximal to mid small intestine (Shirazi-Beechey 2008).  Horses 
on a concentrate diet have a 2 – 5 fold increase in SGLT1 protein expression in the mid 
and distal small intestine, compared to horses kept on pasture, which enhances their 
ability to absorb monosaccharides (Shirazi-Beechey 2008). 
Fructans are a group of fructose oligosaccharides which are produced as storage 
CHO in plants (Bailey et al. 2007).  Their general structure consists of a glucose 
molecule linked to varying numbers of fructose molecules (van Eps and Pollitt 2006).  
Degradation of fructans entering the equine gastrointestinal tract starts with microbial 
fermentation and acid hydrolysis within the stomach and small intestine, however, it is 
likely that the bulk of fructans reach the hindgut where they undergo microbial 
fermentation (Coenen et al. 2006; Longland and Byrd 2006).  Absorption of fructose in 
the small intestine occurs via facilitated diffusion primarily through GLUT5 molecules 
expressed on the brush border membrane of the villus enterocytes (Merediz et al. 2004).  
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Transport of fructose out of the enterocytes across the basolateral membrane occurs via 
the facilitative transporter GLUT2 (Drozdowski et al. 2004).  Absorbed monosaccharides 
then enter the portal system and are transported to the liver (Fonyo 2003). 
Degradation of dietary pectin, cellulose, and hemicellulose is mediated by 
anaerobic bacteria, protozoa, and fungi present in the equine hindgut (Shirazi-Beechey 
2008).  Anaerobic metabolism of these fermented CHOs through the Embden-Meyerhoff 
pathway leads to the formation of pyruvate and subsequently the volatile fatty acids, 
acetate, propionate, and butyrate, as well as the gases carbon dioxide (CO2), methane 
(CH4), and hydrogen (Shirazi-Beechey 2008).  Under normal circumstances only a small 
amount of lactate is formed.  Volatile fatty acids are absorbed from the large intestine 
through a monocarboxylate/H+ symporter, and supply 45 to 82 % of the absorbed energy 
depending on the composition of the diet (Shirazi-Beechey 2008; Vermorel et al. 1997). 
Excessive intake of hydrolysable and/or rapidly fermentable CHO may result in 
their delivery to the hindgut where they undergo rapid bacterial fermentation (Longland 
and Byrd 2006).  The presence of large amounts of starch and fructan in the hindgut 
facilitates the proliferation of streptococci and lactic acid-producing bacteria (Elliott and 
Bailey 2006; Milinovich et al. 2007).  Decreased intraluminal pH, associated with 
increased lactic acid production, not only triggers the death of resident Gram-negative 
bacteria but also increases the permeability of the wall of the large intestine (Garner et al. 
1978; Weiss et al. 2000).  Due to this altered permeability of the large intestine, 
endotoxins released upon the death of Gram-negative bacteria, as well as biologically 
active amines present in the intestinal lumen, enter the systemic circulation and may 
contribute to the development of laminitis (Elliott and Bailey 2006). 
 
1.1.2 Insulin and insulin secretion: 
 
The role of the pancreas in the development of diabetes was first demonstrated by 
German scientists Minkowski and Von Mering in 1889 (Wilcox 2005).  Three decades 
later in 1921, insulin was isolated and experiments were begun in dogs (Wilcox 2005).  
In their studies, Banting, Best, and McLeod successfully lowered blood glucose 
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concentrations in dogs that had been rendered diabetic by pancreatectomy by 
administering them chilled saline extracts of pancreas.  Successful human experiments 
were completed in 1922, earning Banting and McLeod the Nobel Prize in 1923 (Wilcox 
2005). 
Insulin is a protein hormone coded on the short arm of chromosome 11 in 
humans, and is produced by the β-cells of the islets of Langerhans within the pancreas 
(Wilcox 2005).  Insulin is produced as preproinsulin in the ribosomes of the rough 
endoplasmic reticulum.  Proinsulin is formed following the cleavage of a signal sequence 
responsible for the intracellular transport of the molecule.  Secretory vesicles transfer 
proinsulin into the Golgi apparatus.  As immature vesicles form within the Golgi, a 
peptide chain referred to as connecting-peptide (C-peptide) is removed from the 
proinsulin molecule, transforming it into insulin.  Thus, serum C-peptide concentrations 
reflect insulin secretion, and unlike insulin, C-peptide undergoes very little first-pass 
clearance by the liver after secretion from the pancreas (Johnson et al. 2005).  The 
structure of insulin consists of two peptide chains connected by disulfide bonds.  Six of 
these insulin molecules complex with zinc to form insoluble hexamers within mature 
granules (Wilcox 2005). 
Insulin secretion is modulated by blood concentration of various nutrients, most 
importantly glucose (Wilcox 2005).  Glucose enters the β-cells via GLUT2 proteins, 
which have a low glucose affinity at physiological blood glucose levels (Gould and Bell 
1990).  Once inside the cell, glucose is phosphorylated by the enzyme glucokinase to 
glucose-6-phosphate, which is subsequently oxidized to generate ATP.  An increased 
intracellular ATP/ADP ratio then results in the closure of ATP-sensitive potassium 
channels, causing membrane depolarization, which in turn opens voltage-dependent 
calcium channels.  Insulin release is stimulated by this increase in intracellular Ca2+ 
concentration (Bratanova-Tochkova et al. 2002; Wilcox 2005). 
Glucose-mediated insulin secretion is augmented by both ATP-sensitive 
potassium channel-independent calcium-dependent and ATP-sensitive potassium 
channel-independent calcium-independent pathways.  Enhanced insulin secretion also 
occurs in response to activation of phospholipases and protein kinase C (PKC), triggered 
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by acetylcholine.  Other mediators that facilitate insulin release include vasoactive 
intestinal peptide and glucose-dependent insulinotropic polypeptide.  These hormones act 
through the G-protein coupled mechanisms to activate adenyl cyclase and protein kinase 
A (PKA), and thereby potentiate insulin secretion (Bratanova-Tochkova et al. 2002).  
Glucagon-like peptide 1 exerts its effect on insulin secretion by inhibiting ATP-sensitive 
potassium channels and enhancing currents through voltage-dependent calcium channels 
via cAMP/PKA dependent pathways, as well as by inhibiting currents through voltage 
dependent K+ channels (MacDonald et al. 2002).  Arginine, a positively charged amino 
acid that enters the β-cells via cationic amino acid transporters, triggers depolarization of 
cell membrane and gating of voltage-dependent calcium channels, causing insulin 
excretion (Bratanova-Tochkova et al. 2002; Soria et al. 2004).  In contrast, somatostatin 
produced by the δ-cells of the islets of Langerhans and catecholamines acting through α2-
adrenoreceptors inhibit insulin release (Wilcox 2005). 
 In humans, basal insulin secretion accounts for 50% of total daily insulin 
secretion, and 60% of insulin secreted into the portal vein is subsequently removed by the 
liver (Wilcox 2005).  In the basal state, insulin secretion into the portal vein is 
characteristically pulsatile due to coordinated secretory bursts from islet cells (Porksen et 
al. 2002).  In cases of type 2 diabetes mellitus (type 2 DM), pulsatile insulin secretion 
may be impaired (Porksen et al. 2002).  Restoration of oscillatory insulin secretion in 
type 2 DM improves insulin action in liver, muscle, and adipose tissues (Porksen et al. 
2002).  Insulin secretion from the β-cells in response to sustained glucose stimulation is 
characteristically biphasic, with the first phase occurring promptly after exposure to 
glucose, followed by a decrease to a nadir, and then a prolonged second phase 
(Bratanova-Tochkova et al. 2002; Wilcox 2005).  The first rapid phase of insulin release 
is attributed to the secretion of readily releasable pool of secretory granules (Bratanova-
Tochkova et al. 2002; Soria et al. 2004).  The second phase requires the amplifying 
action of glucose, increasing the efficacy of Ca2+ on exocytosis of insulin granules 
(Henquin et al. 2002), and is preceded by the mobilization of granules from a reserve 
pool to the readily releasable pool (Bratanova-Tochkova et al. 2002). 
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1.1.3 Insulin signal transduction: 
 
Effects of insulin are mediated by membrane bound insulin receptors.  The insulin 
receptor is a heterotetrameric membrane glycoprotein containing 2 α and 2 β subunits 
linked together by disulfide bonds (Kido et al. 2001).  Insulin binding to the extracellular 
α subunits results in a conformational change that enables ATP binding to the 
intracellular domain of the β subunits, resulting in autophosphorylation, which in turn 
triggers its tyrosine kinase activity.  In addition to binding insulin, the insulin receptor 
also binds insulin-like growth factor (IGF; Kido et al. 2001). 
Signal transduction through the insulin receptor can be divided into 
phosphatidylinositol 3 (PI3)-kinase dependent and independent pathways (Chang et al. 
2004; Kido et al. 2001; Watson and Pessin 2001).  In the PI3-kinase dependent pathway, 
the autophosphorylated insulin receptor phosphorylates intracellular substrate proteins 
known as insulin receptor substrates (IRS).  There are four closely related members of 
the IRS family and a more distantly related homolog, Gab-1 (Kido et al. 2001).  Tyrosine 
phosphorylation of IRS-1 can be mediated by the receptors of insulin and IGF-1 (Withers 
and White 2000).  Insulin receptor substrate-1 is most abundantly expressed in skeletal 
muscle and primarily mediates mitogenic effects and insulin-stimulated peripheral 
glucose uptake (Kido et al. 2001; Withers and White 2000).  Deletion of IRS-1 in mice 
leads to significant growth retardation, a twofold increase in β-cell mass, and an 80 
percent decrease in the response to insulin in muscle (Burks and White 2001).  However, 
only mild insulin resistance is detected and insulin signaling within the liver remains 
close to normal (Burks and White 2001).  The relatively normal glucose homeostasis 
exhibited by IRS-1 knockout mice may be due to compensatory hyperinsulinemia and to 
the near normal response to insulin in the liver, primarily mediated by IRS-2 (Burks and 
White 2001). 
In addition to its important role in the liver, IRS-2 is also important for the normal 
growth of pancreatic β-cells (Kido et al. 2001).  Insulin receptor substrate-2 knockout 
mice show profound insulin resistance primarily affecting the liver, and their β-cell mass 
is approximately 50% lower compared to healthy controls (Burks and White 2001).  
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Carbohydrate metabolism is significantly altered in these animals.  In IRS-2 knockout 
mice, the inhibitory effect of insulin on hepatic gluconeogenesis is weak and the 
glycogen content of the liver is low, but insulin action in skeletal muscle and adipose 
tissue remains close to normal (Burks and White 2001).  Mice deficient in IRS-2 become 
overtly diabetic by 12 weeks of age, and if untreated, die from dehydration and 
hyperosmolar coma (Burks and White 2001). 
Insulin receptor substrate-3 is located within adipose tissue, β-cells, and the brain, 
whereas IRS-4 is found in thymus, brain, and kidney (Withers and White 2000).  Insulin 
receptor substrates 3 and 4 appear to play redundant roles in the IRS signaling system 
(Sesti et al. 2001).  In adipocytes obtained from IRS-1 knockout mice, approximately 
50% of GLUT4 translocation was preserved by a signaling pathway involving IRS-3 
(Sesti et al. 2001).  In vivo studies found no major physiologic role of IRS-4 in 
controlling growth or metabolism in mice (Sesti et al. 2001). 
The carboxy (COOH) terminus of each IRS protein contains a set of tyrosine 
phosphorylation sites that regulate different downstream signaling proteins.  Each site 
binds and activates specific effector proteins including adapter proteins and enzymes, 
such as PI3-kinase (Withers and White 2000).  The p85 regulatory subunit of PI3-kinase 
recognizes the phosphorylated insulin receptor substrate molecules and brings the p110 
catalytic subunit of the heterodimer enzyme to the vicinity of its physiological substrate, 
phosphatidylinositol (4,5) bisphosphate (Lizcano and Alessi 2002; Shepherd and Kahn 
1999).  Phosphatidylinositol (4,5) bisphosphate is subsequently phosphorylated in the D3 
position generating phosphatidylinositol (3,4,5) trisphosphate (PIP3; Lizcano and Alessi 
2002).  A key effector of PIP3 is protein kinase B (PKB), which is also known as Akt 
(Lizcano and Alessi 2002).  PIP3 mediated recruitment of PKB from the cytosol brings it 
closer to another protein kinase termed phosphoinositide-dependent protein kinase-1 
which contributes to the activation of PKB (Lizcano and Alessi 2002; Watson and Pessin 
2001).  Protein kinase B phosphorylates and thereby inactivates glycogen synthase 
kinase-3 (GSK3; Lizcano and Alessi 2002).  Inactivation of GSK3 leads to disinhibition 
of glycogen synthase.  Insulin-mediated glycogen synthesis is therefore facilitated by the 
activation of PKB.  Protein kinase B also phosphorylates cyclic AMP phosphodiesterase-
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3-B (PDE3B) and the increased activity of this enzyme lowers intracellular cAMP 
concentrations within adipocytes, which prevents the activation of PKA.  In the absence 
of active PKA, hormone sensitive lipase remains inactive, which therefore explains the 
inhibitory effect of insulin on lipolysis (Salway 2004).  Atypical protein kinase C 
(PKCζ/λ) is also activated by phosphoinositide-dependent protein kinase-1, downstream 
of PI 3-kinase (Chang et al. 2004). 
A PI3-kinase independent insulin signaling pathway also exists within cells.  This 
pathway is localized in lipid raft microdomains, which are specialized regions of the 
plasma membrane (Chang et al. 2004).  Activation of the insulin receptor in these plasma 
membrane subdomains leads to the recruitment and phosphorylation of the adaptor 
protein called associated protein substrate (APS), which in turn facilitates the 
phosphorylation of the proto-oncogene Cbl (Chang et al. 2004).  Next, the Cbl associated 
protein (CAP) is recruited with Cbl to the insulin receptor:APS complex (Chang et al. 
2004).  At this point, the CAP-Cbl complex dissociates from the insulin receptor:APS 
complex and interacts with the lipid raft domain protein, flotillin (Chang et al. 2004).  
Tyrosine-phosphorylated Cbl then interacts with CrkII, a protein constitutively associated 
with C3G, resulting in their translocation to the lipid raft (Chang et al. 2004).  Upon its 
translocation to lipid raft, C3G can catalyze the activation of the small G-proteins TC10α 
and TC10β, which triggers GLUT4 translocation through interaction with a number of 
potential effector molecules (Chang et al. 2004). 
Recruitment of PKCζ/λ, an enzyme downstream of PI3-kinase, to lipid rafts in a 
TC10-dependent manner, represents a point of convergence for the PI3-kinase dependent 
and PI3-kinase independent pathways (Chang et al. 2004). 
The mitogen activated protein kinase (MAPK; also known as extracellular signal-
regulated kinase) cascade is also involved in the insulin signal transduction (Saltiel and 
Kahn 2001).  This pathway involves the tyrosine phosphorylation of IRS proteins which 
subsequently interact with the adapter protein Grb2, recruiting the Son-of-sevenless  
exchange protein to the plasma membrane for activation of Ras.  After its Son-of-
sevenless-mediated activation, Ras operates as a molecular switch stimulating stepwise 
activation of Raf, mitogen activated protein kinase kinase, and MAPK.  Activated MAPK 
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translocates to the nucleus, where it catalyses the phosphorylation of transcription factors 
initiating cellular differentiation or proliferation (Saltiel and Kahn 2001).  A src-
homology-2 domain containing protein called SHC, which is another substrate of the 
insulin receptor, is also capable of activating the Ras/MAPK pathway through the adapter 
protein Grb2, independent of IRS-1 (Figure 1.1; Bevan 2001).  
Shortly after insulin binding, the insulin receptor-insulin complex is internalized 
into endosomes (Bertacca et al. 2007; Bevan 2001).  The endocytosis of the activated 
receptor-insulin complex enables phosphorylation of substrate molecules that are 
spatially distinct from those accessible at the plasma membrane (Bevan 2001).  
Acidification of the endosomal lumen results in the dissociation and degradation of 
insulin from the insulin receptor (Bevan 2001).  This loss of the ligand receptor complex 
attenuates any further insulin receptor rephosphorylation (Bevan 2001).  The receptor is 
recycled back to the plasma membrane (Bertacca et al. 2007), while the insulin is 
degraded by the endosomal acidic insulinase (Bevan 2001).  Tyrosine phosphatases also 
play an important role in termination of the signal generated by insulin by 
dephosphorylating the insulin receptor and its targets (Kido et al. 2001).  Mice lacking 
protein tyrosine phosphatase 1b have significantly enhanced insulin-stimulated whole 
body glucose disposal.  Interestingly, increased insulin sensitivity in these mice was 
found to be tissue specific, occurring mainly in skeletal muscle (Klaman et al. 2000). 
The insulin signaling pathway has a negative feed-back loop, which is activated 
by insulin and involved in the inhibition or termination of the metabolic branch of the 
insulin receptor pathway (Ye 2007).  Inducible Ser/Thr phosphorylation of IRS-1 leads to 
the inhibition of IRS-1 function and also contributes to the development of insulin 
resistance (Ye 2007).  Several of the serine kinases capable of inhibiting IRS-1 are 
activated by insulin, including PI3-kinase,  MAPK, PKB, and PKC, forming the negative 
feedback loop in the insulin receptor signaling pathway (Ye 2007). 
Insulin-stimulated glucose uptake is mediated by translocation of GLUT4 from 
the intracellular pool to the plasma membrane (Kido et al. 2001).  A synaptic vesicle 
model has been proposed to explain how GLUT4 molecules dock and fuse with the 




Figure 1.1 – Signal transduction in insulin action.  The insulin receptor is a tyrosine 
kinase which undergoes autophosphorylation after ligand binding and catalyzes 
phosphorylation of cellular proteins eventually resulting in alterations in glucose 
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1.1.4 Glucose transporters: 
 
Since glucose does not diffuse readily through plasma membrane, its entry into 
cells is carried out by proteins belonging to two distinct molecular families (Shepherd 
and Kahn 1999).  Energy independent transport of glucose is mediated by members of 
facilitative glucose transporter family of glucose carriers (Gould and Holman 1993).  
This type of glucose transport is saturable, bidirectional, and stereoselective (Bell et al. 
1993).  The second family is represented by the sodium-linked glucose transporters, 
which are largely restricted to the kidneys and intestines (Shepherd and Kahn 1999).  
They utilize the electromechanical Na2+ gradient to actively transport glucose and 
galactose against their concentration gradient (Bell et al. 1993). 
The current model of GLUT proteins includes 12 membrane-spanning α-helical 
segments, connected by short, hydrophilic chains of 7 to 14 amino acids, with a large 
intracellular loop connecting transmembrane segments 6 and 7 (Bell et al. 1993).  The 12 
α-helices are combined to form a central aqueous pore, with up to 8 of the 12 helices 
contributing to parts of the surface lining of the pore (Manolescu et al. 2007).  Both the 
COOH and amino (NH2) terminals of the molecule are located on the intracellular side of 
the plasma membrane.  The NH2 half of the protein appears to have a role in correctly 
inserting the molecule into the plasma membrane, while the COOH terminus is involved 
in sugar transport itself (Bell et al. 1993).  It is currently thought that glucose transport 
occurs by a mechanism in which the transporter alternates between two conformational 
states, with the substrate-binding site facing in either an extracellular or intracellular 
direction (Bell et al. 1993).  It is believed that GLUT1 exists in tetramers increasing its 
catalytic activity 2-8 fold (Bell et al. 1993).  Recent sequencing of the human genome 
identified 14 members of the solute carrier family 2 (SLC2) genes, which are known to 
encode GLUT proteins (Manolescu et al. 2007).  Sequence alignments indicate that the 
14 GLUT proteins encoded by these genes can be clustered into three families or 
subclasses I, II, and III (Manolescu et al. 2007). 
Glucose transporter 1 is the erythrocyte type glucose transporter.  It is an integral 
membrane protein that can be found in erythrocytes, fetal tissues, kidney, liver, colon, 
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and brain (Fonyo 2003).  This transporter is also expressed in most cultured cells (Gould 
and Bell 1990; Gould and Holman 1993). 
Glucose transporter 2 is preferentially expressed in the liver, on the basolateral 
membrane surface of kidneys and small intestinal epithelia, and in the insulin-producing 
β-cells of the pancreas (Bell et al. 1993; Gould and Bell 1990).  This glucose transporter 
has a high Kmax value of 42 mmol/L for glucose (Shepherd and Kahn 1999), providing a 
rationale for its localization to those tissues that are involved in the net release of glucose 
during fasting (liver), glucose sensing (β-cells of the pancreas), and transepithelial 
transport of glucose (kidney and small intestine; Gould and Holman 1993).  The high 
Kmax of GLUT2 prevents its saturation at physiological glucose concentrations, therefore 
glucose flux through GLUT2 changes in an almost linear fashion with 
intracellular/extracellular glucose concentrations (Gould and Holman 1993). 
Messenger RNA coding the glucose transporter 3 has been found in most tissues, 
but is most abundant in kidney, brain, placenta, and platelets (Gould and Bell 1990; 
Heijnen et al. 1997).  Using immunocytochemical methods, GLUT3 has been localized to 
the α-granule membrane in resting platelets, and it is from this location that it moves to 
the cell surface following thrombin stimulation (Heijnen et al. 1997).  Elevated GLUT3 
mRNA levels have also been detected in the hippocampus of diabetic rats, likely 
representing a compensatory mechanism to increase glucose utilization during diabetes 
(Reagan et al. 1999). 
Adipose tissue and muscle possess a unique, insulin-sensitive glucose transporter 
designated as GLUT4 (Gould and Holman 1993).  Immunoblot analysis has been used to 
characterize GLUT4 protein in equine skeletal and cardiac muscle suggesting a mean 
theoretical value of 53.3 ± 0.5 kDa for equine GLUT4 (Lacombe et al. 2003).  Further 
investigation revealed that the molecule contains 509 amino acids, which are coded by a 
DNA segment measuring 1,623 base pairs in length, including 1530 base pairs of open 
reading frame (Jose-Cunilleras et al. 2005).  Glucose transporter 4 protein expression was 
demonstrated to be higher in equine skeletal muscle fiber type 2B than in types 1 or 2A 
using indirect immunofluorescence assays (van Dam et al. 2004).  Insulin facilitates 
translocation of GLUT4 from the intracellular pools to the cell membrane in adipose and 
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muscle tissue, thereby increasing glucose uptake across the plasma membrane within 
minutes (Gould and Bell 1990).  Interestingly, insulin also causes a 3-fold increase in the 
number of GLUT1 molecules on the surface of adipocytes (Gould and Bell 1990).  
Studies examining rats made diabetic by streptozocin treatment have shown significant 
reduction in GLUT4 mRNA within muscle tissue and adipocytes, suggesting that insulin 
not only plays a role in the translocation of GLUT4 from the intracellular pools to the cell 
membrane, but also influences GLUT4 synthesis (Garvey et al. 1989). 
In skeletal muscle, both insulin stimulation and increased muscle activity cause 
translocation of GLUT4 from the intracellular pool to the cell surface, with the exercise- 
sensitive pool associated with an endosomal transferrin receptor (van Dam et al. 2004).  
Indeed, two distinct pools of GLUT4 molecules have been identified in rat skeletal 
muscle (Aledo et al. 1997).  One fraction is highly enriched with transferrin receptor and 
annexin II, characteristic for the early endosome compartment, whereas the other fraction 
is proven to be insulin sensitive (Aledo et al. 1997).  In rats, exercise not only enhances 
GLUT4 translocation but also influences GLUT4 expression at both the transcriptional 
and translational level (Dohm 2002).  Skeletal muscle GLUT4 gene expression was also 
found to be increased in horses following exercise (Jose-Cunilleras et al. 2005; Lacombe 
et al. 2003).  Conversely, McCutcheon et al. (2002) demonstrated no significant change 
in equine skeletal muscle GLUT4 content in samples collected from horses within 2 
minutes after cessation of exercise.  Ingestion of starch-rich meals did not influence 
GLUT4 gene expression in horses compared with the consumption of isocaloric fiber-
rich meals or feed withdrawal following exercise (Jose-Cunilleras et al. 2005).  
Administration of dexamethasone also failed to induce a significant change in equine 
skeletal muscle GLUT4 protein content (Tiley et al. 2008). 
Glucose transporter 5 is expressed at high levels in human small intestine(Gould 
and Bell 1990), and plays an important role in fructose transport (Manolescu et al. 2007; 
Merediz et al. 2004).  This protein has a 42%, 40%, 39% and 42% homology with 
glucose transporters 1, 2, 3, and 4, respectively (Gould and Bell 1990).  In the equine 
small intestine, GLUT5 is expressed on the brush-border membrane of the villous 
enterocytes with its levels decreasing from the duodenum towards the ileum (Merediz et 
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al. 2004).  The presence of GLUT5 in the equine small intestine suggests the capacity of 
equine small intestine to absorb fructose.  Kinetic studies suggest that the GLUT5 
molecules are low affinity and high capacity transporters (Merediz et al. 2004). 
Glucose transporter 6 mRNA is principally expressed in the spleen, brain, and 
peripheral leukocytes and appears to be a low affinity facilitator (Joost and Thorens 
2001).  Both glucose and fructose are proposed substrates for glucose transporter 7, 
which is primarily expressed in the apical membrane of the enterocytes of the small 
intestine and colon, although its mRNA has been detected in the testes and prostate as 
well (Cheeseman 2008). 
Glucose transporter 8 (formerly designated as GLUTX1), like GLUT6, belongs to 
the class III sugar transport facilitators because it contains the characteristic glycosylation 
motif in loop 9 (Joost and Thorens 2001).  It is expressed in the heart, skeletal muscle, 
brain, spleen, prostate and intestine, with the highest level of expression in the testis (Kim 
and Moley 2007).  Expression of GLUT8 has also been demonstrated to play an 
important role in blastocyst survival (Kim and Moley 2007). 
Glucose transporter 9 is a high affinity glucose transporter which also transports 
fructose (Kim and Moley 2007).  Human GLUT9 is expressed in the kidney, liver, heart 
and adrenal gland.  In mice, GLUT9 has two splice variants: GLUT9a, which is a long 
form that has 12 transmembrane segments, and GLUT9b that has a deletion resulting in 
the loss of 2 transmembrane spanning domains (Kim and Moley 2007). 
Both GLUT10 and GLUT11 were identified using homology-based searches of 
expressed sequence tag databases (Doege et al. 2001; McVie-Wylie et al. 2001).  
Northern blot analysis revealed that GLUT10 is expressed at the highest levels in the 
liver and pancreas, and a lower level of expression was detected in heart, brain, placenta, 
lung, skeletal muscle and kidneys (McVie-Wylie et al. 2001).  Glucose transporter 11 has 
also been detected exclusively within heart and skeletal muscle in humans.  It appears to 
transfer fructose with comparable affinity for glucose, which is consistent with its 
sequence similarity to GLUT5 (Doege et al. 2001). 
A novel glucose transporter-like protein, GLUT12, was found in MCF-7 breast 
cancer cells (Rogers et al. 2002).  Immunoblotting also demonstrated its presence in 
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adipose tissue, skeletal muscle, and small intestine (Rogers et al. 2002).  It was located 
inside the cell in the perinuclear region in the absence of insulin, suggesting that it may 
play a role in insulin-mediated glucose uptake (Rogers et al. 2002). 
The only glucose transporter demonstrated to use a proton gradient to energize the 
movement of substrate is the GLUT13 (H+/myoinositol transporter), which is a proton 
coupled myo-inositol transporter (Manolescu et al. 2007).  Glucose transporter 14 
appears to have resulted from a gene duplication of GLUT3 (Manolescu et al. 2007; Wu 
and Freeze 2002).  It has two alternatively spliced forms, which are both specifically 
expressed in the testes.  The mRNA level of GLUT14 in testicular tissue is approximately 
four times higher than that of GLUT3 (Wu and Freeze 2002). 
 
1.1.5 Physiologic role of insulin: 
 
Insulin is of paramount importance in controlling metabolism by regulating 
cellular energy supply, macronutrient homeostasis, and anabolic processes (Wilcox 
2005).  At the cellular level, insulin influences carbohydrate, lipid, and amino acid 
metabolism as well as mRNA transcription and translation.  Insulin exerts its action in 
concert with other counter regulatory hormones that influence metabolism, including 
glucagon, glucocorticoids, and catecholamines.  Insulin-mediated growth hormone 
secretion also helps to prevent insulin-induced hypoglycemia (Wilcox 2005). 
Insulin profoundly influences glucose uptake into skeletal muscle by facilitating 
GLUT4 translocation to the sarcolemma from intracellular pools (Shepherd and Kahn 
1999).  Muscle tissue accounts for 60 to 70 % of insulin-mediated whole body glucose 
disposal (Fonyo 2003).  In the fed state, insulin activates glycogen synthase and promotes 
glycogen synthesis, while also suppressing catabolic processes and maintaining muscle 
mass (Fonyo 2003; Wilcox 2005).  In skeletal muscle, GLUT4 translocation into the 
plasmalemma is also facilitated by exercise (van Dam et al. 2004). 
Basal glucose uptake of adipose tissue is mediated via GLUT1, whereas insulin-
mediated glucose transport occurs via both GLUT1 and GLUT4 molecules (Tafuri 1996).  
In rat adipose tissue, insulin produces an approximately 20- to 30-fold increase in glucose 
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uptake, whereas in human adipocytes only a 2- to 4-fold increase is demonstrated (Gould 
and Holman 1993).  It has been estimated that adipose tissue accounts for 10 % of 
insulin-stimulated whole body glucose disposal (Wilcox 2005).  Insulin also increases fat 
stores by promoting lipid synthesis and inhibiting lipolysis (Saltiel and Kahn 2001).  
Insulin-mediated glucose uptake and the presence of free fatty acids (FFA) are both 
necessary for triglyceride (TG) synthesis in adipose tissue.  The most available source of 
FFAs is triglyceride carried within lipoproteins that is metabolized by lipoprotein lipase 
(LPL) bound to the endothelial surface of capillaries (Adam 2004).  Insulin stimulates 
gene transcription and synthesis of LPL in adipocytes (Salway 2004).  Insulin also 
enhances the activity of enzymes involved in lipogenesis within adipose tissues, 
including pyruvate dehydrogenase, fatty acid synthase, and acetyl-CoA-carboxylase 
(Saltiel and Kahn 2001).  Protein kinase A-mediated activation of hormone sensitive 
lipase, and therefore lipolysis, is inhibited by insulin (Fonyo 2003; Saltiel and Kahn 
2001; Wilcox 2005).  This occurs through insulin-mediated activation of PDE3B and 
lowers intracellular cAMP levels, which prevents the activation of PKA (Salway 2004). 
One of the most important effects of insulin is to control glucose homeostasis by 
regulating metabolic processes in the liver (Guyton and Hall 2006).  Although 
hepatocellular glucose transport occurs via insulin-independent GLUT2 molecules 
(Wilcox 2005) insulin still increases hepatic glucose uptake by facilitating intracellular 
glucose trapping through glucokinase-mediated phosphorylation (Guyton and Hall 2006).  
Insulin inhibits the production and release of glucose by blocking gluconeogenesis and 
glycogenolysis within the liver (Saltiel and Kahn 2001).  Transcription of gluconeogenic 
genes encoding phosphoenolpyruvate-carboxykinase, fructose 1,6-bisphosphatase, and 
glucose 6-phosphatase are reduced under the influence of insulin (Salway 2004).  Insulin 
also inhibits glycogenolysis by interfering with the PKA-mediated activation of glycogen 
phosphorylase (Salway 2004).  Insulin generated signals are also important in the 
activation of the enzyme protein phosphatase-1G, which is capable of dephosphorylating, 
and thereby activating, the enzyme glycogen synthase.  This facilitates glycogen 
synthesis (Salway 2004). 
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Insulin administration has also been shown to stimulate glycolysis by increasing 
the rate of pyruvate kinase synthesis in the liver (Miyanaga et al. 1982).  The ketone 
bodies β-hydroxy-butyrate and acetic acid are synthesized from FFAs in the liver.  Insulin 
prevents ketogenesis by lowering the amount of available FFAs (Fonyo 2003).  
Mitogenic effects of insulin and growth hormone are mediated by hepatic production of 
IGFs (Wilcox 2005). 
Insulin deficiency is permissive of protein catabolism, releasing amino acids 
which are subsequently utilized for gluconeogenesis (Wilcox 2005).  Insulin is anabolic 
in conjunction with IGF-1 in the presence of amino acids by modulating the 
phosphorylation status of intermediates in the protein synthetic pathway (Wilcox 2005). 
In addition to its essential metabolic actions, insulin has important vascular 
actions as well.  It stimulates the production of nitric oxide (NO) via the PI3-kinase-
dependent pathway in endothelial cells leading to vasodilatation and increased blood flow 
(Kim et al. 2006).  Insulin also facilitates the secretion of the vasoconstrictor endothelin-
1 (ET-1) from endothelia (Kim et al. 2006).  Effects of insulin on the vascular system are 
discussed in greater detail below. 
Although neuronal glucose uptake is not dependent upon insulin, the hormone 
acts as a neuropeptide, and insulin is involved in satiety and the regulation of appetite 
(Wilcox 2005).  In the anterior pituitary gland, insulin stimulates growth hormone 
secretion, which in turn promotes IGF-1 production by the liver (Wilcox 2005). 
 
1.1.6 Insulin resistance: 
 
Insulin resistance (IR) is defined as a state in which normal concentrations of 
insulin fail to elicit the expected physiological response (Hoffman et al. 2003; Kahn 
1978).  Insulin sensitivity is influenced by certain physiological and pathological factors 
such as diet.  Consumption of a diet rich in sugar and starch lowered insulin sensitivity in 
Thoroughbred geldings, compared to a diet containing primarily fat and fiber (Hoffman 
et al. 2003).  In men, glucose, fatty acids, and dietary fiber are all known to upregulate 
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glucagon-like peptide 1 and by doing so improve insulin sensitivity (MacDonald et al. 
2002). 
Pregnancy is another physiologic factor associated with insulin resistance (Butte 
2000).  In women, insulin action is 50-70% lower than normal during late pregnancy, and 
both basal and 24h mean insulin concentrations show a two-fold increase (Butte 2000).  
Postprandial glucose concentration, basal endogenous hepatic glucose production, and 
total gluconeogenesis are also increased during late pregnancy.  These alterations are 
most likely due to the rising concentrations of prolactin, cortisol, and glucagon that serve 
to ensure continuous delivery of nutrients to the growing fetus (Butte 2000).  
Hyperinsulinemia, enhanced β-cell sensitivity to endogenous and exogenous glucose, 
increased degradation of insulin and decreased insulin sensitivity have also been 
demonstrated in pregnant mares (Fowden et al. 1984). 
Stressors activating the hypothalamus-pituitary-adrenal axis cause increased 
secretion of counter-regulatory hormones such as catecholamines and glucocorticoids, 
resulting in decreased insulin sensitivity (Rosmond 2005).  Conditions associated with 
elevated glucocorticoid levels are characterized by increased glucose production in the 
liver and decreased peripheral glucose transport and utilization, leading to IR (Ruzzin et 
al. 2005; Saad et al. 1993).  A study performed on rat skeletal muscle revealed that 
dexamethasone treatment lowered insulin-stimulated glucose uptake, glycogen synthesis, 
and glycogen synthase fractional activity (Ruzzin et al. 2005).  It was also demonstrated 
that chronic dexamethasone treatment impairs insulin-mediated PKB activation, so the 
enzyme is unable to inactivate GSK3 via phosphorylation.  Glycogen synthase kinase-3, 
in its active form, phosphorylates and thereby inactivates glycogen synthase, interfering 
with glycogen synthesis (Ruzzin et al. 2005).  The authors speculated that the decreased 
PKB activity is due to a dexamethasone-mediated increase in the expression of the p85α 
subunit of the upstream enzyme PI3-kinase, which may act as a competitive antagonist of 
the p85α-p110 heterodimer in IRS-1 binding (Ruzzin et al. 2005).   
Another study identified lower activity of PI3-kinase in rat liver and skeletal 
muscle following dexamethasone administration (Saad et al. 1993).  Pretreatment with 
glucocorticoids decreased insulin-stimulated glucose uptake in rat adipocytes, but uptake 
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was restored by preincubation with conventional PKC inhibitors (Kawai et al. 2002). 
These results indicate that PKC plays an important role in glucocorticoid-induced IR.  
Using the minimal model analysis of the frequently sampled intravenous glucose 
tolerance test (FSIGTT), Tiley et al. (2007) established that insulin sensitivity decreases 
in horses receiving 0.08 mg/kg bodyweight (bwt) dexamethasone intravenously every 
other day for 3 weeks. 
Epinephrine was demonstrated to raise plasma glucose concentrations in humans 
by reducing peripheral glucose clearance and increasing hepatic glucose production via 
gluconeogenesis or glycogenolysis (Nonogaki 2000; Vicini et al. 2002).  Epinephrine, but 
not norepinephrine, also inhibits insulin-stimulated glucose uptake in skeletal muscle 
(Nonogaki 2000).  An in vivo study of human subjects revealed that elevated epinephrine 
concentrations significantly delay the inhibitory action of insulin on hepatic glucose 
production without influencing the maximal inhibitory effect of insulin (Vicini et al. 
2002).  Similarly, physiologic epinephrine concentrations were demonstrated to reduce 
muscle glucose uptake activated by a moderate, but not high, physiological insulin 
concentration through the suppression of IRS-1 associated PI3-kinase activation (Hunt 
and Ivy 2002).  Endocrinopathies, such as pheochromocytomas and pituitary pars 
intermedia dysfunction (PPID) have also been associated with IR in horses (Cefalu 2001; 
Garcia and Beech 1986). 
There are several pathologic processes associated with reduced insulin sensitivity.  
In humans, obesity and IR are significantly related (Garca-Estevez et al. 2004).  The 
degree of IR increases along with increasing body mass index (BMI; Garca-Estevez et al. 
2004).  However, the decrease in insulin sensitivity was blunted above a BMI value of 30 
kg × m-2 (Garca-Estevez et al. 2004; Kern et al. 2001).  Chronic, low grade inflammation 
associated with obesity is an important factor in the development of decreased insulin 
sensitivity (de Luca and Olefsky 2008).  Increased tumor necrosis factor α (TNFα) 
secretion by adipocytes and higher circulating plasma interleukin (IL)-6 levels were 
demonstrated in obese subjects (Kern et al. 2001).  Both of these factors were 
significantly associated with IR, and therefore implicated in its development (Kern et al. 
2001).  Tumor necrosis factor α lowers insulin sensitivity by enhancing lipolysis 
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(Trayhurn and Wood 2005), by decreasing LPL activity (Kern et al. 1995), and by 
inhibiting insulin receptor signaling within adipocytes (Borst 2007).  Impaired insulin 
signaling and increased hepatic glucose production have been demonstrated in 
association with IL-6 (Borst 2007).  Resistin, an adipokine expressed predominantly in 
adipose tissue, provides another link between obesity and IR (Shuldiner et al. 2001).  In 
obese, insulin-resistant mice, injection of antibodies raised against resistin decreased 
blood glucose concentrations and improved insulin sensitivity (Shuldiner et al. 2001).  
Leptin, a different adipokine secreted by adipocytes, exerts its effect through activation of 
leptin receptors in the hypothalamus (Borst 2007).  The primary role of leptin is to 
decrease food intake and increase energy expenditure through uncoupling proteins, 
present in mitochondria.  Leptin is also an insulin sensitizing hormone, therefore reduced 
leptin responsiveness associated with obesity is likely to contribute to the development of 
insulin resistance (Borst 2007).  Adiponectin, a hormone produced exclusively by 
adipocytes also enhances insulin sensitivity, but in contrast to leptin, its concentration is 
low in obese people and increases after weight loss (Borst 2007). 
Elevated FFA concentrations contribute to IR in people by hampering glycogen 
synthesis in skeletal muscle via inhibition of transmembrane glucose transport (Shulman 
2004).  It was demonstrated that the FFA-mediated decrease in transmembrane glucose 
transport is associated with abolished insulin-stimulated, IRS-1-associated PI3-kinase 
activity (Shulman 2004).  It is hypothesized that increased amounts of fatty acid-derived 
metabolites (e.g. fatty acyl-CoA, diacylglycerol) activate PKC leading to inhibition of 
IRS-1 by Ser/Thr phosphorylation (Shulman 2004).  Additionally, elevated plasma FFA 
concentrations have also been shown to cause IR by increasing insulin concentrations 
within the blood (Ye 2007).  There are three proposed mechanisms explaining FFA-
mediated beta cell activation.  The G-protein coupled receptor 40 is a molecule that is 
abundantly expressed on the surface of pancreatic beta cells and is capable of amplifying 
the glucose signal, which enhances insulin secretion.  This occurs when G-protein 
coupled receptor 40 is activated by its ligand, long-chain fatty acids.  Derivates of FFAs 
such as long chain acyl-CoA and malonyl CoA may directly promote the beta cell 
response as well.  Finally, FFA activates G-protein coupled receptor 120 in the intestinal 
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tract, stimulating glucagon-like peptide 1 secretion which in turn enhances insulin release 
(Ye 2007).  Chronic hyperinsulinemia induces IR primarily involving the glycogen 
synthetic pathway and by increasing lipogenesis (Koopmans et al. 1999).  Indeed, 
induction of chronic, physiologic hyperinsulinemia in rats resulted in an impairment of 
insulin’s ability to suppress plasma FFA levels, as well as reduced whole body insulin 
mediated glucose uptake by 38% (Koopmans et al. 1999). 
Defective muscle glycogen synthesis is also important in the development of IR 
(Shulman 2004).  In skeletal muscle, control of glucose uptake is distributed among three 
steps: delivery, transmembrane transport, and phosphorylation of glucose (Wasserman 
and Ayala 2005).  Exercise facilitates muscle glucose uptake by modulating all three 
steps of the control mechanisms.  Exercise and insulin not only stimulate GLUT4 
translocation to the sarcolemma, but also cause marked hyperemia and capillary 
recruitment in muscle, thereby facilitating glucose delivery.  Additionally, both insulin 
and exercise have been suggested to increase the rate of intracellular glucose 
phosphorylation by causing hexokinase to bind to mitochondria, providing it easy access 
to ATP, a substrate necessary for the glucose-6-phosphate synthesis.  Disturbances 
affecting any of these three steps of muscle glucose uptake could result in the 
development of IR (Wasserman and Ayala 2005).  Using magnetic resonance 
spectroscopy, Shulman et al. (2004), demonstrated that the insulin-stimulated change in 
intracellular concentration of glucose-6-phosphate, an intermediate metabolite between 
glucose transport and glycogen synthesis, is blunted in human patients with type 2 DM.  
This observation suggests that either decreased glucose transport or decreased hexokinase 
activity is the cause of IR within the skeletal muscle of these patients.  Further 
experiments performed in humans with type 2 DM have revealed that intracellular 
glucose concentrations are far lower than would be expected if hexokinase were the 
primary rate-limiting enzymatic step for insulin-mediated glycogen synthesis (Shulman 
2004).  Therefore, it appears that impaired insulin-mediated glucose uptake plays the 
central role in the defective muscle glycogen synthesis in cases of type 2 DM. 
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1.1.7 IR in Horses 
 
Horses and ponies are affected by IR with obesity being one of the most important 
predisposing factors for this condition (Frank et al. 2006; Hoffman et al. 2003; Jeffcott et 
al. 1986).  Oral glucose tolerance tests revealed impaired glucose tolerance and 
hyperinsulinemia in ponies that were obese or had previously suffered from laminitis 
(Jeffcott et al. 1986).  The presence of IR was confirmed by the failure of exogenous 
insulin to lower serum glucose concentrations when these animals were compared with 
healthy nonobese ponies and Standardbred horses (Jeffcott et al. 1986).  Similarly, a 
study by Powell et al. (2002) demonstrated that horses with a body condition score <5 
were less insulin resistant than horses with a body condition score >8.  Decreased insulin 
sensitivity was also detected in obese Thoroughbred geldings when compared to their 
nonobese counterparts (Hoffman et al. 2003).  Resting insulin concentrations and leptin 
levels, along with plasma VLDL, HDL-cholesterol, and nonesterified fatty acid 
concentrations were significantly elevated in obese horses with IR compared to their 
healthy counterparts (Frank et al. 2006).  In this study, insulin resistance was defined as 
maintenance of plasma glucose concentrations above the pre-injection concentration for ≥ 
45 minutes during a combined glucose-insulin test (Frank et al. 2006).  The same study 
revealed that neck circumference, as well as resting insulin and leptin concentrations, 
were helpful in identifying horses with IR (Frank et al. 2006).  In another study of 60 
horses, increased obesity was associated with elevated plasma concentrations of TNFα 
protein and enhanced blood mRNA expression of IL-1 and TNFα (Vick et al. 2007).  
Furthermore, body condition score and plasma TNFα concentrations were inversely 
related to insulin sensitivity.  These findings suggest that increased concentrations of 
inflammatory cytokines contribute to the development of IR in obese horses, which is 
consistent with findings in other species (Kern et al. 1995; Trayhurn and Wood 2005; 
Vick et al. 2007).  Negative correlation between percent body fat and plasma adiponectin 
concentrations, demonstrated in mature mares and weanling fillies (Kearns et al. 2006) 
may provide further explanation for the decreased insulin sensitivity registered in obese 
horses. 
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Insulin sensitivity in horses is profoundly influenced by diet, in part by affecting 
body weight and body condition score (Vick et al. 2006).  In obese mares, feed restriction 
resulted in a significant decrease in body weight, percentage body fat and circulating 
concentrations of leptin and insulin, accompanied by a significantly increased insulin 
sensitivity, relative to obese mares fed ad libitum (Vick et al. 2006).  Insulin sensitivity 
was also found to be significantly lower in Thoroughbred geldings fed a diet rich in sugar 
and starch when compared to geldings eating forage and a supplement rich in fat and 
fiber (Hoffman et al. 2003).  Consumption of pasture grass containing large amounts of 
NSC is associated with high glycemic and insulinemic responses, likely contributing to 
the exacerbation of IR (Longland and Byrd 2006).  In humans, increased consumption of 
fructans has been associated with enhanced de novo lipogenesis and triglyceride synthesis 
in the liver, which contributes to the development of IR (Basciano et al. 2005).  Serum 
insulin concentration measurements were used to investigate the effects of fructan 
supplementation on insulin sensitivity in ponies (Bailey et al. 2007).  After the addition 
of inulin to a basal hay diet, serum insulin concentrations were significantly increased in 
laminitis-predisposed ponies, and a similar, albeit not significant, increases in insulin 
levels were also demonstrated in healthy ponies, suggesting exacerbation of IR.  Plasma 
TG concentrations were higher, but not significantly increased, in laminitis-predisposed 
ponies when consuming basal hay diet supplemented with fructans relative to basal hay 
diet alone (Bailey et al. 2007). 
Genetic factors also seem to play a role in the development of IR in horses 
(Johnson et al. 2004).  Specific breeds that have been associated with the occurrence of 
IR include Morgan horses, domesticated Spanish mustangs, European Warmbloods, 
American Saddlebreds, and different pony breeds (Johnson 2002; Johnson et al. 2004).  
A higher degree of IR was also noted in healthy ponies relative to Dutch Warmblood 
horses (Rijnen and van der Kolk 2003).  The presence of a certain level of insulin 
insensitivity in ponies has been suggested to originate from natural selection, facilitating 
survival under harsh circumstances (Jeffcott et al. 1986).  Thus, ponies may have 
developed a highly efficient metabolism, with a degree of IR in the muscle, enhancing 
CHO delivery to the liver where coexistent hyperinsulinemia promotes lipid synthesis 
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(Jeffcott et al. 1986).  Genetic variability with respect to insulin action has been 
implicated in the development of equine Cushing’s syndrome as well (Johnson et al. 
2004). 
Equine Cushing’s disease and IR are commonly registered as comorbid conditions 
in horses, suggesting associations between these conditions (Johnson et al. 2004).  
Resting hyperinsulinemia, a nonspecific indicator of IR (Kronfeld et al. 2005a), was 
detected in horses with pituitary adenoma (Garcia and Beech 1986).  Insulin resistance 
was confirmed in these horses by a subsequent intravenous glucose tolerance test 
demonstrating prolonged hyperglycemia (Garcia and Beech 1986).  However, the lack of 
correlation between plasma cortisol and glucose concentrations in horses suffering from  
hyperadrenocorticism suggests that cortisol is not the only factor influencing the 
development of IR in these cases (van der Kolk et al. 1995).  Additionally, serum insulin 
concentrations have been successfully used as a prognostic indicator for survival in 
horses with equine Cushing’s disease (McGowan et al. 2004).  Insulin resistance is also a 
hallmark feature of equine metabolic syndrome (EMS), or “peripheral Cushing’s 
syndrome” (Johnson 2002).  Horses suffering from EMS are characteristically obese, 
prone to develop laminitis, aged between 8-18 years, often have a cresty neck, and are 
described by their owners as “easy keepers”, implying that it is difficult to reduce the 
weight of these horses (Johnson 2002). 
Lower insulin sensitivity has been described in pregnant mares, likely 
representing a physiologic adaptation process aimed at enhancing nutrient delivery to the 
developing fetus (Fowden et al. 1984).  Reduced insulin sensitivity was implied by the 
significantly higher insulin concentrations seen in mares less than 270 days pregnant than 
in non-pregnant animals or in mares nearer to term.  Increased insulin concentrations 
were attributed to the enhanced responsiveness of pancreatic β-cells to glucose.  
Additionally, exogenous insulin infusion decreased plasma glucose concentrations to a 
lesser degree in mares more than 270 days pregnant than in non-pregnant animals, 
providing corroborative evidence of IR in pregnant mares (Fowden et al. 1984). 
In weanlings with osteochondritis dissecans, plasma insulin and glucose 
concentrations were significantly greater 2 hours after feeding a concentrate meal, 
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relative to unaffected foals, indicating insulin resistance, although insulin/glucose ratios 
were not significantly different between groups (Pagan 2001).  Higher basal IGF-I 
concentrations were also observed in Thoroughbred weanlings rendered insulin resistant 
by feeding them a diet rich in sugar and starch (Treiber et al. 2005a).  Increased IGF-I 
may be a risk factor for osteochondrosis dissecans, explaining the association between 
high CHO diets, IR and osteochondrosis dissecans (Treiber et al. 2005a).  Similar to 
humans (Reaven 2003), IR has been associated with elevated blood pressure in a group of 
laminitis prone ponies (Bailey et al. 2008). 
 
1.1.8 Factors enhancing insulin sensitivity in horses: 
 
There are a number of factors known to enhance insulin sensitivity in humans 
including exercise, weight reduction, a calorie restricted diet and pharmacologic 
interventions (Cefalu 2001).  Exercise has been demonstrated to enhance GLUT4 gene 
transcription and translation in rats, as well as translocation of GLUT4 molecules from 
the intracellular pools to the sarcolemma (Dohm 2002).  The effect of submaximal 
treadmill exercise prior to and following 6 weeks of exercise training was examined on 
equine skeletal muscle GLUT4 protein content and on glucose transport in muscle 
membrane vesicles (McCutcheon et al. 2002).  Middle gluteal muscle GLUT4 protein 
content increased 2- to 3-fold by the end of the training program relative to values 
measured at the initiation of the study.  Conversely, GLUT4 content was not different at 
the end of the 60 min submaximal exercise period from values measured preceding it.  
Following treadmill exercise, increased glucose transport was demonstrated in the muscle 
membrane vesicles; however, this response was blunted by 6 weeks of training, 
suggesting a reduction in the extent of translocation of GLUT4 to the sarcolemma in 
trained muscle (McCutcheon et al. 2002).  Another study in horses has demonstrated that 
6 weeks of exercise training lowers glucose production and whole body glucose disposal 
by approximately 22%, relative to pre-training values, when the same absolute workload 
is used (Geor 2006).  No significant change was registered when the same relative 
workload was applied after completion of training.  During submaximal exercise, insulin 
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concentrations decreased whereas glucagon concentrations increased.  Training blunted 
these alterations during submaximal exercise at the same absolute, but not relative, 
workload (Geor et al. 2002).  In another study, euglycemic hyperinsulinemic clamp 
(EHC) procedures performed 24 hours after the completion of 7 consecutive days of light 
exercise revealed 60 and 48% increases in insulin sensitivity in obese and lean horses, 
respectively, relative to sedentary controls (Powell et al. 2002).  Insulin sensitivity 
returned to pre-exercise values 9 days following the cessation of the exercise program 
(Powell et al. 2002). 
A study investigating the role of obesity and diet on glucose and insulin dynamics 
in horses revealed that obese Thoroughbred geldings were significantly less insulin 
sensitive than nonobese ones, and a diet rich in fat and fiber enhanced insulin sensitivity 
relative to a feed rich in starch and sugar (Hoffman et al. 2003).  A study by Vick et al. 
(2006) has confirmed that feed restriction in obese mares significantly decreases body 
weight and improves IR compared to results obtained from obese mares fed ad libitum. 
Short and long term oral administration of levothyroxine sodium has been 
demonstrated to increase insulin sensitivity in horses (Frank et al. 2008; Frank et al. 
2005b).  Levothyroxine sodium was speculated to enhance insulin sensitivity by 
increasing abundance of glucose transporter proteins in adipose tissue and skeletal 
muscle (Casla et al. 1990; Matthaei et al. 1995; Romero et al. 2000; Weinstein et al. 
1994), as well as by increasing GLUT1 gene expression and the partitioning of glucose 
transporters into the cell membrane within hepatocytes (Haber et al. 1995).  From the 
variety of medications available for the management of IR in humans, only the biguanide 
metformin and the sulfonylurea glyburide have been evaluated for use in horses (Durham 
et al. 2008; Johnson et al. 2005; Vick et al. 2006).  In a Spanish Mustang suffering from 
diabetes mellitus, with the diagnosis based on the concurrent presence of 
hypoinsulinemia and hyperglycemia, treatment was attempted using glyburide and 
metformin (Johnson et al. 2005).  This treatment successfully lowered the interstitial 
glucose concentration to physiologic levels within 4.5 h (Johnson et al. 2005).  Oral 
metformin treatment at a dosage of 15 mg/kg twice daily significantly improved insulin 
sensitivity in horses and ponies with a history of laminitis, with the magnitude of effect 
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greatest early in the course of treatment (Durham et al. 2008).  Similarly, insulin 
sensitivity increased significantly only at the end of the first 30 day treatment period 
when mares were treated with 1.5, 3, and 4.5 g metformin twice daily for successive 
periods of 30 days (Vick et al. 2006). 
Oral administration of chromium L-methionine has been shown to decrease 
postprandial insulin secretion without affecting plasma glucose concentrations in aged 
mares, suggesting enhanced insulin sensitivity (Ralston 2002).  These findings, however, 
were not substantiated by performing an intravenous glucose tolerance test (Ralston 
2002).  Studies performed in mice demonstrated that chromium supplementation 
enhances insulin sensitivity by facilitating tyrosine-phosphorylation and inhibiting serine-
phosphorylation of IRS-1, the latter occuring through the downregulation of C-Jun NH2-
terminal kinase (JNK; Chen et al. 2008).  Furthermore, addition of chromium to the diet 
also significantly reduced TNFα and IL-6 in the serum of diabetic mice (Chen et al. 
2008). 
 
1.1.9 IR and laminitis: 
 
Laminitis refers to inflammation of the lamellae within the hoof capsule that can 
result in the failure of the attachment between the distal phalanx (coffin bone) and the 
inner hoof wall (Fagliari et al. 1998).  The distal phalanx is suspended within the hoof 
capsule by a resilient lamellar apparatus containing the primary epidermal lamellae, 
which form the hard keratinized backbone to which the semi-keratinized secondary 
epidermal lamellae attach.  The primary and secondary epidermal lamellae interdigitate 
with the primary and secondary dermal lamellae that are attached to the periosteum of the 
third phalanx.  A basement membrane (BM), found at the basal side of the epidermal 
basal cells separates the epidermal compartment of the hoof from the dermal 
compartment (French and Pollitt 2004a; Johnson et al. 1998; Mungall and Pollitt 2001; 
Pollitt 1994). 
When laminitis occurs, attachment of the BM at the dermo-epidermal junction 
fails, and the distal phalanx separates from the hoof capsule (French and Pollitt 2004a).  
 28
Epidermal basal cells are attached to the BM by electron dense plaques called 
hemidesmosomes (HD).  The major components of the HD intracellular plaque are 
plectin, BP230, BP180, and integrin α6β4.  Anchoring filaments connect the HD to the 
lamina densa of the basement membrane.  Intermediate filaments of the basal cell 
cytoskeleton insert into the HD connecting the cytoskeleton to the plasmalemma (French 
and Pollitt 2004a). 
There are at least two mechanisms proposed to explain why separation occurs at 
the dermo-epidermal junction during laminitis (French and Pollitt 2004a).  In the absence 
of glucose, the number of HDs decline and the intermediate filaments of the cytoskeleton 
lose their attachment to the intracellular dense plaque of the HD.  This results in 
weakening of the connection between the germinal cells and basement membrane.  
Failure of the cytoskeleton also causes basal cell nuclei to become rounded and then more 
spindle shaped; they are positioned more basally instead of apically (French and Pollitt 
2004a).  The second mechanism involves matrix metalloproteinases (MMP).  Cultured 
equine hoof explants secrete the inactive pro-enzymes MMP-2 and MMP-9 which are 
activated by a multistep process when they are needed (Mungall and Pollitt 2002; Pollitt 
1996).  Mononuclear phagocytes present in higher concentration within laminitic hooves 
are also a potential source of MMPs (French and Pollitt 2004a; Pollitt and Daradka 
1998).  Activation of MMPs results in the destruction of the anchoring filaments, but 
HDs remain unaffected (French and Pollitt 2004a).  The importance of MMPs in the 
development of laminitis is emphasized by the fact the connective tissue samples 
obtained from laminitic horses have significantly greater MMP activity (Johnson et al. 
1998).  Bacterial proteases such as thermolysin are also capable of activating MMPs 
(Mungall and Pollitt 2001). 
Impaired glucose delivery to the laminar keratinocytes in horses suffering from IR 
may contribute to the development of laminitis.  Healthy laminar keratinocytes express 
GLUT1, GLUT4 and epithelial sodium channel (ENaC; Mobasheri et al. 2004).  The 
presence of GLUT4 suggests that these cells are metabolically active and their glucose 
uptake is stimulated by insulin.  In severe cases of laminitis, immunostaining of GLUT1, 
GLUT4, and the α-subunit of ENaC markedly decrease, suggesting necrotic death of 
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resident laminar keratinocytes (Mobasheri et al. 2004).  However, insulin mediated 
glucose uptake into equine lamellar tissues has been questioned by Asplin et al. (2007a), 
who failed to demonstrate increased glucose uptake in lamellar explants after insulin 
stimulation.  Furthermore, the same study demonstrated no evidence of GLUT4 gene 
expression in laminar tissues, suggesting that glucose uptake in the hoof occurs thorough 
the insulin independent GLUT1 molecules which are expressed in the coronary band and 
lamellar tissues (Asplin et al. 2007b). 
The importance of IR in the development of pasture associated laminitis has been 
emphasized by Treiber et al. (2006b), because this group was able to identify ponies 
suffering from prelaminitic metabolic syndrome (PLMS) with 74% sensitivity and 79% 
specificity using three or more of the following characteristics: IR, compensatory β-cell 
response, hypertriglyceridemia, or obesity.  The same study revealed that ponies with 
PLMS have an odds ratio of 10 for the development of pasture associated laminitis when 
compared to ponies without PLMS (Treiber et al. 2006b).  Further evidence for the role 
of IR in the development of laminitis is provided by results of a study in which prolonged 
hyperinsulinemia was induced by application of an EHC for up to 72 h, which led to the 
development of Obel grade 2 laminitis in clinically normal ponies (Asplin et al. 2007b). 
Changes in the digital vasculature are also proposed to occur during the acute 
stage of equine laminitis, with shunting of blood away from lamellar capillaries via 
arteriovenous anastomoses (Pollitt and Molyneux 1990).  If this phenomenon lasts for 
long enough, lamellar ischemia is thought to develop, which results in ischemic necrosis 
of digital lamellae (Pollitt and Molyneux 1990).  During the prodromal stages of 
laminitis; lamellar microvascular blood flow fluctuates.  The blood flow decreases in the 
first 2 hours and then returns to near baseline value before finally decreasing again 8 
hours after administration of black walnut extract (Adair et al. 2000).  Insulin resistance 
may also contribute to the vascular changes preceding laminitis.  Inhibited insulin 
signaling via the PI3-kinase pathway, involved in NO synthesis, was demonstrated during 
IR, whereas the Ras/MAPK pathway mediated production of ET-1 remained undisturbed 
(Jiang et al. 1999; Kim et al. 2006).  The additive effect of these mediators likely leads to 
pathologic vasoconstriction (Kim et al. 2006).  The dyslipidaemia that develops in insulin 
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resistant patients plays a central role in diabetic microangiopathy (Jenkins et al. 2004a; 
Jenkins et al. 2004b).  Microvascular changes demonstrated in diabetic patients may 
occur in the laminar vessels of horses with chronic IR and contribute to the development 
of laminitis. 
Accumulation of platelets in the equine hoof wall distal to the coronary band 
occurs at the onset of laminitis, implicating microvascular thrombosis and systemic 
coagulopathy in the development of CHO induced laminitis (Weiss et al. 1994).  
Elevated fasting insulin levels, a characteristic feature of IR (Cefalu 2001), have been 
associated with impaired fibrinolysis and hypercoagulability in people (Meigs et al. 
2000).  In human subjects, a strong positive association was demonstrated between 
fasting insulin concentrations and levels of plasminogen activator inhibitor 1, fibrinogen, 
von Willebrand factor, and factor VII (Meigs et al. 2000). 
Destruction of the basement membrane between the dermal and epidermal 
compartment of the hoof by MMPs is often implicated in the development of laminitis 
(Kyaw-Tanner et al. 2008; Souza et al. 2006).  Increased MMP-1 and MMP-2 protein 
levels, as well as increased MMP-2 activity, were registered in human umbilical vein 
endothelial cell culture media following exposure to high (25 nM) glucose concentrations 
for 48 h (Death et al. 2003).  Furthermore, the mRNA, protein, and activity levels of 
MMP-9 were all significantly higher in human monocyte-derived macrophages exposed 
to a high glucose concentration, compared with cells exposed to either a normal glucose 
concentration or a high concentration of mannitol (Death et al. 2003).  Thus, IR and 
accompanying hyperglycemia likely plays an integral role in the development of laminitis 
by activating MMPs (Treiber 2005). 
 
1.1.10 Nonspecific indicators of IR in horses: 
 
Measurement of basal hyperglycemia is one of the most common screening tests for 
diabetes mellitus in human beings, but it does not differentiate between inadequate 
insulin secretion by pancreatic β-cells and the reduced ability of peripheral tissues to take 
up glucose (Firshman and Valberg 2007; Kronfeld et al. 2005a).  It has been applied to 
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horses as well, albeit in conjunction with intravenous glucose tolerance testing (Jeffcott et 
al. 1986). The primary advantage of using basal hyperglycemia as an indicator of IR is 
the ease of sample collection and measurement of plasma glucose concentrations.  On the 
other hand, the nonspecific nature of this test as an indicator for IR is an important 
drawback.  Glucose responses vary significantly even when measured 5-6 h after feeding 
and are influenced by the type of feed provided (Ralston 2002).  If basal glucose 
measurements are taken, samples should be chilled after collection, and plasma glucose 
concentrations should be determined promptly, to prevent registering false-low results 
due to glucose consumption by red blood cells (Christopher and O'Neill 2000).  Stress-
induced variations in cortisol may also influence findings, so stress should be minimized 
prior to sample collections (Ralston 2002). 
Fasting hyperinsulinemia has also been used as an indicator of IR (Kronfeld et al. 
2005b).  Hyperinsulinemia develops to compensate for IR but declines if compensation 
becomes inadequate (Firshman and Valberg 2007; Kronfeld et al. 2005a).  False negative 
responses may therefore occur during impending type 2 DM, a decompensation that is 
common in human beings but rare in horses (Kronfeld et al. 2005a).  Enhanced β-cell 
sensitivity to glucose has been implicated in the development of basal hyperinsulinemia 
during pregnancy in mares (Fowden et al. 1984).  Advantages of measuring fasting 
insulin concentrations to establish IR include uncomplicated sample collection and 
inexpensive sample processing.  The primary disadvantage of this method is its low 
accuracy, because insulin secretion and clearance are profoundly influenced by a 
multitude of factors including diet, duration of fasting, diurnal variations, and stress-
induced alterations in cortisol concentrations (Ralston 2002).  The nonspecific character 
of this test has been demonstrated in horses, and only a trend (P = 0.065) for higher basal 
insulin concentrations was registered in geldings fed diets high in sugar and starch 
relative to geldings consuming feed rich in fat and fiber (Treiber et al. 2005a).  On the 
other hand, the minimal model analysis of FSIGTT demonstrated a (P = 0.007) 
significant difference in insulin sensitivity for the same groups of horses (Treiber et al. 
2005a). 
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Glucose tolerance is assessed by the plasma glucose response to oral or intravenous 
glucose administration (Firshman and Valberg 2007; Kronfeld et al. 2005a).  The oral 
glucose tolerance test is used to evaluate small intestinal absorption, hepatic glucose 
uptake, and the endocrine function of the pancreas (Firshman and Valberg 2007).  The 
intravenous glucose tolerance test on the other hand, provides information about the 
functional turnover rate of glucose, a measure of insulin sensitivity (Firshman and 
Valberg 2007).  Marked or prolonged elevation of plasma glucose levels may be 
attributable to impaired insulin secretion or decreased insulin sensitivity (Kronfeld et al. 
2005a).  The intravenous glucose tolerance test has been used in horses to evaluate the 
effects of diet and pituitary pars intermedia dysfunction on glucose and insulin responses 
(Garcia and Beech 1986). 
The insulin tolerance test measures the blood glucose response to an exogenous 
insulin challenge (Firshman and Valberg 2007).  The inability of exogenous insulin to 
elicit a decrease in blood glucose levels is suggestive of insulin resistance.  It has been 
successfully applied to horses and ponies to assess insulin sensitivity (Jeffcott et al. 
1986).  However, glycemic responses to exogenous insulin are confounded by 
endogenous insulin secretion (Kronfeld et al. 2005a).  In healthy horses, completion of an 
insulin tolerance test, comprising the administration of 0.1 U/kg insulin intravenously, 
resulted in hypoglycemia that reached a nadir at approximately 40 min with blood 
glucose concentrations then returning to baseline values by 130 min (Eiler et al. 2005). 
The combined glucose-insulin test (CGIT) provides more information than either 
the glucose tolerance test or insulin tolerance test alone (Eiler et al. 2005).  During the 
test, insulin and glucose are administered concurrently as a bolus at the initiation of the 
study, then successive blood samples are collected for 150 minutes.  For the CGIT, 
insulin resistance is defined as maintenance of blood glucose concentrations above the 
baseline level for ≥ 45 min (Frank et al. 2006).  Frank et al. (2006) applied the CGIT 
method to define insulin resistance in obese horses.  The advantages of this procedure 
include its simplicity to perform and the low number (n=14) of blood samples collected 
during the test, which makes it a useful clinical diagnostic test (Eiler et al. 2005).  
Although in its current form no quantitative measures of glucose and insulin dynamics 
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are obtained from this procedure, calculations of area under the glucose (AUCg) and 
insulin (AUCi) curves may remedy this deficiency.  Nevertheless, administration of 
exogenous insulin at the initiation of the procedure interferes with the evaluation of 
endogenous insulin response. 
In human subjects, glucose-to-insulin ratios correlate positively with insulin 
sensitivity, whereas the insulin-to-glucose ratio correlates with insulin secretion 
(Kronfeld et al. 2005a).  An initial decrease in the insulin-to-glucose ratio during 
intravenous glucose tolerance test in horses with pituitary adenoma indicated an impaired 
insulin response to acute hyperglycemia (Garcia and Beech 1986). 
Surrogates for quantitative methods have been developed for screening IR in people 
and horses as well (Kronfeld et al. 2005a).  The quantitative insulin sensitivity check 
index (QUICKI) estimates insulin sensitivity in human beings from fasting insulin (I0) 
and glucose (G0) concentrations using the following formula: QUICKI = 1/[log(I0) + 
log(G0)] (Katz et al. 2000).  In people, the correlation between QUICKI and EHC was 
stronger than the correlation between EHC and minimal model analysis of glucose and 
insulin dynamics (Katz et al. 2000). 
Two proxies, the reciprocal of the square root of insulin (RISQI) and the modified 
insulin-to-glucose ratio (MIRG), were developed by Treiber et al. (2005b) for the 
prediction of insulin sensitivity and beta cell responsiveness, respectively.  Beta cell 
responsiveness represented by the MIRG is similar to the acute insulin response to 
glucose [AIRg], obtained via minimal model analysis of frequently sampled intravenous 
glucose tolerance test (FSIGTT) data (Treiber et al. 2005b).  Resting glucose and insulin 
concentrations are measured for the calculations.  Insulin sensitivity is derived using the 
following formula: 
Insulin sensitivity = 7.93 × (RISQI) – 1.03 
where RISQI is the reciprocal of the square root of basal insulin concentration.  Acute 
insulin response to glucose can be calculated by using the following equation: 
AIRg = 70.1 × (MIRG) – 13.8 
where MIRG = [800 - 0.3 × (basal insulin concentration - 50)2] / (basal glucose 
concentration – 30) (Treiber et al. 2006b).  These proxies compared favorably with 
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proxies used successfully in human studies when comparisons were made with insulin 
sensitivity and AIRg values obtained from the minimal model.  The combined use of 
RISQI and MIRG facilitates distinction between compensated and uncompensated IR in 
horses (Treiber et al. 2005b).  The aforementioned proxies were used in a study to 
establish metabolic predispositions and nutritional risk factors for development of 
pasture-associated laminitis in ponies (Treiber et al. 2006b).  However, one disadvantage 
of using proxy measurements is that factors other than insulin sensitivity affect fasting 
insulin concentrations.  Furthermore, if RISQI values of < 0.32 mU/L0.5 are used to define 
IR, as suggested by Treiber et al. (2006b), any horse with a fasting insulin concentration 
≥ 10 mU/L would be classified as insulin resistant, even though fasting insulin 
concentrations of 5 to 20 mU/L are usually considered normal in horses (Ralston 2002). 
 
1.1.11 Quantitative methods for the evaluation of IR: 
 
In contrast to nonspecific indications of insulin resistance, the euglycemic-
hyperinsulinemic clamp technique allows the quantification of insulin sensitivity (Rijnen 
and van der Kolk 2003).  During the EHC, euglycemia and hyperinsulinemia are induced 
by the concurrent infusion of glucose and insulin.  Blood samples are collected during the 
procedure to confirm that blood glucose concentrations are maintained on a constant, 
euglycemic level, which is achieved by the adjustment of the glucose infusion rate.  In a 
successful clamp, the rate of glucose infusion used to maintain euglycemia equals cellular 
glucose uptake mediated by the exogenously administered insulin.  The glucose disposal 
rate is usually calculated from the mean glucose infusion rate used during the last 60 
minutes of the 120- or 180-minute test.  Arterial samples are preferable because insulin 
administration increases differences between arterial and venous blood glucose 
concentrations.  Disadvantages of the method include its labour intensive nature and the 
use of supraphysiologic insulin concentrations (Kronfeld et al. 2005a).  The EHC 
technique was successfully applied to determine reference range values indicative of 
insulin sensitivity in horses and ponies (Rijnen and van der Kolk 2003).  Vick et al. 
(2008) also used the EHC technique in horses to demonstrate that lipopolysaccharide 
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administration induces a transient increase in insulin sensitivity followed by a reduction 
in insulin sensitivity at 24h.  The effects of short term exercise training and the influence 
of dexamethasone administration on insulin sensitivity in horses have also been 
investigated using the EHC technique (Powell et al. 2002; Tiley et al. 2008). 
The insulin suppression test is another quantitative method that has been used in 
people to measure the ability of a fixed rate insulin infusion to dispose of a glucose load 
(Kronfeld et al. 2005a).  Endogenous insulin secretion is suppressed by administration of 
somatostatin or octreotide, and infusion rates are controlled to yield a relatively steady 
level of insulin and glucose concentration during the last 60 minutes of the test.  The 
steady state plasma glucose concentration is determined as the mean glucose 
concentration of 6 blood samples obtained every 10 minutes during the last hour of the 
test.  It reflects insulin-mediated glucose disposal which is directly related to IR.  The 
limiting factors of this method are the adverse effects of insulin suppressant drugs, 
inconsistency of the steady-state, and an elevated steady-state glucose concentration 
which exceeds the renal threshold (Kronfeld et al. 2005a).  To date, there are no reports 
detailing the use of this method in horses. 
The minimal model of glucose-insulin dynamics has been used to interpret data from 
the FSIGTT.  The minimal model partitions glucose disposal into glucose-dependent and 
insulin-dependent parts by fitting a nonlinear model to the data obtained from the 
FSIGTT.  In the model, the glucose-time curve is described by two differential equations, 
one represents glucose-mediated glucose uptake, whereas the other explains insulin-
mediated glucose disposal.  The insulin modified FSIGTT involves the intravenous 
administration of a glucose bolus (300mg/kg of bwt) at 0 min followed by a bolus 
infusion of insulin (30 mU/kg of bwt) at 20 min (Kronfeld et al. 2005a).  Over the course 
of the test, 31 blood samples are obtained at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 
19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150 and 180 min relative 
to glucose infusion, to determine glucose and insulin concentrations.  The FSIGTT has 




X’(t) = -p2 × X(t) + (p3 × [I(t) – Ib]) 
SI = p3/ p2 
Where X’(t) (min-2) represents the change in insulin action over time; parameter  p2 
represents the rate (min-1) of decline of insulin action; X(t) is insulin action (min-1) (i.e. 
the acceleration of glucose disposal at time t associated with insulin concentration above 
basal); parameter p3 represents the rate (min-1) of introduction of insulin into the 
interstitial space; I(t) represents the insulin concentration (mU/L) at time t; and Ib 
represents basal insulin concentration (mU/L). Assumptions were X(0) = 0 and {I(t)-Ib} 
= 0 if I(t) < Ib. Besides the SI value, the minimal model analysis of the FSIGTT also 
provides a measure of glucose effectiveness (Sg), a value representing the net fractional 
glucose clearance independent of insulin.  The equation used to calculate Sg is: 
G’(t) = -(X+Sg) × G(t) + (Sg × Gb) 
Where G’(t) represents the rate of glucose clearance from plasma; X represents insulin 
action; G(t) represents plasma glucose concentration at time t with G(0) being the 
theoretical glucose concentration at time 0, as calculated using the minimal model; and 
Gb represents basal glucose concentration (Hoffman et al. 2003).  Further variables 
provided by minimal model analysis of the insulin modified FSIGTT data include AIRg 
and the disposition index (DI; Kronfeld et al. 2005a).  The AIRg is the increase in plasma 
insulin concentrations above baseline levels integrated from 0 to 10 min after glucose 
administration (Treiber et al. 2005a). 
AIRg = ∫ [I(t) –Ib] × dt 
Where I(t) and Ib represents insulin concentrations at time t and baseline, respectively.  
This variable therefore characterizes the responsiveness of pancreatic β-cells to a glucose 
load.  The DI represents the ability of the pancreatic β-cells to compensate for decreased 
insulin sensitivity and it is derived from the minimal model by multiplying AIRg with SI 
(Bergman 2005).  The minimal model analysis of the insulin modified FSIGTT has been 
successfully used to investigate the effects of obesity and diet on insulin sensitivity in 
horses (Hoffman et al. 2003).  Tiley et al. (2008) also applied the minimal model to 
establish the effects of dexamethasone on insulin sensitivity and glucose dynamics in 
Standardbreds.  A study examining the repeatability of EHC versus minimal model 
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analysis of FSIGTT data demonstrated that EHC results were more repeatable under the 
experimental conditions used (Pratt et al. 2005).  Further disadvantages of this technique 
include the potential loss of glucose into the urine during the FSIGTT, which is not 
accounted for in minimal model analysis.  The AIRg values, which are calculated from 
insulin concentrations measured in the peripheral blood, are also confounded by hepatic 
insulin extraction and by the whole body insulin clearance rate (Toffolo et al. 1999).  In 
human subjects, these confounding factors are controlled by using C-peptide 
measurements for the assessment of pancreatic β-cell function (Toffolo et al. 1999). 
 
1.2 Endotoxin – endotoxemia: 
 
1.2.1 Structure of the endotoxin: 
 
Endotoxin is a heat stable macroamphiphile lipopolysaccharide (LPS) molecule 
found in the cell membrane of Gram-negative bacteria, which may cause severe 
physiological derangements when it enters the circulation in mammals (Rietschel et al. 
1994).  It constitutes approximately three quarters of the outer leaflet of the bacterial cell 
membrane and functions as a protective layer inhibiting the entry of toxic compounds.  It 
is also important in the transport of nutrients, so it is essential for bacterial viability 
(Rietschel et al. 1994). 
Lipopolysaccharide is composed of a hydrophilic heteropolysaccharide and a 
covalently bound lipid component, termed lipid-A.  In certain bacteria, such as members 
of the Enterobacteriaceae genus, the heteropolysaccharide can be further divided into the 
O-specific chain and the core oligosaccharide (Rietschel et al. 1994). The O-specific 
chain is a polymer of oligosaccharides, containing one to eight glycosyl residues.  The 
structure of the repeating units creates considerable variability between strains.  It 
determines the serological specificity of the LPS and thus, functions as an important 
surface antigen (Rietschel et al. 1994). 
The core region consists of a heterooligosaccharide which can be further divided 
into outer (O-specific chain proximal) and inner (lipid-A proximal) portions (Rietschel et 
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al. 1994).  The outer core in Salmonella spp. and Escherichia coli serotypes contains 
hexoses such as D-glucose, D-galactose and N-acetyl-D-glucosamine, while the inner 
core is composed of heptoses and 3-deoxy-D-manno-octulosonic acid.  Most of the 
structural diversity of the core region is related to the outer core while the innermost part 
appears to be highly conserved amongst Gram-negative bacteria (Rietschel et al. 1994). 
Lipid-A constitutes the toxic and immunomodulating principle of LPS and it is 
the most conserved region of the endotoxin molecule.  Chemically, it is a 
phosphoglycolipid containing D-gluco-configurated pyranosidic hexosamine residues 
present as a β-linked homo- or heterodimer.  Changes in its hydrophilic backbone (ie, 
omission of phosphoryl groups) or addition of a fatty acid to its hydrophobic region both 
significantly reduce the bioactivity of lipid-A.  Full endotoxic activity is expressed by a 
molecule containing two hexosamine residues, two phosphoryl groups and six fatty acids 
including 3-acyloxylacyl groups (Reed 2003; Rietschel et al. 1994). 
 
1.2.2 Cellular recognition and signal transduction of endotoxin: 
 
After endotoxin is released into the systemic circulation, it is recognized by the 
innate immune system, including macrophages and monocytes (Chow et al. 1999; 
Werners et al. 2005).  The effects of LPS on macrophages are markedly enhanced by the 
presence of a protein called lipopolysaccharide-binding protein (LBP; Martin 2000; 
Werners et al. 2005).  Lipopolysaccharide-binding protein mainly functions as a transport 
protein which disaggregates LPS and transfers it to targets on cellular membranes and to 
lipoproteins in solution.  Lipopolysaccharide molecules bound to and transported by HDL 
are biologically inactive, therefore HDL binding provides a mechanism for detoxification 
of LPS in the plasma (Martin 2000).  Lipopolysaccharide-binding protein is a 50-kDa 
polypeptide that is glycosylated and secreted as a 60-kDa glycoprotein primarily by the 
liver and lungs (Martin 2000; Wan et al. 1995).  As a type I acute phase response protein, 
LBP mRNA expression is stimulated by LPS, IL-1, IL-6 and TNFα in primary rat 
hepatocyte cultures (Wan et al. 1995).  Lipopolysaccharide-induced LBP mRNA 
expression was markedly enhanced in hepatocytes isolated from rats previously injected 
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with LPS, suggesting the existence of a priming mechanism which facilitates a more 
rapid and vigorous response to a subsequent challenge (Wan et al. 1995). 
The LPS-LBP complexes are transported to the cluster-of-differentiation antigen 
14 (CD14), a molecule existing in two forms (Werners et al. 2005).  A tail composed of 
glycosylphosphatidylinositol may anchor CD14 molecules to the cell membrane or they 
may be present in a soluble form that lacks the glycosylphosphatidylinositol tail (Martin 
2000; Werners et al. 2005).  Binding of LPS-LBP complexes to CD14 present on 
monocytes, macrophages and neutrophil granulocytes leads to cellular activation and 
production of proinflammatory cytokines (Downey and Han 1998; Werners et al. 2005).  
Soluble CD14 receptors are also capable of binding LPS-LBP complexes and facilitate 
LPS-dependent activation of some CD14 negative cells such as endothelial, epithelial, 
and smooth muscle cells (Downey and Han 1998).  
Once it was determined that CD14 lacks a cytoplasmic domain (Werners et al. 
2005), it was then found that LPS-stimulated signal transduction occurs through Toll-like 
receptors (TLR; Chow et al. 1999).  Lipopolysaccharide signaling through the TLR4 
receptor, however, also requires the presence of myeloid differentiation factor 2, a protein 
physically associated with TLR4 on the cell surface (Shimazu et al. 1999; Werners et al. 
2005; Yang et al. 2000).  To date, at least 11 different TLRs have been cloned in 
mammalian species (Werners et al. 2005).  Both TLR2 and TLR4 appear to play a role in 
LPS-induced signal transduction (Chow et al. 1999; Kirschning et al. 1998).  Human 
embryonic kidney 293 cells transiently transfected with human TLR4 or TLR2 cDNA 
demonstrated a significantly increased responsiveness to LPS in the presence of CD14 as 
measured by the activation of nuclear factor κB (NF-κB; Chow et al. 1999). 
After ligand binding, TLR4 dimerizes and undergoes a change in conformation 
that is necessary to initiate intracellular signaling events (Werners et al. 2005).  The best 
characterized LPS-induced pathways are the NF-κB pathway and three MAPK-associated 
pathways (Yang et al. 2000): 
•  MAPK (extracellular signal regulated kinase) 
• C-Jun NH2-terminal kinase 1 and 2 
• p38 MAPKs (Downey and Han 1998). 
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Endotoxin-induced activation of NF-κB via TLR4 is initiated by the association of the 
TLR4 receptor with myeloid differentiation protein.  This protein stimulates the IL-1 
receptor-associated kinase which in turn facilitates recruitment of TNF receptor 
associated factor-6 (Yang et al. 2000).  The activation of these proximal signaling 
molecules leads to stimulation of members of the MAPK kinase kinase family that 
activate inhibitory kappa B kinases.  Inhibitory kappa B kinases phosphorylate the 
inhibitory kappa B proteins, which are subsequently degraded resulting in the liberation 
of NF-κB and its translocation to the nucleus (Yang et al. 2000).  Almost all genes 
important in the pathogenesis of LPS-induced systemic inflammation contain promoter 
elements for NF-κB such as TNFα, IL-1β, IL-6, IL-8, inducible nitric oxide synthase and 
cyclo-oxygenase (COX) -2 (Downey and Han 1998).  In addition to the aforementioned 
cellular activation mechanisms, PKC and SRC family kinases were also found to be 
activated following LPS stimulation (Downey and Han 1998). 
 
1.2.3 Pathogenesis of endotoxemia:  
 
Endotoxin is liberated from the outer membrane of the cell wall of Gram-negative 
bacteria upon rapid proliferation or lysis of the organisms (Werners et al. 2005), thus the 
equine intestinal tract contains large amounts of LPS (Morris 1991).  Normally there are 
three mechanisms preventing the access of LPS to the peripheral circulation: the mucosal 
cell barrier of the intestines, the ability of bile acids to bind LPS, and the clearance of 
LPS from the blood by the Kupffer cells of the liver (Hardie and Kruse-Elliott 1990a; 
Morris 1991).  In order to cause disease, large amounts of endotoxin must be absorbed 
from the gastro-intestinal tract and then overwhelm the liver’s detoxifying ability, or the 
number of Kupffer cells in the liver must be reduced due to pathologic processes (Hardie 
and Kruse-Elliott 1990a; Morris 1991). 
In cases of endotoxemia the source of endotoxin can be endogenous or 
exogenous.  The gastro-intestinal tract is an endogenous source and endotoxin release 
occurs during acute abdominal disease.  In contrast, the source of endotoxin is exogenous 
in cases of metritis, pleuropneumonia, or neonatal septicemia (Werners et al. 2005).  The 
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interaction of LPS with mononuclear phagocytes, and subsequent activation of these cells 
are pivotal early events in the pathogenesis of endotoxemia (MacKay 2001).  Activated 
macrophages possess an increased ability of adherence and pseudopod formation (Morris 
1991).  Most importantly, activated macrophages secrete a wide variety of inflammatory 
mediators, such as cytokines, lipid mediators, and free oxygen radicals, which play a 
central role in the pathogenesis of endotoxemia (Hardie and Kruse-Elliott 1990a; Morris 
1991; Werners et al. 2005).  The most extensively studied cytokines, IL-1, IL-6, and 
TNFα are all pyrogens, and are capable of stimulating acute phase protein production by 
the liver (Werners et al. 2005). 
Tumor necrosis factor-α is a polypeptide produced by activated macrophages, 
vascular smooth muscle cells, blood leukocytes, and mesothelial cells (Barton and 
Collatos 1999; Detmer et al. 2001; Hardie and Kruse-Elliott 1990a).  The plasma half life 
of TNFα is short (approximately 6 min), and it rapidly binds to specific receptors in 
target tissues, such as lungs, kidneys, and liver (Hardie and Kruse-Elliott 1990a).  As a 
proximal mediator of LPS effects, TNFα is important in neutrophil activation and 
adherence, alterations to the vascular endothelium, and decreased LPL synthesis (Hardie 
and Kruse-Elliott 1990a).  This cytokine also enhances the synthesis of class I major 
histocompatibility complex antigen and triggers the secretion of the second wave of 
inflammatory cytokines, including IL-6 and granulocyte-monocyte colony stimulating 
factor (Hardie and Kruse-Elliott 1990a; MacKay 2001).  In humans and mice, 
intravenous infusion of endotoxin induces a marked increase in TNFα concentrations at 2 
hours, followed by a return to baseline levels by 4 hours post-infusion (Copeland et al. 
2005).  Stimulation with LPS significantly increased TNFα production in blood from 10 
horses, however the magnitude of this response showed wide inter-animal variation 
(Werners et al. 2006). 
Interleukin-1 plays a central role in the control of fever, neutrophil and T 
lymphocyte chemotaxis, expression of intracellular adhesion molecules in vascular 
endothelium, and also triggers an increase in the number of circulating immature 
neutrophils (Hardie and Kruse-Elliott 1990a).  Macrophages and vascular smooth muscle 
cells secrete IL-1 in response to bacterial LPS or TNFα (Detmer et al. 2001; Hardie and 
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Kruse-Elliott 1990a).  Increased plasma concentrations of IL-1β were detected in mice at 
multiple time points following intravenous LPS administration whereas in people, no 
circulating IL-1 was detected following endotoxin challenge (Copeland et al. 2005; van 
Deventer et al. 1990).  Exposure to Escherichia coli O111:B4 LPS has also been shown 
to increase IL-1β mRNA expression in equine monocytes (Figueiredo et al. 2008). 
Interleukin-6, a phosphoglycoprotein produced by fibroblasts, mononuclear, and 
endothelial cells, stimulates the final differentiation of B-lymphocytes into plasma cells 
and induces production of acute phase proteins by hepatocytes (Morris 1991).  In mice 
and people, endotoxin administration increased IL-6 concentration with a peak registered 
2 h after endotoxin infusion (Copeland et al. 2005).  Van Deventer et al. (1990) 
demonstrated that release of IL-6 was delayed approximately 15 minutes relative to 
TNFα in human subjects receiving an LPS infusion, indicating that TNFα may stimulate 
the release of IL-6 from the monocyte/macrophage compartment, or alternatively, from 
endothelial cells.  Interleukin-6 secretion was also registered in equine monocytes 
exposed to LPS (Figueiredo et al. 2008). 
Lipopolysaccharide binding also destabilizes cell membranes and activates the 
nearby phospholipases A2, C, and D (Stief 2007).  Phospholipase A2 cleaves the 
membrane phospholipids in the sn-2 position, thereby generating lysophospholipids and 
arachidonic acid (Stief 2007), with the latter further converted into leukotrienes via the 5-
lipoxygenase pathway or into prostanoids via the COX pathway (Hardie and Kruse-
Elliott 1990a).  Thromboxane-A2 is a COX end-product that causes vasoconstriction 
during endotoxemia and induces platelet aggregation (Morris 1991).  Prostacyclin is 
another arachidonic acid derivate that is often released more gradually, and causes 
vasodilatation and inhibition of platelet aggregation (Morris 1991).  There are four 
different leukotrienes released during endotoxemia.  Of these, leukotriene-C4, 
leukotriene-D4, and leukotriene-E4 are potent bronchoconstrictors and vasoconstrictors 
that also increase capillary permeability of postcapillary venules, whereas leukotriene-B4 
promotes neutrophil-endothelial adherence and is a potent chemoattractant for 
neutrophils (Hardie and Kruse-Elliott 1990a).  Exposure to endotoxin has been shown to 
increase the expression of COX-2 protein and mRNA in equine digital vein endothelial 
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cells and equine digital artery smooth muscle cells, respectively (Menzies-Gow et al. 
2008; Rodgerson et al. 2001). 
Platelet activating factor is another important molecule mediating LPS effects 
(Carrick et al. 1993).  It is synthesized by leukocytes, platelets, and endothelial cells 
through phospholipase A2-mediated hydrolysis.  Its biological effects include platelet and 
neutrophil activation and aggregation, bronchoconstriction, pulmonary hypertension, and 
increased vascular permeability (Carrick 1989; Carrick et al. 1993).  Although treatment 
with a platelet activating factor receptor antagonist delayed the onset of fever, 
tachycardia, and leukopenia in horses that received endotoxin, the drug failed to change 
any of the clinical or laboratory data (Carrick et al. 1993). 
 
1.2.4 Clinical conditions related to endotoxemia: 
 
Endotoxin-induced systemic inflammatory response syndrome causes profound 
derangements in whole body homeostasis that ultimately affect multiple organ systems 
(Morris 1991).  Endotoxemia most commonly occurs following gastro-intestinal 
compromise because of an increase in the permeability of the intestinal mucosa.  
Ischemic insults and severe bowel inflammation therefore facilitate endotoxin absorption 
from the lumen (Morris 1991).  Absorbed endotoxin itself has a pronounced effect on the 
gastrointestinal tract.  Lipopolysaccharide delays gastric emptying, decreases gastric acid 
output, and increases gastric pH (Doherty et al. 2003; Valk et al. 1998). 
Platelet counts were lower and there was a trend towards increased coagulation 
times (thrombin time, prothrombin time and activated partial thromboplastin time) in 
ponies that received endotoxin intravenously (Fessler et al. 1982).  Interestingly, the 
decline in platelet counts was more pronounced in ponies given flunixin meglumine, 
perhaps because this drug reduces the release of prostacyclin, which is known to inhibit 
platelet aggregation (Fessler et al. 1982).  An endotoxin-induced elevation in fibrinogen 
concentration was also detected in ponies, which was prevented by the administration of 
dexamethasone, prednisolone succinate, or flunixin meglumine (Ewert et al. 1985). 
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One of the most characteristic consequences of endotoxemia is neutropenia.  Tumor 
necrosis factor, IL-1, and LPS itself stimulate the expression of adhesion molecules such 
as p- and e-selectins on endothelial cells, and stimulates neutrophil adhesion (MacKay 
2001; Morris 1991).  Profound granulocytopenia was registered in human subjects 60 
minutes after IV administration of LPS, which then shifted to granulocytosis two hours 
after infusion (Richardson et al. 1989).  Granulocytosis persisted for 4 hours and returned 
to baseline levels by 24 hours.  Rebound neutrophilia is attributed to an increase in 
colony stimulating factors released by macrophages following TNFα exposure (Morris et 
al. 1990).  Endotoxin-induced monocytopenia and lymphopenia are also detected in 
humans (Richardson et al. 1989).  Monocytopenia persists longer than neutropenia and 
lasts for up to 6 hours (Pernerstorfer et al. 1999).  Significant lymphocytopenia is 
observed for 1 to 6 hours after endotoxin infusion (Richardson et al. 1989). 
In a study of anesthetized ponies that received 0.2 mg/kg bwt endotoxin IV, 
multiple derangements in hemogram and blood-gas parameters were observed (Bottoms 
et al. 1981; Fessler et al. 1982).  During the first 4 hours, there was a marked decrease in 
white blood cell count (WBC) due to a reduction in the number of neutrophils (Fessler et 
al. 1982).  Significantly elevated packed cell volume (PCV) values were also detected in 
animals receiving LPS, which was likely to have been a consequence of catecholamine-
mediated splenic contraction (Fessler et al. 1982).  Higher circulating catecholamine 
concentrations have been previously detected in humans and laboratory animals with 
endotoxemia (Hinchcliff et al. 2005).  Respiratory acidosis detected during the 
experiment was related to general anesthesia, however, significantly elevated blood 
lactate levels and lower venous pH values were suggestive of a shift from aerobic to 
anaerobic metabolism (Fessler et al. 1982).  Flunixin meglumine administration 
ameliorated this shift to anaerobic metabolism, presumably by maintaining better 
peripheral blood flow, as demonstrated in a previous study (Bottoms et al. 1981; Fessler 
et al. 1982). 
Circulating endotoxin has a direct toxic effect on tissues and initiates an 
exaggerated inflammatory response which causes vascular dysfunction (Hardie and 
Kruse-Elliott 1990a).  This can result in distributive shock, multiple organ failure and 
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ultimately death.  Toxic radicals released upon activation of leukocytes also contribute to 
cellular death (Hardie and Kruse-Elliott 1990a).  Changes in blood biochemical values 
can reflect deteriorating organ function.  Blood biochemical parameters were examined in 
anesthetized ponies receiving a lethal dose of endotoxin (Ewert et al. 1985).  Elevated 
creatinine kinase activities were detected in all groups, but ponies that received 
dexamethasone, prednisolone succinate, or flunixin meglumine were less affected.  
Lactate dehydrogenase levels increased gradually during the shock period, with the 
highest levels detected in the group of ponies that did not receive anti-inflammatory 
drugs (Ewert et al. 1985). 
Endotoxemia causes profound hemodynamic changes culminating in endotoxic 
shock, which is classified as a distributive shock (Muir 1998).  Exposure of endothelial 
cells, neutrophils, and macrophages to LPS activates their inducible nitric oxide synthase 
enzyme leading to excessive generation of NO (Muir 1998).  Nitric oxide causes 
vasodilatation, hypotension, and possibly arteriovenous shunting.  Cardiac output is often 
elevated during the early phases of endotoxemia, which causes injected, warm mucous 
membranes.  However, when endotoxin shock develops, arterial blood pressure and 
cardiac output decrease, resulting in reduced peripheral perfusion indicated by pale, cold 
mucosal membranes (Muir 1998).  Compensatory responses include tachycardia and 
peripheral vasoconstriction mediated by thromboxane-A2, ET-1, arginine-vasopressin, 
and angiotensin II.  As the disease progresses, decompensation becomes apparent by 
progressive systemic hypotension, which is confounded by direct myocardial suppression 
of NO, and increased vascular permeability.  Increased plasma concentrations of 
prostacyclin, prostaglandin-E2, and bradykinin are often detected during the 
decompensation phase (Reed 2003).  Increased blood levels of ET-1 have also been 
detected in various species during endotoxemia (Wanecek et al. 2000).  Endothelin-1 is 
produced by vascular endothelial cells, mast cells, macrophages, and smooth muscle cells 
and is involved in the regulation of vascular tone.  It causes concentration-dependent 
vasoconstriction which is mediated by endothelin-A and endothelin-B2 receptors 
(Wanecek et al. 2000).  During endotoxemia, ET-1 contributes to endotoxin-induced 
coronary vasoconstriction, late phase pulmonary hypertension, splanchnic 
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vasoconstriction, and acute renal failure (Wanecek et al. 2000).  Endothelin-1 
concentrations were elevated in laminar connective tissue collected from horses with 
laminitis, suggesting that ET-1 plays a role in the pathogenesis of this disease (Katwa et 
al. 1999). 
 
1.2.5 Endotoxemia and IR: 
 
In a study by Fessler et al. (1982), plasma insulin and glucose concentrations were 
evaluated following endotoxin administration.  Ponies receiving endotoxin demonstrated 
an initial hyperglycemia without any alterations in insulin level, followed by 
hypoglycemia accompanied by transient hyperinsulinemia (Fessler et al. 1982).  It was 
concluded that early hyperglycemia facilitated insulin release, which triggered 
subsequent rebound hypoglycemia (Fessler et al. 1982). 
Endotoxemia caused whole body insulin resistance in rats with a 37% decrease in 
glucose disposal (Virkamaki and Yki-Jarvinen 1994).  The decrease was partially 
attributed to a defect in muscle glycogen synthesis (Virkamaki and Yki-Jarvinen 1994).  
The same study examined the effects of α- and β-adrenergic blockade on glucose 
metabolism during endotoxemia.  Although α- and β-blockade abolished the transient 
hyperglycemia observed after endotoxin administration, it failed to normalize glucose 
disposal or skeletal muscle glycogen synthesis, so LPS-induced insulin resistance was not 
corrected during the late (6-8 hrs) phase (Virkamaki and Yki-Jarvinen 1994).  Continuous 
LPS infusion significantly decreased the number of insulin receptors, insulin-stimulated 
tyrosine phosphorylation of insulin receptors, abundance of IRS-1 molecules, and 
tyrosine phosphorylation of IRS-1 molecules in rat liver tissue, whereas only tyrosine 
phosphorylation of IRS 1 molecules was significantly affected in skeletal muscle 
(McCowen et al. 2001).  The effect of endotoxin on IRS-1 is mediated by TNFα, which 
activates C-Jun NH2-terminal kinase and I kappa B kinase resulting in the inhibition of 
IRS-1 signaling through serine307 phosphorylation (Aguirre et al. 2000; de Luca and 
Olefsky 2008). 
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In a prospective study of apparently healthy, middle aged women, elevated levels of 
the systemic inflammatory markers IL-6 and C-reactive protein were found to be 
determinants of risk for type 2 DM (Pradhan et al. 2001).  In horses, Vick et al. (2008) 
investigated the effects of systemic inflammation on insulin sensitivity using the EHC 
method.  Systemic inflammation induced by intravenous administration of 0.045 μg/kg 
bwt lipopolysaccharide induced a transient increase in insulin sensitivity followed by 
profound IR at 24 h (Vick et al. 2008).  The IR that develops during the systemic 
inflammatory response likely aims to provide high glucose flow to cells involved in 
immune and inflammatory reactions and other non insulin-dependent cells (Fitzgerald 
2004).  In a study of humans where the EHC method was used to asses glucose dynamics 
during endotoxemia, LPS administration resulted in a biphasic response in glucose 
utilization, similar to that registered in horses (Agwunobi et al. 2000; Vick et al. 2008).  
The glucose infusion rate had to be increased 120 minutes after LPS administration, after 
which time it had to be progressively lowered.  By the 420 minute time point, the glucose 
infusion rate was significantly lower in the group receiving LPS compared to control, 
indicating that insulin resistance had developed (Agwunobi et al. 2000).  The difference 
in glucose infusion rate was attributed to alterations in nonoxidative glucose disposal.  
After an initial rise in glucose storage rate, it started to decline progressively and then 
reached statistical significance 420 minutes after LPS administration (Agwunobi et al. 
2000). Endotoxin-mediated activation of TLR-4 receptors in 3T3-L1 adipocytes has also 
been shown to provoke insulin resistance (Song et al. 2006). 
 
1.2.6 Endotoxemia and laminitis: 
 
In horses, approximately 75% of acute laminitis is preceded by alterations 
involving the gastrointestinal system (Weiss et al. 1998).  Changes in the caecal flora, 
including a concomitant increase in the number of lactic acid producing bacteria and 
reduction in the Gram-negative bacterial population, were demonstrated during the onset 
of acute laminitis induced by CHO overload in horses (Garner et al. 1978).  These 
findings were further substantiated by registering that fecal and caecal bacterial 
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populations also change during oligofructose-induced laminitis from a predominantly 
Gram-negative population to one dominated by Gram-positive bacteria (Milinovich et al. 
2007; Milinovich et al. 2006).  Specifically, Streptococcus lutetiensis, a member of the 
Streptococcus bovis/equinus complex, demonstrated a marked population increase 
between 8 and 16h after OF administration (Milinovich et al. 2006).  A sharp decline in 
the number of OF-utilizing organisms occurred between 16 and 24 hours and this was 
accompanied by a sharp decline in fecal pH, followed by the development of clinical 
laminitis between 24 and 32h (Milinovich et al. 2006).  The lower pH likely contributes 
to the transient increase in intestinal mucosal permeability registered during the 
prodromal stages of alimentary laminitis (Weiss et al. 1998).  Altered intestinal 
permeability allows endotoxin absorption into the circulation, as demonstrated by the 
elevated endotoxin levels registered in 11/13 horses developing Obel grade 3 laminitis 
following CHO overload (Sprouse et al. 1987).  The role of endotoxemia in the 
development of laminitis has been further supported by results of a study investigating 
factors associated with the development of laminitis in hospitalized horses (Parsons et al. 
2007).  This study revealed that horses suffering from clinically evident endotoxemia 
have an odds ratio of 5 to develop laminitis when compared with horses that have no 
clinical signs of endotoxemia (Parsons et al. 2007).  Additionally, an in vitro study 
implicated the streptococcal pyrogenic exotoxin B in the development of laminitis by 
demonstrating its ability to trigger laminar separation in equine hoof explants (Mungall et 
al. 2001). 
The expression of extracellular MMPs, notably MMP-2 and MMP-9, is 
significantly higher in hoof laminar tissues obtained from laminitic horses versus hoof 
laminar tissues obtained from non-laminitic animals (Johnson et al. 1998).  Endotoxin or 
inflammatory cytokine mediated activation of these gelatinases may further explain the 
strong association between endotoxemia and laminitis (Bailey et al. 2004; Johnson et al. 
1998). 
The vascular theory suggests that laminitis is a consequence of digital ischemia 
and subsequent reperfusion (Adair et al. 2000; Menzies-Gow et al. 2005).  Equine digital 
smooth muscle cells exposed to endotoxin demonstrated an increased expression of 
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COX-2 mRNA (Rodgerson et al. 2001).  Vasoactive prostanoids, produced via the COX-
2 pathway, may be important in the vasoconstrictive events preceding laminitis 
(Rodgerson et al. 2001).  Concentrations of ET-1, a potent vasoconstrictor, were also 
increased in laminar connective tissue of horses suffering from laminitis (Katwa et al. 
1999).  Decreased digital blood flow and high plasma ET-1 concentrations were found in 
horses with severe endotoxemia as well, providing yet another example of how 
endotoxemia and laminitis may be interconnected (Menzies-Gow et al. 2005).  
Microvascular thrombosis, demonstrated in ponies with carbohydrate-induced laminitis, 
likely contributes to alterations in digital blood flow (Weiss et al. 1994).  
Lipopolysaccharide-mediated activation of phospholipase A2 increases cell membrane 
perturbation causing cell fragmentation (Stief 2007).  These cell fragments subsequently 
activate the intrinsic (contact) pathway of the coagulation cascade by facilitating the 
conversion of prekallikrein to kallikrein (Stief 2007).  Endotoxin has been shown to 
enhance tissue factor expression on equine peritoneal macrophages, which activates the 
extrinsic pathway of the coagulation cascade (Barton et al. 1996).  In conclusion, 
endotoxin-mediated activation of both arms of the coagulation cascade is likely to 
contribute to the development of laminitis by altering digital blood flow. 
 
1.2.7 Endotoxin tolerance and endotoxin hyporesponsiveness: 
 
Repeated exposure to endotoxin can lead to the development of tolerance, which 
is reflected by a characteristic decrease in TNFα concentration (West and Heagy 2002).  
Endotoxin tolerance can be divided into early and late tolerance (Hardie and Kruse-Elliott 
1990b).  In one study, early endotoxin tolerance developed after lipopolysaccharide was 
administered twice 24 h apart (Allen et al. 1996).  After the second injection, horses 
showed a decreased activity, lower concentration of TNFα, shorter duration of elevated 
rectal temperature, and smaller rise in blood pressure (Allen et al. 1996).  Macrophages 
obtained from horses with acute gastrointestinal disease also produce significantly less 
TNFα in vitro when compared with similarly treated macrophages obtained from healthy 
animals (Barton et al. 1996).  Early endotoxin tolerance seems to be a plausible 
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explanation for this latter phenomenon.  During early phase endotoxin tolerance, 
impaired NF-κB activation and translocation, and altered IL-1 receptor-associated kinase 
and MAPK functions were demonstrated, leading to reduction in TNFα, IL-6, and IL-8 
levels, while prostaglandin E2 and IL-10 concentrations increased (West and Heagy 
2002).  LPS exposure induces translocation of p65 and p50 subunits of NFκB from the 
cytosol to the nucleus in both LPS responsive and LPS tolerant THP-1 cells (Chan et al. 
2005).  However, NFκB p65 binding to the IL-1β promoter is rapidly and transiently 
increased in LPS responsive monocytes whereas it is significantly limited in LPS tolerant 
cells.  Concomitant alterations in chromatin remodeling are also present in LPS tolerant 
cells (Chan et al. 2005).  Endotoxin-mediated overexpression of the dual specific 
phosphatase MKP-1 has been shown to contribute to the development of endotoxin 
tolerance by negatively regulating the p38 MAPK, which is an enzyme that is important 
for the post-transcriptional stabilization of TNFα mRNA (Nimah et al. 2005).  While it 
has been shown in humans that early tolerance lasts only for a few days, late tolerance 
extends for several weeks (Hardie and Kruse-Elliott 1990b).  Late tolerance is O-antigen 
dependent and may be mediated by specific antibodies (Hardie and Kruse-Elliott 1990b). 
The ability of an individual to respond to endotoxin is highly variable (Arbour et 
al. 2000).  Common, co-segregating missense mutations affecting the TLR4 receptor 
have been shown to be responsible for differences in the response to inhaled LPS in men 
(Arbour et al. 2000).  Large individual differences in the response to LPS have also been 
documented in peripheral blood mononuclear cells and whole blood and alveolar 
macrophages obtained from horses (Werners et al. 2006).  Genotyping TLR-4, myeloid 
differentiation factor 2, and CD-14 receptors in 10 horses, including 3 horses with 
significantly lower LPS-induced TNFα responses, revealed mutations involving the 
sequence of the TLR4 receptors (Werners et al. 2006).  However, these changes could 
not be linked to the hyporesponsiveness to LPS (Werners et al. 2006).  No mutations 
were found to affect the genes coding for either the myeloid differentiation factor 2 or 
CD-14 receptors, suggesting that these are more highly conserved structures (Werners et 
al. 2006). 
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CHAPTER 2  
Effects of an intravenous endotoxin challenge on glucose and 
insulin dynamics in horses 
 
This chapter is a revised version of a paper by the same name published in the 
American Journal of Veterinary Research in 2008 by Ferenc Tόth, Nicholas Frank, Sarah 
B. Elliott, Raymond J. Geor and Raymond C. Boston. 
 
Reference: Tόth, F., Frank, N., Elliott, S. B., Geor, R. J. and Boston, R.C. Effects of an 





Endotoxin is a heat-stable lipopolysaccharide (LPS) located within the outer 
membrane of Gram-negative bacteria that can be released as a result of rapid bacterial 
growth or cell death (Morris 1991; Werners et al. 2005).  In healthy animals, endotoxin is 
located within the intestines and is contained there by the mucosal barrier and mucus 
layer (Werners et al. 2005).  If endotoxin enters the portal blood system via active 
transport or passive diffusion from the intestinal tract, LPS molecules are removed from 
circulation by the Kupffer cells of the liver (Morris 1991).  Clinical signs of endotoxemia 
develop when body defenses are compromised and blood endotoxin concentration 
increases. In horses, endotoxemia is most commonly associated with gastrointestinal tract 
disturbances such as colic and colitis that involve bacterial overgrowth and increased 
intestinal wall permeability (French et al. 2002; Larsen 1997; Morris and Moore 1989).  
Endotoxemia develops when the mucosal barrier is compromised and there is movement 
of endotoxin into the blood and lymphatic system, or when endotoxin passes through the 
serosa into the peritoneal cavity (French et al. 2002; Larsen 1997; Morris and Moore 
1989).  Horses that develop retained fetal membranes, pleuropneumonia, wound 
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infections, or Gram-negative bacteremia are also at risk for endotoxemia (Morris 1991; 
Werners et al. 2005). 
Insulin resistance is a state in which normal concentrations of insulin fail to elicit 
a normal physiologic response (Kahn 1978), and this condition develops as a 
consequence of endotoxemia in humans (Agwunobi et al. 2000) and rats (Virkamaki and 
Yki-Jarvinen 1994).  This disturbance in glucose metabolism in horses is a concern 
because of its putative link with laminitis.  Administration of a high dose of LPS (125 
µg/kg) to ponies induces hyperglycemia within the first hour, followed by significant 
hypoglycemia compared to values registered before endotoxin administration, but plasma 
insulin concentrations remained unchanged (Ewert et al. 1985; Fessler et al. 1982).  
Effects of endotoxemia on insulin sensitivity are relevant because insulin resistance (IR) 
is a risk factor for pasture-associated laminitis in ponies (Treiber et al. 2006b), and there 
is in vitro evidence that hoof laminar tissues require an adequate supply of glucose to 
maintain structural integrity (Pass et al. 1998).  If IR is an important risk factor for 
laminitis, then endotoxemia may exacerbate this disturbance in glucose metabolism and 
further increase the risk of disease. 
Administration of exogenous LPS is used to experimentally induce endotoxemia 
but does not represent development of the disease clinically, which may explain why 
laminitis has not developed in LPS-treated horses (Barton et al. 2004; Doherty et al. 
2003; Kiku et al. 2003; MacKay et al. 1999; Moore et al. 1981).  However, endotoxemia 
may still play a role in the development of laminitis, and this method allows physiologic 
responses to LPS administration to be isolated and studied.  Endotoxemia has been 
associated with acute laminitis in two studies (Parsons et al. 2007; Sprouse et al. 1987), 
although a causal relationship has not been established.  Parsons et al. (2007) 
retrospectively evaluated horses that developed acute laminitis during hospitalization.  
This group determined that the odds of a horse with clinical endotoxemia developing 
acute laminitis during hospitalization were 5 times those of a horse with no clinical signs 
of endotoxemia.  However, endotoxemia was only inferred from clinical signs and not 
confirmed by endotoxin assay.  Sprouse et al. (1987) also reported that plasma endotoxin 
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concentrations significantly increased in 11 of 13 horses that developed Obel grade 3 
laminitis after alimentary carbohydrate overload. 
Clinical signs consistent with endotoxemia have been observed in horses during 
the development of laminitis after oligofructose administration (van Eps and Pollitt 
2006).  Horses that received 10 g of oligofructose/kg via intragastric administration 
developed diarrhea within 12 hours and had signs of depression, inappetence, fever, and 
tachycardia within the 48-h period following treatment (van Eps and Pollitt 2006).  Mean 
white blood cell (WBC) and neutrophil counts initially decreased, but then increased 
within 48 hours of oligofructose administration.  These findings suggest that endotoxemia 
contributes to the development of laminitis associated with carbohydrate overload in 
horses (Bailey et al. 2004).  Carbohydrate overload causes an overgrowth of intestinal 
bacteria that lowers the intraluminal pH and increases intestinal wall permeability (Al 
Jassim et al. 2005; Elliott and Bailey 2006; Harris et al. 2006; van Eps and Pollitt 2004).  
Endotoxemia detected during the development of carbohydrate-induced laminitis may 
reflect this increase in intestinal wall permeability (Sprouse et al. 1987). 
The purpose of the study reported here was to evaluate the effects of endotoxin 
administered intravenously on glucose and insulin dynamics in horses.  We hypothesized 
that endotoxemia would induce alterations in glucose and insulin dynamics in horses.  
The frequently sampled intravenous glucose tolerance test (FSIGTT) was elected to test 
our hypothesis because data from this test can be assessed via minimal model analysis.  
The minimal model of glucose and insulin dynamics is a nonlinear model that uses data 
obtained from the FSIGTT to partition glucose disposal into glucose- and insulin-
mediated fractions (Kronfeld et al. 2005a).  It provides values for glucose effectiveness 
(Sg), insulin sensitivity (SI), and acute insulin response to glucose (AIRg; Hoffman et al. 
2003; Kronfeld et al. 2005a; Treiber et al. 2006a).  Glucose effectiveness describes the 
capacity of glucose to mediate its own disposal, whereas SI represents the ability of 
insulin to promote glucose disposal and decrease endogenous glucose production.  The 
acute insulin response to glucose is a measure of initial phase endogenous insulin 
secretion in response to exogenous glucose.  The ability of pancreatic beta cells to 
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increase insulin secretion in response to decreased insulin sensitivity is represented by the 
DI (Bergman 2005). 
 
2.2 Materials and Methods: 
 
Horses – Sixteen healthy mares from the University of Tennessee teaching and 
research herd were evaluated during the study period (February to June 2006).  Horses 
were admitted to the University of Tennessee Large Animal Hospital in pairs, and each 
pair of horses remained hospitalized for 14 days.  Only mares were selected to eliminate 
differences attributable to sex.  The horses were 4 to 12 years old (mean age, 9.1 years; 
median, 9.5 years); breeds included mixed (n = 8), Quarter horse (3), Tennessee Walking 
Horse (1), Appaloosa (1), and Paint (3).  Horses were weighed at the time of admission; 
weights ranged from 436 kg to 563 kg (mean weight, 493.6 kg; median, 498.6 kg).  Body 
condition score (on a scale of 1 to 9) ranged from 4 to 6 (Henneke et al. 1983).  The study 
protocol was approved by the University of Tennessee Institutional Animal Care and Use 
Committee. 
Experimental design – A randomized crossover study design with repeated 
measures was used; each horse received the LPS and control treatments.  Eight horses 
were randomly selected to receive an injection of LPS during the first of the 2-week 
period and then an injection of sterile saline (0.9% NaCl) solution (control treatment) 
alone the second week; the remaining 8 horses received the LPS and control treatments in 
the reverse order.  Horses were weighed and physical examinations were performed on 
the first day (Friday), and then each horse was housed separately in 3.7 X 3.7-m stalls 
within the veterinary teaching hospital.  Grass hay and water were provided ad libitum 
and each horse was acclimated to its new environment for approximately 72 hours.  
Horses were evaluated during each of the 2 study weeks; each week, procedures were 
performed according to the same schedule.  On the first day of the week (Monday), an IV 
catheter was placed and a sham FSIGTT was performed.  An FSIGTT was performed 24 
hours before treatment (Tuesday; baseline [–24 hours]), and the infusion of LPS or saline 
solution was administered between 1200 and 1230 on Wednesday (designated time = 0).  
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Frequently sampled IV glucose tolerance test procedures were performed 24 (Thursday) 
and 48 hours (Friday) after treatment.  All FSIGTTs were performed between 12:00 and 
3:00 PM. Intravenous catheters were removed at the end of each study week. 
Lipopolysaccharide administration – Escherichia coli O55:B5 LPS was mixed 
with 60 mL of sterile saline (0.9% NaCl) solution under a fume hood by an investigator 
(SBE) wearing gloves and a respirator to minimize exposure.  The LPS solution (20 
ng/kg) or 60 mL of saline solution alone was infused via the IV catheter during a 30-
minute period.  Horses were observed for signs of colic and physical examination 
variables, including rectal temperature, heart rate, respiratory rate, mucous membrane 
color, and capillary refill time with the results recorded every 15 min for the first 3 h, 
then every 30 min for the following 3 hours, and then every 2 hours for 18 hours. 
CBC analysis – Blood was collected from the indwelling jugular catheter into 
tubes containing EDTA before the LPS or saline solution infusion was initiated 
(commenced at time = 0) and 3 hours later (ie, 2.5h after completing the LPS infusion).  
Samples were immediately transported to the clinical pathology laboratory for complete 
blood count (CBC) analysis. 
FSIGTT procedure – On the first day of each study week, each horse was 
weighed and a 14-gauge polypropylene catheter1 was inserted into the left jugular vein.  
During tests, the horse was allowed access to grass hay and water ad libitum.  Patency of 
the IV catheter was maintained between tests by injection of 5 mL of saline solution 
containing heparin into the catheter every 6 hours.  An injection cap and infusion set2 
(length, 30 cm; internal diameter, 0.014 cm) were attached to the catheter.  The FSIGTT 
procedure first described for use in horses by Hoffman et al. (2003) was used.  Briefly, a 
bolus (300 mg of glucose/kg) of a 50% (wt/vol) dextrose solution3 was administered to 
each horse via the infusion line and catheter, followed by injection of saline solution 
containing heparin (4 U/mL).  Blood samples were collected via the catheter immediately 
before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after infusion of dextrose.  At 
                                                 
1 Abbocath-T 14G X 140 mm, Abbott Laboratories, North Chicago, Ill. 
2 Butterfly, Abbott Laboratories, North Chicago, Ill. 
3 Dextrose 50% injection, Abbott Laboratories, North Chicago, Ill. 
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20 min, regular insulin4 (30 mU/kg) was administered followed by another infusion of 
saline solution containing heparin.  Blood samples were subsequently collected via the 
catheter at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 min 
after the dextrose infusion.  At each time point, 3 mL of blood was withdrawn from the 
infusion line and discarded.  A 6-mL blood sample was then collected, followed by 
infusion of 5 mL of saline solution containing heparin.  Half the volume of the blood 
sample was transferred to a tube containing sodium heparin, which was immediately 
cooled on ice and then refrigerated.  The remaining blood was transferred to a tube 
containing no anticoagulant.  Those samples were allowed to clot at 22oC for 1h and then 
serum was harvested via low-speed (1,000 × g) centrifugation.  Plasma and serum 
samples were stored at –20oC until further analyzed.  
Plasma glucose and serum insulin concentrations – Plasma glucose 
concentrations were measured by use of a colorimetric assay5 on an automated discrete 
analyzer6.  Serum insulin concentrations were determined by use of a radioimmunoassay7 
that has been validated for use in horses (Freestone et al. 1991).  Each sample was 
assayed in duplicate and intra-assay coefficients of variation < 5% or < 10% were 
required for acceptance of glucose and insulin assay results, respectively. 
Interpretation of FSIGTT data by use of the minimal model – Values of SI, 
Sg, AIRg, and disposition index (DI) were calculated for each FSIGTT in accordance 
with the minimal model (Bergman et al. 1981) by use of commercially available 
software8,9 and previously described methods (Hoffman et al. 2003).  Disposition index 
was calculated via multiplication of AIRg by SI. 
Statistical analysis – Horses were classified as responders or nonresponders 
according to their response to endotoxin, and groups were compared by use of the 
nonparametric Mann-Whitney U test.  Mixed-model ANOVA for repeated measures was 
performed by use of statistical software10 to determine the effects of treatment (LPS vs 
                                                 
4 Humulin R, Eli Lilly & Co, Indianapolis, Ind. 
5 Glucose, Roche Diagnostic Systems Inc, Somerville, NJ. 
6 Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ. 
7 Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, Calif. 
8 MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, Pa. 
9 Stata 9.2, Stata Corp, College Station, Tex. 
10 PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC. 
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saline solution) and time (−24, 24, or 48 hours) on Sg, SI, AIRg, and DI.  When a 
significant treatment × time effect was detected, the Bonferroni test for multiple 
comparisons was used to identify significant differences between least squares means.  




The response to endotoxin was determined via observation of signs of colic and 
detection of leukopenia, which was defined as WBC count < 5.6 X 103 WBCs/µL 
(Duncan et al. 1994) at 3 hours after LPS administration.  Compared with horses that 
were classified as nonresponders (n = 3), rectal temperature, heart rate, WBC count, 
percentage decrease (from baseline) in WBC count, and neutrophil count differed 
significantly in horses that were identified as responders (n = 13; Table 2.1). 
In responders, signs of colic detected within 3 hours of LPS administration 
included pawing, rolling, and stretching.  Nonresponders did not develop signs of colic.  
Frequently sampled intravenous glucose tolerance tests were successfully performed, and 
mean ± SE plasma glucose and serum insulin concentrations were calculated (Figures 
2.1 and 2.2).  Data from a single FSIGTT performed 48 hours after LPS administration in 
1 horse were excluded from the statistical analysis because the DI value was clearly an 
outlier and had a studentized residual (adjusted by dividing it by an estimate of its SD ) of 
7.44. 
Compared with the control treatment, injection of LPS significantly decreased SI 
(time × treatment; P = 0.040) and increased AIRg (time × treatment; P = 0.006) over 
time (Table 2.2).  Mean ± SD SI significantly decreased from 2.9 ± 1.9 × 10-4 L•min-
1•mU-1 at baseline (ie, prior to LPS administration) to 0.9 ± 0.9 × 10-4 L•min-1•mU-1 after 
24 hours (69% reduction); however, the value at 48 hours did not differ significantly 
from the pretreatment value.  Mean AIRg significantly increased from 520 ± 196 
mU•min•L-1at –24 hours to 938 ± 620 mU•min•L-1 and 712 ± 400 mU•min•L-1 at 24 and 
48 hours after LPS treatment, respectively.  After LPS treatment, mean DI significantly 
(time × treatment; P = 0.024) decreased from the baseline value of 14 ± 10 × 10-2 to 
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Table 2.1 – Mean ± SD physical examination variable and WBC count data in 16 horses 
that received Escherichia coli O55:B5 LPS in 60 mL of sterile physiologic saline (0.9% 
NaCl) solution (20 ng/kg) administered IV and developed signs of colic and leukopenia 
(responders) or did not respond to treatment (nonresponders). 
Variable 
Nonresponder 
group (n = 3) 
Responder group 
(n = 13) 
Maximal heart rate (beats/min) 49 ± 7 67 ± 17* 
Maximal rectal temperature (ºC) 38.2 ± 0.6 39.1 ± 0.5* 
Decrease in WBC count at 3 hours after 
treatment, compared with pretreatment 
value (%) 
9.4 ± 5.1 45.1 ± 11.1* 
WBC count at 3 hours after treatment  
(× 103 cells/µL) 
7.4 ± 1.4 4.0 ± 0.9* 
Neutrophil count (× 103 cells/µL) 5.5 ± 0.7 2.3 ± 0.8* 
Leukopenia was defined as WBC count < 5.6 × 103 WBCs/µL. Reference range for heart 
rate: 28-40 beats/min. Reference range for rectal temperature: 37.8-38.8 ºC. Reference 
range for neutrophil count: 2.9-8.5 × 103 cells/µL. 
*For this variable, value was significantly (Mann-Whitney U test; P < 0.05) different 











































Figure 2.1 – Mean ± SE plasma glucose concentrations during FSIGTTs performed in 16 
horses that received an IV infusion of saline (0.9% NaCl) solution (60 mL) or 
Escherichia coli O55:B5 LPS (endotoxin; 20 ng/kg) in 60 mL of saline solution during 
the first study week according to a randomized crossover design. Tests were conducted 
24 hours before (white circles) and 24 (black squares) and 48 hours (white triangles) after 
administration of saline solution (panel A) or LPS (panel B). Values derived at 48 hours 











































Figure 2.2 – Mean ± SE serum insulin concentrations during FSIGTTs performed in 16 
horses that received an IV infusion of saline (0.9% NaCl) solution (60 mL) or 
Escherichia coli O55:B5 LPS (endotoxin; 20 ng/kg) in 60 mL of saline solution during 
the first study week according to a randomized crossover design. Tests were conducted 
24 hours before (white circles) and 24 (black squares) and 48 hours (white triangles) after 
administration of saline solution (panel A) or LPS (panel B). Values derived at 48 hours 
after LPS infusion are calculated from 15 horses. 
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Table 2.2 – Mean ± SD minimal model analysis values obtained from FSIGTT data 
derived from 16 horses that received an IV infusion of physiologic saline solution (60 
mL; control treatment) or E coli O55:B5 LPS in 60 mL of physiologic saline solution (20 
ng/kg) during each week of a 2-week study period according to a randomized crossover 
design. The FSIGTTs were conducted 24 hours before and 24 and 48 hours after 
administration of the injection. 
  Time point 
Variable Treatment Before treatment 24 hours
 48 hours * 
Control 3.0 ± 1.9a 2.7 ± 1.5a,b 2.7 ± 1.3a,b SI 
(L•min-1•mU-1) 
× 10–4 LPS 2.9 ± 1.9
a,b 0.9 ± 0.9c 1.5 ± 0.9b,c 
Control 2.3 ± 0.6a 2.5 ± 0.8a 2.4 ± 0.8a Sg 
( min-1) 
× 10–2 LPS 2.3 ± 0.6
a 1.9 ± 0.6a 2.1 ± 0.7a 
Control 503 ± 260a 594 ± 319a,b 537 ± 275a,b AIRg 
(mU•min•L-1) LPS 520 ± 196a,b 938 ± 620c 712 ± 400c,b 
Control 13 ± 8a 14 ± 6a 13 ± 6a DI 
× 10-2 LPS 14 ± 10a 6 ± 5b 10 ± 9a,b 
* Mean ± SD values for the endotoxin group are calculated from data derived from 15 
horses. 
a-c For variables with significant (P < 0.05) treatment × time effects, mean values with 
different superscripts differ significantly, as determined by use of an ANOVA for 
repeated measures and via comparison of least squares mean values by use of a 
Bonferroni adjustment. Treatment-time effects were detected for SI (P = 0.041), AIRg   
(P = 0.006), and DI (P = 0.024). 
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6 ± 5 × 10-2 at 24 hours after endotoxin administration.  No significant treatment × time 
effects were detected for Sg. 
In the 3 horses that did not develop a clinical response to endotoxin 
administration, mean SI increased by 12% and then decreased by 27% at 24 and 48 hours 
following LPS infusion, respectively, compared with the value before treatment.  
Compared with the pretreatment value, mean AIRg was decreased by 2% and increased 
by 7% at 24 and 48 hours after injection, respectively; mean Sg was decreased by 36% 
and increased by 14% at 24 and 48 hours after injection.  The DI values did not increase 
or decrease from baseline by > 1% after LPS administration.  After the completion of the 




In the present study, 13 of 16 healthy horses that received Escherichia coli 
O55:B5 LPS via IV infusion at a dose of 20 ng/kg developed signs of mild colic and 
leukopenia (ie, WBC count < 5.6 X 103 WBCs/µL).  At 24 hours after LPS 
administration, insulin sensitivity was significantly lower than the value prior to 
treatment and AIRg increased to compensate for this alteration in glucose dynamics. 
Signs of colic, fever, tachycardia, and leukopenia were detected in the horses that 
responded to LPS in the present study, and these findings are consistent with those of 
previous reports (Barton et al. 2004; Doherty et al. 2003; Kiku et al. 2003; MacKay et al. 
1999; Moore et al. 1981).  In 1 study (MacKay et al. 1999), IV administration of 
Escherichia coli O55:B5 LPS at a dose of 30 ng/kg decreased the WBC count, compared 
with baseline values, with the nadir occuring at 2 hours after infusion.  Horses developed 
mild restlessness, sweating, increased respiratory effort, and tachypnea in response to 
LPS; mean rectal temperature increased over time, and a peak value > 39oC (102.2oF) 
was detected 4 hours after initiation of the endotoxin infusion.  Plasma interleukin-6 and 
TNFα activities were also increased in treated horses.  In another study (Barton et al. 
2004), E coli O26:B5 LPS was administered to horses at the dose used in the present 
study (20 ng/kg).  In those horses, mean rectal temperature was approximately 39°C at 3 
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hours after initiation of the LPS infusion; mean heart rate also significantly increased 
from baseline values, and peaked at approximately 50 beats/min after 1.5 hours.  In that 
same study, neutrophil counts were assessed every 30 minutes and the lowest mean value 
(< 3,000 cells/µL) was detected 1 hour after LPS infusion.  However, similar to the 
finding in the responder group of the present study, the mean neutrophil count remained 
less than the pretreatment value for 3 hours after LPS was infused. 
In the study reported here, 3 horses failed to develop signs of colic or leukopenia. 
This lack of response may be attributable to circulating anti-endotoxin antibodies or 
genetic polymorphism within intracellular LPS signal transduction pathways (Arbour et 
al. 2000; Hardie and Kruse-Elliott 1990b).  Toll-like receptor-4, myeloid differentiation 
factor-2, and cluster differentiation factor-14 can all be affected (Arbour et al. 2000).  In 
humans, missense mutations affecting the extracellular domain of the Toll-like receptor 4 
are associated with a diminished response to inhaled LPS (Arbour et al. 2000).  However, 
a common mutation was not identified when this hypothesis was tested in horses that had 
blunted responses to LPS (Werners et al. 2006). 
Glucose and insulin dynamics were assessed in horses by use of FSIGTT and 
minimal model analysis procedures in the present study.  These methods have been 
previously used in horses and are preferred over the EHC technique, which is alternative 
method of quantifying SI (Hoffman et al. 2003; Kronfeld et al. 2005a; Pratt et al. 2005).  
One advantage of the minimal model is that it provides measures of the pancreatic 
response (AIRg) and ability of glucose to mediate its own disposal (Sg), as well as SI 
(Bergman 2005).  The DI, which represents the ability of pancreatic beta cells to 
compensate for decreased insulin sensitivity, can also be calculated (Hoffman et al. 
2003).  Measures of AIRg, Sg, and DI are not provided by use of the EHC technique.  
The EHC technique is also more difficult to perform from a technical standpoint because 
an infusion line must remain connected to each horse throughout the 2- to 3-hour study 
period (Pratt et al. 2004), which provides more opportunity for equipment failure and 
stress. 
Insulin sensitivity values prior to LPS infusion and those determined in horses 
during the week that they received the control treatment compared favorably with results 
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of previous studies (Hoffman et al. 2003; Treiber et al. 2005b).  A mean SI value of 1.9 × 
10–4 L•min-1•mU-1 was reported for nonobese Thoroughbred geldings (Hoffman et al. 
2003) and the mean value for a group of 46 horses was 2.1 × 10–4 L•min-1•mU-1 (Treiber 
et al. 2005b).  In contrast, lower mean SI values of 0.39 × 10–4 L•min-1•mU-1 and 0.08 × 
10–4 L•min-1•mU-1 have been detected in healthy ponies and ponies that had previously 
had laminitis (Treiber 2005), which suggests that insulin sensitivity is generally lower in 
ponies than horses (Jeffcott et al. 1986; Rijnen and van der Kolk 2003).  Mean SI 
significantly decreased following LPS administration in the horses of the present study.  
At 24 hours after treatment, mean SI was significantly lower than the mean value before 
LPS infusion; at 48 hours after treatment, mean SI was still lower than the mean value 
before LPS infusion, but this difference was not significant.  A biphasic glucose response 
has been detected after LPS administration in humans (Agwunobi et al. 2000).  Glucose 
infusion rates during EHC procedures were significantly higher 120 minutes after LPS 
was administered, compared with saline controls, but then progressively decreased and 
were significantly lower than what was registered in saline controls at 420 minutes after 
LPS administration.  Endotoxemia also induces IR in rats, as evidenced by a 37% 
decrease in glucose disposal following LPS administration (Virkamaki and Yki-Jarvinen 
1994).  At the tissue level, continuous LPS infusion significantly decreased insulin 
receptor abundance, inhibited insulin-stimulated tyrosine phosphorylation of insulin 
receptors, and decreased the number of IRS-1 molecules within liver tissues collected 
from treated rats (McCowen et al. 2001).  In contrast, only tyrosine phosphorylation of 
IRS-1 molecules was significantly affected in rat skeletal muscle tissue.  Results of those 
studies suggest that IR can be rapidly induced through interference with tissue insulin 
signaling pathways; however, in those experiments, rats received markedly larger doses 
of LPS than those administered to horses in the study reported here. 
Increases in serum TNFα activity have been detected in the plasma of horses 
following the experimental induction of endotoxemia, and this cytokine may mediate the 
development of IR in equids (Barton et al. 2004; MacKay et al. 1999; Rui et al. 2001).  
Results of a study (Rui et al. 2001) involving rodents indicated that TNFα induces serine 
phosphorylation of IRS-1, which disrupts the interaction of IRS-1 with the catalytic 
 65
domain of the insulin receptor and inhibits insulin-stimulated activation of the 
phosphatidylinositol 3-kinase cascade.  Alternatively, IR may develop in horses after LPS 
administration because of increases in circulating cortisol concentrations.  Administration 
of LPS significantly increases cortisol concentrations in ponies, and pretreatment of rat 
adipocytes with glucocorticoids inhibits insulin-mediated glucose uptake in vitro (Ewert 
et al. 1985; Fessler et al. 1982; Kawai et al. 2002).  Increased catecholamine 
concentrations have also been detected in humans after injection of LPS and this response 
may lower SI (Krabbe et al. 2001).  In an in vitro study (Hunt and Ivy 2002) of isolated 
rat muscle, physiologic concentrations of epinephrine inhibited insulin-mediated glucose 
uptake into tissues by modulating activation of IRS-1–associated phosphatidylinositol 3-
kinase.  Intravenous administration of epinephrine has also been shown to delay the 
ability of insulin to inhibit endogenous glucose production in humans (Vicini et al. 2002). 
Glucose effectiveness in horses was not altered by LPS administration in the 
present study and values were consistent with those previously reported.  In nonobese and 
moderately obese Thoroughbred geldings, mean ± SE Sg values of 1.43 ± 0.16 × 10–2 and 
1.59 ± 0.19 × 10–2 have been detected, respectively, and for 46 healthy horses, a 95% 
confidence interval for Sg of 0.12 to 2.95 × 10–2 has been reported (Hoffman et al. 2003; 
Treiber et al. 2005b).  In the study reported here, mean AIRg was 83% and 45% higher 
than the pretreatment value at 24 and 48 hours after LPS administration, respectively.  
Before LPS infusion and during the week that horses received the control treatment, 
AIRg values were higher than the mean value of 270 mU•min•L-1 detected in 46 healthy 
horses, but were within the 95% reference interval of 67 to 805 mU•min•L-1 previously 
reported for this variable (Treiber et al. 2005b).  Minimal model analysis values may vary 
between study populations because of differences in evaluation techniques and breed, 
sex, age, or diet of the study horses. 
The results of our study have indicated that pancreatic beta cells of horses respond 
to endotoxin-induced IR by secreting more insulin.  Compensated IR has been previously 
described in ponies and is recognized by the presence of hyperinsulinemia in chronically 
insulin-resistant animals (Treiber et al. 2006b).  However, in the horses of the present 
study, mean DI decreased by 57% over 24 hours in response to LPS, which suggests that 
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this compensatory response was inadequate.  More time may be required for the 
pancreatic beta cells to fully respond to the decrease in SI or alternatively, endotoxin may 
directly inhibit pancreatic function. 
The data obtained in the present study may be relevant to the pathogenesis of 
laminitis because laminar keratinocytes appear to have a high requirement for glucose 
(Pass et al. 1998).  The presence of insulin-sensitive glucose transporter 4 protein within 
equine hoof tissues suggests that insulin plays an important role in glucose uptake 
(Mobasheri et al. 2004).  In vitro experiments performed with freshly isolated hoof 
explants have also revealed that laminae separate at the dermoepidermal junction when 
glucose concentrations are decreased within the tissue culture medium (Pass et al. 1998).  
Insulin resistance might also predispose horses to laminitis by inducing endothelial cell 
dysfunction.  This may increase endothelin-1 synthesis and cause a concurrent decrease 
in nitric oxide production in the endothelium, resulting in vasoconstriction (Kim et al. 
2006). It has previously been shown that endothelin-1 concentrations are higher in 
laminar connective tissues from horses with laminitis (Eades et al. 2007; Katwa et al. 
1999).  In a recent study in horses, Eades et al. (2007) determined that digital venous 
blood endothelin-1 concentrations were significantly higher than baseline values 11 hours 
after carbohydrate was administered to induce laminitis. 
In the present study, administration of 20 ng of E coli O55:B5 LPS/kg decreased 
insulin sensitivity while enhancing the acute insulin response to glucose and did not alter 
glucose effectiveness in horses.  Results suggest that endotoxemia will further 
compromise glucose and insulin dynamics in chronically insulin-resistant horses, which 
may place them at higher risk for development of laminitis. 
 
2.5 Evaluation of the euglycemic hyperinsulinemic clamp procedure 
 
The initial protocol for this study included a comparison of FSIGTT and 
euglycemic hyperinsulinemic clamp (EHC) techniques.  It was originally our intent to 
evaluate the effects of LPS on glucose and insulin dynamics using both techniques, with 
8 horses evaluated with each procedure.  However, results of preliminary studies revealed 
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unacceptably high coefficients of variation for consecutive EHC tests.  A study was 
therefore designed to test the hypothesis that the EHC has a low repeatability when 




Four adult mares were evaluated and each mare underwent four EHC procedures 
24 h apart.  Horses were hospitalized in pairs and acclimated to their new environment 
for 72 h before testing commenced.  A 14-gauge intravenous catheter was inserted into 
each jugular vein and a sham test was performed at the end of the acclimation period.  
The sham test consisted of repeated blood sample collections according to the EHC 
protocol.  The first of four consecutive EHC procedures was then initiated 24 hours after 
completion of the sham test.  During the tests, horses remained in their stalls and were 
provided with grass hay ad libitum. 
During the EHC procedure, three blood samples were collected at – 10, – 5, and 0 
min before initiating of the insulin and glucose infusions, to determine baseline glucose 
concentrations.  At t = 0, a priming insulin dose of 0.018 IU/kg was administered 
intravenously, immediately followed by the continuous rate infusion (CRI) of regular 
insulin at a rate of 0.003 IU/min/kg for 3h.  A CRI of 50% dextrose solution was 
concurrently administered using a syringe pump through the contralateral jugular 
catheter.  Blood glucose concentrations were monitored every 5 min during the 3-hour 
clamp using a handheld glucometer.11  These results were used to adjust the dextrose 
infusion rate to maintain euglycemia.  At 15 min intervals, blood samples were collected 
for measurement of serum insulin and plasma glucose concentrations.  The first 150 min 
period of each clamp was considered to be an equilibration period, so data from the final 
30 min was used to calculate whole-body glucose uptake (M), steady state insulin 
concentration (I), and their ratio (M/I), which is a measure of insulin sensitivity (Pratt et 
al. 2005).  Steady state insulin concentrations were calculated by averaging insulin 
                                                 
11 Precision Q•I•D System, MediSense, Birmingham, UK 
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concentrations measured during the last 30 min of the clamp.  The M value was derived 
as follows: 
M = GIR – SC 
where GIR is the glucose infusion rate (mmol/kg/min) and SC equals the space 
correction, which is calculated using the formula: 
SC = (G2 – G1) × (0.19 × bwt) / (T × bwt) 
where G1 and G2 are the blood glucose concentrations at the beginning and end of each 5 
min time interval (T) and (0.19 × bwt) is the glucose space in liters.  Coefficient of 
variation (CV) values for the M/I ratio were calculated for the 4 procedures performed in 




No adverse effects were registered during EHC procedures; however 3 of 16 EHC 
procedures were unsuccessful because steady state glucose concentrations could not be 
maintained.  Coefficient of variation values calculated for successful clamps in four 
horses were 20.2% (n = 4), 49.6% (n = 3), 13.3% (n = 3), and 20.2% (n = 3; Table 2.3).  
Mean ± SD interday CV for M/I ratios obtained from 4 horses undergoing 13 successful 




Results of this study demonstrated higher CV for the EHC procedure than the 
value of 14.1 ± 5.7 % previously reported by Pratt et al. (2005).  Furthermore, a steady 
state glucose concentration could not be attained in 3 of 16 clamps, which represents a 
19% failure rate for this procedure.  Calculation of an M/I ratio was not possible in these 
situations.  One explanation for our results may be that Pratt et al. (2005) restrained 
horses in stocks during EHC procedures, thereby limiting their activity.  Conversely, 
mares undergoing EHC procedures in this study were kept in stalls and their activity level 
varied from standing calmly to pacing nervously in their stalls, over the course of a single 
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test.  Exercise enhances glucose delivery and facilitates glucose uptake in the muscle by 
increasing capillary recruitment and stimulating GLUT4 translocation to the sarcolemma, 
respectively (Wasserman and Ayala 2005).  Therefore, altered muscle glucose delivery 
and uptake associated with different levels of activity, provide a plausible explanation for 
the higher CV registered in our study.  Furthermore, changes in activity frequently 
observed within a single EHC procedure may explain the difficulty of attaining a steady 
state glucose concentration during some of the clamps. 
Based on these results, it is apparent that horses should be restrained in standing 
stocks during the EHC procedure to control for alterations in glucose and insulin 
dynamics associated with differences in physical activity.  Additionally, horses that are 
not accustomed to standing in stocks and being separated from their herd mates should be 
trained to tolerate long-term confinement to standing stocks before EHC procedures are 
performed in order to prevent stress-induced changes in insulin sensitivity (Harewood 
2005; Irvine and Alexander 1994; Rosmond 2005).  Housing the horse with a companion 
during the EHC procedure may also reduce the stress associated with separation. 
Results demonstrated that the EHC had a 19% failure rate and low repeatability in 
our research setting, so the FSIGTT was selected to evaluate the effects of endotoxemia 
on glucose and insulin dynamics in horses. 
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Table 2.3 – Ratios of whole body glucose uptake and steady state insulin concentrations 
(M/I) registered in four horses during four euglycemic hyperinsulinemic clamps 
performed 24 h apart.  Coefficient of variation values are calculated for the M/I ratios for 
successful clamps.  Euglycemic hyperinsulinemic clamps that failed, due to unsuccessful 
clamping of blood glucose concentrations during the last 30 min of the procedures, are 
indicated with the word “failed”. 
M/I ratio (×10-4) 
Horse 
24h clamp 48h clamp 72h clamp 96h clamp 
CV (%) 
1 1.47 1.37 1.34 0.89 20.22 
2 Failed 0.43 0.4 0.14 49.64 
3 0.55 0.71 Failed 0.65 13.29 
4 Failed 0.3 0.24 0.21 20.21 
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CHAPTER 3  
Evaluation of the insulin-modified frequently sampled 




Insulin resistance (IR), is an important condition in horses, and has become a 
frequent subject of publications in equine medicine in recent years (Hurley and Moore 
2007).  Insulin resistance is a state in which normal concentrations of insulin fail to elicit 
a normal physiologic response (Kahn 1978).  Previous studies have suggested an 
association between IR and various clinical conditions, including laminitis and reduced 
reproductive performance (Hurley and Moore 2007; Johnson 2002; Pass et al. 1998; 
Treiber et al. 2006a; Treiber et al. 2006b). 
There are several methods available to evaluate glucose and insulin dynamics in 
the horse.  Nonspecific indicators of IR include basal hyperglycemia, basal 
hyperinsulinemia, decreased glucose tolerance and altered results of proxy measurements 
(Kronfeld et al. 2005a; Treiber et al. 2005b).  Ponies suffering from prelaminitic 
metabolic syndrome have been successfully identified using the modified insulin-to-
glucose ratio and reciprocal of the square root of insulin proxy measurements (Treiber et 
al. 2006b).  Data obtained from the combined glucose-insulin test (CGIT) has facilitated 
the estimation of insulin sensitivity (SI), glucose effectiveness (Sg) and net insulin 
response in mares (Frank et al. 2005a; Frank et al. 2005b).  Nevertheless, quantitative, 
specific assessment of insulin sensitivity in horses can only be achieved by using the 
euglycemic hyperinsulinemic clamp (EHC), the minimal model analysis of the 
frequently sampled intravenous glucose tolerance test (FSIGTT) or the insulin 
suppression test (Kronfeld et al. 2005a).  Although it was demonstrated in one study that 
minimal modeling of the FSIGTT has lower repeatability than the EHC (Pratt et al. 
2005), the minimal model provides additional information about glucose and insulin 
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dynamics such as Sg and the acute insulin response to glucose (AIRg), which are not 
supplied by the EHC (Kronfeld et al. 2005a). 
Minimal modeling of FSIGTT data was first applied to horses by Hoffmann et al. 
(2003), using the same technique utilized in man.  Dosages of dextrose and insulin 
administered during this established FSIGTT are identical to those used in humans 
(Avogaro et al. 1996; Bergman et al. 1987; Hoffman et al. 2003; Trout et al. 2007).  
However, plasma glucose concentrations above 350 mg/dL are often detected during this 
established FSIGTT, which exceeds the estimated renal threshold for glucose of 160 to 
180 mg/dL for horses (Carlson 2002). 
If urinary glucose spilling is present during the established FSIGTT it is likely to 
influence data supplied by minimal model analysis, because urinary glucose loss is not 
taken into account in this model (Avogaro et al. 1996).  The extent to which this 
deficiency influences minimal model indices has not yet been investigated (Avogaro et 
al. 1996).  Glucose concentrations exceeding the estimated renal threshold occur early in 
the FSIGTT, so Sg values, calculated mainly between 8 and 20 min after glucose bolus, 
are most likely to be affected (Avogaro et al. 1996).  Furthermore, plasma glucose 
concentrations can remain above renal threshold beyond 20 min in horses (Toth et al. 
2008), which could influence SI values. 
The pancreatic insulin response to different glucose loads has never been studied 
in horses.  Intravenous administration of 0.33 g/kg bwt dextrose to horses as a bolus 
resulted in maximum glucose and insulin concentrations 1 and 2 min relative to glucose 
infusion, respectively, but measurements were only performed for 30 min (Giraudet et al. 
1994).  Altered pancreatic function has been associated with IR in several species, 
including the horse (Brunton et al. 2006; Hoffman et al. 2003; Toth et al. 2008), which 
suggests that this aspect of glucose metabolism warrants further investigation.  Given that 
the horse has been recently proposed as a potential model for human metabolic 
syndrome, careful investigation of methods used for measuring insulin and glucose 
dynamics in horses is also warranted (Hodavance et al. 2007). 
In the study reported here we aimed to evaluate the effects of different dosages of 
dextrose and insulin on the glycemic and insulin response in horses during the FSIGTT.  
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We also aimed to develop a new FSIGTT that minimized urine glucose spillover and 
compare it with the established FSIGTT and the CGIT, which is another commonly used 
test for IR in horses.  It was hypothesized that lowering the dextrose dosage administered 
during the FSIGTT would eliminate urinary glucose spillover, while still providing 
sufficient data for minimal model analysis.  We also hypothesized that marked urinary 
glucose spillover occurs during the established FSIGTT and CGIT. 
 
3.2 Materials and Methods 
 
Horses – Six mares from the University of Tennessee teaching and research herd 
were evaluated during the study period (February to June 2007).  Horses were admitted to 
the teaching hospital in pairs.  To eliminate differences attributable to sex, only mares 
were selected.  Horses were 6 to 13 years of age (mean age, 9.3 years; median, 9 years) 
and breeds of horse included Quarter horse / Tennessee Walking horse crossbred (n = 3), 
Quarter horse (2) and Standardbred (1).  Horses were weighed at the time of admission; 
weights ranged from 461 kg to 523 kg (mean weight, 497 kg; median, 501 kg) with body 
condition scores (on a scale of 1 to 9) ranging from 4 to 6 (Henneke et al. 1983).  The 
study protocol was approved by the University of Tennessee Institutional Animal Care 
and Use Committee. 
Experimental design – Effects of six different dextrose and insulin dosages on 
glucose and insulin dynamics were assessed in six mares across a 5–week period.  Urine 
glucose spillover was also measured during the last week of the testing period.  Horses 
were admitted to the hospital 3 days before the beginning of the study period to facilitate 
acclimation to their new environment.  Animals were weighed and physical examinations 
were performed upon admission, and each horse was housed separately in 3.7-m × 3.7-m 
stall.  Grass hay and water were provided ad libitum over the course of the study period.  
Mares were examined to ensure that they were not pregnant and 2.2 mg/mL altrenogest1 
(10mL; orally once a day) was administered throughout the study to control for the 
                                                 
1 Regu-Mate®, Intervet Inc, Millsboro, Del 
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confounding effects of estrus cycle.  Each week during the study, an IV catheter was 
placed on day 1 and left in place for 4 days. 
In the first phase of the study, each horse received six different dosages of 
dextrose2 (50, 100, 150, 200, 250 or 300 mg/kg bwt) on days 2, 3, 4 of weeks one and 
two, according to a Latin square design.  Insulin was not administered during this phase 
of the study.  Blood samples were collected in accordance with the FSIGTT protocol. 
During the second phase of the study, on days 2, 3, 4 of weeks three and four, 
each horse was given 300 mg/kg bwt dextrose followed by a variable dosage of regular 
insulin3 (5, 10, 15, 20, 25 and 30 mU/kg bwt) 20 min later, with the order of insulin 
administration determined by the Latin-square design.  Blood samples were again 
collected in accordance with the FSIGTT protocol. 
During the third phase of the study, on days 2, 3 and 4 of week five, each horse 
was given the following three different combinations of dextrose and insulin: 300 mg/kg 
bwt dextrose followed by 30 mU/kg insulin 20 min later (established FSIGTT), 100 
mg/kg bwt dextrose followed by 20 mU/kg insulin 20 min later (new FSIGTT) and 150 
mg/kg bwt dextrose and 100 mU/kg insulin administered sequentially at the beginning of 
the test (CGIT).  The sequence of treatments was determined by a crossover study design.  
A 24-French Foley catheter with a 30 mL inflatable balloon was inserted into the urinary 
bladder and urine samples were collected immediately before dextrose administration and 
then every 10 min for 3 h thereafter.  Blood samples were collected according to the 
FSIGTT and CGIT protocols.  Urinary catheters were removed every day at the 
conclusion of the study. 
After completing the first three phases of the study an additional fourth phase was 
designed to determine total urinary glucose loss during the established FSIGTT and new 
FSIGTT and CGIT in two of the mares.  Urine collection was achieved using the same 
methodology as that described above, except that all urine produced was collected during 
the procedure, including urine that was voided around the catheter. 
                                                 
2 Dextrose 50% injection, Abbott Laboratories, North Chicago, Ill 
3 Humulin R, Eli Lilly and Co, Indianapolis, Ind. 
 75
FSIGTT – On the first day of each study week, horses were weighed and a 14-
gauge polypropylene catheter4 was inserted into the jugular vein.  Horses were given 
access to grass hay and water ad libitum during the test period.  Patency of the IV 
catheter was maintained between tests by infusion of 5 mL of 0.9% saline solution 
containing heparin (4 U/mL) every 6h.  Dextrose (50% wt/vol) solution was infused 
intravenously at six different dosages (50, 100, 150, 200, 250 and 300 mg of glucose/kg) 
via an infusion set5 (length, 30 cm; internal diameter, 0.014 cm) attached to the catheter, 
followed by injection of saline solution containing heparin.  No insulin was administered 
during this part of the study.  Blood samples were collected via the catheter immediately 
before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16,19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 
80, 90, 100, 120, 150, and 180 min after dextrose infusion.  At each time point, 3 mL 
blood was withdrawn from the infusion line and discarded.  A 6 mL blood sample was 
then collected, followed by infusion of 5 mL of saline solution containing heparin.  Half 
the volume of blood collected was transferred to a tube containing sodium heparin, which 
was immediately cooled on ice and refrigerated.  The remaining blood sample was 
allowed to clot at 22oC for 3h and serum was harvested via low-speed (1,000 × g) 
centrifugation.  Plasma and serum samples were stored at –20oC until further analysis. 
During the third and fourth week of the study, a 300 mg/kg bolus infusion of 
dextrose (50% wt/vol) solution was administered to each horse via the infusion line and 
catheter, followed by 5 ml of saline solution containing heparin.  Blood samples were 
collected again via the catheter immediately before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 
16, and 19 min after infusion of dextrose.  At 20 min, regular insulin was infused 
intravenously at one of six different dosages (5, 10, 15, 20, 25 and 30 mU/kg) according 
to the Latin square design, and then 20 mL saline solution containing heparin was infused 
to clear the catheter.  Further blood samples were collected at 22, 23, 24, 25, 27, 30, 35, 
40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 minutes. Samples were handled identically 
to that described above. 
CGIT procedure – The method first described by Eiler et al. (2005), was used 
with increased sampling frequency during the first 30 min of the procedure.  At t = 0, 
                                                 
4 Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, Ill 
5 Butterfly, Abbott Laboratories, North Chicago, Ill. 
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dextrose solution (50% wt/vol) was infused intravenously at a dosage of 150 mg/kg bwt, 
immediately followed by regular insulin at a dosage of 100 mU/kg bwt via the infusion 
set attached to the catheter, followed by infusion of 20 mL saline solution containing 
heparin.  Blood samples were collected via the catheter immediately before and 1, 2, 3, 4, 
5, 6, 7, 8, 10, 12, 14, 16,19, 22, 23, 24, 25, 35, 45, 60, 75, 90, 105, 120, 135, 150, 165, 
and 180 min after dextrose infusion.  Samples were handled identically to that described 
for the FSIGTT procedure. 
Urine collection – To facilitate urine collection for the third and fourth phases of 
the study, a 24-French Foley catheter, with a 30 mL inflatable balloon, was inserted into 
the urinary bladder, and left in-situ during the course of procedures.  In the third phase, 
the bladder was emptied and urine samples were collected every 10 min to measure 
urinary glucose concentrations. 
During the fourth phase of the study, urine production was established in two 
mares by collecting all urine from the bladder every 10 min over the course of each test.  
If any urine was lost due to leakage around the Foley catheter it was collected from the 
floor, which was covered with a plastic sheet to facilitate collection.  At the end of each 
procedure, urine samples from each horse were pooled, and total urine volume and urine 
glucose concentration were determined.  Urinary glucose loss was calculated as the 
product of urine volume and urine glucose concentration, and expressed as a percentage 
of the total amount of glucose administered. 
Plasma and urine glucose concentrations and serum insulin concentrations – 
Glucose concentrations were measured by use of a colorimetric assay6 on an automated 
discrete analyzer (D'Agord Schaan et al. 2003).  Insulin concentrations were determined 
by use of a radioimmunoassay7 that has been validated for equine insulin (Freestone et al. 
1991).  Each sample was assayed in duplicate and intra-assay coefficients of variation of 
less than 5% or 10% were required for acceptance of glucose and insulin assay results, 
respectively. 
Interpretation of FSIGTT data by the minimal model – Values for SI, Sg, 
AIRg, and disposition index (DI) were calculated for each FSIGTT in accordance with 
                                                 
6 Glucose, Roche Diagnostic Systems Inc, Somerville, NJ. 
7 Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, Calif. 
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the minimal model (Bergman et al. 1981) by use of commercially available software8,9 
and previously described methods (Hoffman et al. 2003).  Disposition index was 
calculated by multiplying AIRg by SI.  
Statistical analysis – Area under the curve for glucose (AUCg) and area under 
the curve for insulin (AUCi) values were calculated for each treatment in each phase of 
the study from the glucose and insulin concentrations measured during both FSIGTT 
procedures and the CGIT, by use of the trapezoidal method, using commercially available 
computer software (SAS  9.1)10.  During phases one and two, mixed model analysis of 
variance with orthogonal polynomial contrasts was used to compare AUCi and AUCg 
values as well as minimal model variables, including SI, Sg, AIRg and DI, among 
treatments.  To evaluate urinary glucose spilling, urinary AUCg (uAUCg) values were 
calculated during the third phase of the study based on urine glucose concentrations, 
using the trapezoidal method.  Mixed model analysis of variance was used to evaluate the 
effects of treatments on AUCi, AUCg, uAUCg, and minimal model variables.  Non-
normally distributed data were log transformed for statistical analysis.  If normal 
distribution could not be achieved by transformation, then the non-parametric Mann-
Whitney U test was applied.  When a significant treatment × time effect was detected, a 
protected Least Significant Difference mean separation method for multiple comparisons 
was used to identify significant differences between least squares means.  Results are 
reported as true means ± SD or medians and 25 and 75 percentiles.  Correlation was 
calculated for AUCi and AIRg values obtained throughout the study.  Linear regression 
was performed using urinary glucose measurements during the third phase of study to 





                                                 
8 MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA. 
9 Stata 9.2, Stata Corporation, College Station, TX. 




No abnormalities were detected during daily physical examinations.  
Experimental procedures remained well tolerated by each horse, with the exception of 
one mare which showed mild signs of abdominal pain following insertion of the urinary 
catheter, necessitating its removal 80 min after insertion.  Collection of a urine sample 
was unsuccessful at 28 of 285 time points during the study, including 10 samples lost 
from the mare that did not tolerate the urinary catheter.  Evaluation of baseline insulin 
concentrations and SI values revealed that one horse included in the study was insulin 
resistant.  The mean resting insulin concentration for this horse was 58.3 μU/mL and 
mean SI was determined to be 0.23 × 10–4 L•min-1•mU-1.  Therefore, data from this horse 
were excluded from statistical analyses and results reported here are for 5 horses.  
In the first phase of the study, a significant linear relationship (P < 0.001) was 
detected between the dextrose dosage administered and AUCg, AUCi, and AIRg values, 
with all three variables increasing as the dextrose dosage increased (Table 3.1, Figures 
3.1 and 3.2).  A plateau for AUCg was detected as dextrose dosages of 200 mg/kg or 
above were administered (Figure 3.3). 
During the second phase of the study, a strong inverse linear relationship (P = 
0.023) was apparent between insulin dosage and AUCg during the FSIGTT (Figure 3.4), 
with the AUCg decreasing as the insulin dosage increased.  However, altering the insulin 
dosage did not significantly affect AUCi (P = 0.482), SI (P = 0.878), Sg (P = 0.460), 
AIRg (P = 0.731) and DI (P = 0.948; Table 3.2). 
In the third phase of the study, AUCg (P = 0.003) and AUCi (P < 0.001) differed 
significantly among tests (Figure 3.5).  No significant difference was registered for SI (P 
= 0.424), Sg (P = 0.134), AIRg (P = 0.502) and DI (P = 0.812) when the new and 
established FSIGTT were compared (Table 3.3).  A strong correlation (R = 0.709, P < 
0.001) was found between AUCi and AIRg values measured throughout the study. 
Urine AUCg differed significantly (P < 0.001) among tests, with values of 161.4 
g/dL•min, 34.2 g/dL•min and 58.9 g/dL•min detected for the established FSIGTT, new 
FSIGTT, and CGIT, respectively (Figure 3.5).   
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Table 3.1 – Mean ± SD AUCg and AUCi values median and 25th and 75th percentile 
AIRg values, and obtained from 5 horses following intravenous administration of 50, 
100, 150, 200, 250 and 300 mg/kg bwt 50% dextrose solution.  Procedures were 
conducted over a period of two weeks. 
Glucose dosage (mg/kg bwt) 
Variable 









± 0.6 a 
17.7 
± 0.6 a 
18.3 
± 0.8 a 
21.2 


















± 4.8 c 
9.6 
± 6.3 c < 0.001
median 417a 561a 644b,c 519b,a 756c 785c 
25th  409 504 614 482 543 711 AIRg
 
(mU•min•L-1) 
75th  523 573 686 619 787 1018 
< 0.001
a-c For variables with significant (P < 0.05) treatment effects, values with different 
superscripts differ significantly, as determined by use of an ANOVA and via comparison 
of least squares mean values by use of a Least Significant Difference adjustment. 























Figure 3.1 – Mean ± SE plasma glucose concentrations registered during the first phase 
of the study following intravenous administration of six different dosages of 50% 
dextrose solution to 5 horses.  Dosages: 50 mg/kg (solid triangles), 100 mg/kg (open 
circles), 150 mg/kg (solid squares), 200 mg/kg (open triangles), 250 mg/kg (solid circles) 






















Figure 3.2 – Mean ± SE blood insulin concentrations registered during the first phase of 
the study following intravenous administration of six different dosages of 50% dextrose 
solution to 5 horses.  Doses included: 50 mg/kg (solid triangles), 100 mg/kg (open 
circles), 150 mg/kg (solid squares), 200 mg/kg (open triangles), 250 mg/kg (solid circles) 
and 300 mg/kg (open squares). 
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Figure 3.3 – Mean ± SE area under the curve for glucose (AUCg) values calculated 
during the first phase of the study following intravenous administration of six different 
dosages of 50% dextrose solution to 5 horses.  
a-b Values with different superscripts differ significantly (P < 0.05), as determined by 



























Figure 3.4 – Mean ± SE area under the curve for glucose (AUCg) values calculated in 5 
horses during the second phase of the study after intravenous administration of 300 
mg/kg 50% dextrose solution at t = 0 min followed by 6 different dosages of insulin (5, 
10, 15, 20, 25 and 30 mU/kg) at t = 20 min. 
a-b Values with different superscripts differ significantly (P < 0.05), as determined by 


























Table 3.2 – Mean ± SD AUCg and AUCi values, and median and 25th and 75th percentile 
minimal model analysis values from 5 horses following intravenous administration of 
300 mg/kg bwt 50% dextrose solution at t = 0, followed by the administration of 5, 10, 
15, 20, 25 and 30 mU/kg bwt insulin at t = 20 min. 
Insulin dosage (mU/kg bwt) 
 









± 2.3 a 
22.9 


























median 1.75 1.17 1.33 1.04 1.71 1.97 
25th  1.04 0.94 0.72 1.01 0.31 0.62 
SI 
(L•min-1•mU-1) 
× 10–4 75th  3.22 1.7 1.68 1.17 2.74 2.32 
0.878
median 0.52 2.45 2.92 2.07 1.77 1.95 
25th  0.35 0.9 1.81 1.69 1.12 1.87 
Sg 
(min-1) 
×10–2 75th  1.49 2.64 2.93 2.15 2.21 2.41 
0.460
median 588 651 549 646 654 732 
25th   551 588 547 597 594 562 AIRg
 
(mU•min•L-1) 
75th  751 759 712 765 719 816 
0.731
median 9.63 10.44 8.36 8.59 10.18 11.09 
25th  7.96 3.93 7.27 6.72 2.00 4.54 DI ×10-2 
75th  24.16 12.92 9.13 8.97 19.70 11.68 
0.948
a-c For variables with significant (P < 0.05) treatment effects, mean values with different 
superscripts differ significantly, as determined by use of an ANOVA and via comparison 
of least squares mean values by use of a Least Significant Difference adjustment. 
Nonparametric Mann-Whitney U test was used to compare SI, Sg, AIRg and DI values 
among treatment groups. 
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Figure 3.5 – Mean ± SE area under the curve for urinary glucose (uAUCg), area under 
the curve for glucose (AUCg) and area under curve for insulin (AUCi) values calculated 
for 5 horses during the third phase of the study.  Each horse underwent three tests 
according to a crossover study design: established FSIGTT (300 mg/kg dextrose and 30 
mU/kg insulin; white column), new FSIGTT (100 mg/kg dextrose and 20 mU/kg insulin; 
solid column) and the CGIT (150 mg/kg dextrose and 100 mU/kg insulin; shaded 
column). 
a-c Within each variable, mean values with different superscripts differ significantly (P < 
0.05), as determined by ANOVA and comparison of least squares mean values by use of 
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Table 3.3 – Mean ± SD urine AUCg, AUCi, AUCg and minimal model analysis values 
obtained from 6 horses using the established, new FSIGTT, and CGIT method.  Tests 











(g/dL•min) 161.4 ± 40.2
a 34.2 ± 16.4 b 58.9 ± 8.6 c < 0.001 
AUCg 
(g/dL•min) 20.8 ± 2.2 
a 18.4 ± 1.5 b 15.7 ± 1.2 c 0.003 
AUCi 
(mU/mL•min) 12.4 ± 3.7 




1.64 ± 0.92 2.02 ± 1.54 N/A 0.424 
Sg 
 ( min-1) 
× 10–2 
2.3 ± 0.7 1.6 ± 0.8 N/A 0.133 
AIRg 
(mU•min•L-1) 707 ± 121 632 ± 255 N/A 0.502 
DI 
(× 10-2) 11.25 ± 5.72 11.44 ± 8.54 N/A 0.811 
a-c For variables with significant (P < 0.05) treatment effects, mean values with different 
superscripts differ significantly, as determined by use of an ANOVA and via comparison 
of least squares mean values by use of a Least Significant Difference adjustment. 
N/A = Not applicable; minimal model analysis was not performed. 
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Linear regression calculated from the urinary glucose concentrations during the 
linear phase revealed that the projected time for urinary glucose spillover to cease was 
53.7 min, 27.6 min and 44.8 min, respectively for the tests evaluated.  Mean ± SD % 
urinary glucose loss relative to the mass of glucose administered intravenously for two 
horses undergoing the additional urine collection procedure was 10.11 ± 1.51 %, 2.66 ± 
0.58 % and 4.97 ± 2.14 %, respectively for the established FSIGTT, new FSIGTT and 




The present study demonstrated that increasing the dosage of dextrose 
administered during the FSIGTT caused parallel increases in AUCg, AUCi and AIRg 
values.  A plateau was registered for the AUCg values when the glucose dosage reached 
200 mg/dL.  Increasing the insulin dosage, however, only influenced the AUCg and left 
minimal model and AUCi values unchanged.  Marked urinary glucose spilling was 
apparent when the established FSIGTT was performed in horses.  The new FSIGTT, 
which is performed by infusing 100 mg/kg dextrose and 20 mU/kg insulin, provided 
sufficient data for minimal model analysis while minimizing urinary glucose loss. 
In the first phase of the study, AUCg increased in parallel with the increase in 
dextrose dosage, however, a plateau was reached with dextrose dosages of 200 mg/kg or 
above.  Although no urinary glucose measurements were performed in this phase of the 
study, we assume that this plateau resulted from increased urinary glucose loss.  The 
sudden decline in blood glucose concentrations immediately following the peak after 200, 
250, and 300 mg/kg dextrose was administered may have been a result of immediate 
urinary glucose loss, as well as mixing within the body glucose space.  The same factors 
were implicated for the steep decrease in blood glucose concentrations following the peak 
after intravenous glucose boluses were administered in two studies performed in dogs 
(Kaneko et al. 1978; Rottiers et al. 1981).  Additionally, increased blood glucose 
concentrations are expected to facilitate glucose disposal by their mass effect.  This 
ability  of  glucose  per  se  to  normalize  its  concentration  through  actions  on  glucose  
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Table 3.4 – Net glucose mass infused, total urine volume, urine glucose concentration, 
net urinary glucose loss and glucose lost (%) registered in two horses during the 
established FSIGTT, new FSIGTT and CGIT. 
 Horse Established FSIGTT 
New 
FSIGTT CGIT 
A 163.6 54.5 81.8 Net glucose mass 
administered  
(g/horse) B 155.5 51.8 77.7 
A 750 630 570 Total urine 
volume  
(mL) B 960 480 455 
A 1973.1 265.9 495.9 Urine glucose 
concentration 
(mg/dL) B 1809.9 242.5 1107.5 
A 14.8 1.7 2.8 Net urinary 
glucose loss  
(g) B 17.4 1.2 5 
A 9 3.1 3.5 Glucose lost  
(%) B 11.2 2.3 6.5 
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production and utilization, independent of insulin, is represented by the parameter Sg in 
the minimal model (Pacini et al. 1998).  Indeed, Sg values appeared to be higher in the 
third phase of the study for the established FSIGTT when 300 mg/kg dextrose was 
administered, compared with the new FSIGTT when 100 mg/kg dextrose was infused, 
although the difference was not significant.  Our finding of a strong linear relationship 
between glucose dosage and AUCg is in agreement with the work of Rottiers et al. 
(1981). This group demonstrated that administration of five progressively increasing 
glucose loads caused significantly higher successive post-infusion plasma glucose 
concentrations in dogs (Rottiers et al. 1981).  In the study reported here, AUCi and AIRg 
also increased as the dextrose dosage increased.  Since AIRg provides a measure of 
insulin secretion over the first 10 minutes following glucose administration (Tiley et al. 
2007) it was expected that changes in AIRg would mirror the changes in AUCi.  Several 
studies have demonstrated that total insulin secretion, which is represented by AIRg in 
the minimal model, increases as the glucose dosage increases, which is an observation 
that is similar to the increasing AUCi values registered in our experiment (Lerner and 
Porte 1971; Rottiers et al. 1981). 
It was interesting to note that insulin secretion occurred as a single phase response 
in horses included in this study.  Attributes of biphasic insulin secretion, including a nadir 
and a second insulin peak were absent in the horses studied here.  Our findings are 
consistent with those of Giraudet et al. (1994).  This group found that insulin 
concentrations abruptly increased and then gradually decreased in horses that received 
0.33 g/kg bwt glucose intravenously (Giraudet et al. 1994).  In humans and rats, the 
sudden, sustained increase in plasma glucose concentration triggers biphasic insulin 
secretion, characterized by a rapid increase with a peak, an interpeak nadir and a 
subsequent slower increasing phase (Caumo and Luzi 2004; Henquin et al. 2002).  The 
first phase of the insulin response comes from the readily releasable pool granules located 
adjacent to the cell membrane of the pancreatic β-cells (Bratanova-Tochkova et al. 2002).  
For the second phase to occur, replenishment of the readily releasable pool from the 
reserve pool is necessary (Bratanova-Tochkova et al. 2002).  Second phase insulin 
secretion also requires the augmenting action of glucose, and the magnitude of the second 
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phase response increases with the concentration of glucose administered (Henquin et al. 
2002).  Indeed, prolonged elevation of glucose concentration during the hyperglycemic 
clamp facilitated clearer determination of the second phase insulin response than the 
intravenous glucose tolerance test (Caumo and Luzi 2004). 
Species differences have been also described for biphasic insulin secretion 
(Henquin et al. 2002).  Second phase insulin response to glucose in isolated Islets of 
Langerhans from rats usually increase above the first phase peak, whereas the second 
phase of glucose-induced insulin secretion is often flat and lower than the first phase peak 
in mice (Henquin et al. 2002).  Administration of glucose to dogs at different dosages has 
also failed to elicit biphasic insulin secretion (Kaneko et al. 1978; Rottiers et al. 1981).  
Furthermore, secondary plasma insulin peaks registered in human subjects undergoing 
glucose tolerance tests correspond to exogenous insulin administration or injection of the 
insulin secretagogue tolbutamide (Bergman et al. 1987; Katz et al. 2000).  In the first 
phase of the study reported here, dextrose was administered as a single bolus and blood 
glucose concentrations were not sustained, neither was any insulin or insulin 
secretagogue administered following the glucose infusion, which may explain the 
absence of a distinct second phase of insulin secretion. 
During the second phase of the study, AUCg decreased as the insulin dosage 
increased, however, no significant differences were registered for AUCi, SI, Sg, AIRg 
and DI.  Our inability to detect significant differences in AUCi values in spite of 
administering markedly different dosages of exogenous insulin was an unexpected 
finding.  In retrospect, high variance of AUCi values provides a plausible explanation for 
the lack of significant difference between treatments.  The higher coefficient of variation 
values encountered when plasma insulin concentrations were measured, relative to those 
obtained for plasma glucose, may be partially responsible for the high variance observed 
for AUCi.  Additionally, individual differences in stress-induced cortisol responses 
(Ralston 2002) can influence the insulin response, and by doing so introduce further 
variability into AUCi values.  The absence of a dosage effect on minimal model variables 
may indicate that even small insulin doses are sufficient to facilitate cellular glucose 
uptake.  Indeed the original FSIGTT design did not include administration of exogenous 
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insulin; this was introduced later to facilitate minimal modeling in diabetic patients 
(Pacini et al. 1998).   Previous studies performed in horses used insulin dosages for the 
FSIGTT that ranges from 1.5 mU/kg bwt (Treiber et al. 2005a) to 30 mU/kg bwt 
(Hoffman et al. 2003). 
In the third phase of the study, our primary goal was to compare the newly 
developed FSIGTT procedure with the established FSIGTT and CGIT with respect to 
urinary glucose spillover.  A dextrose dosage of 100 mg/kg bwt was selected for the new 
FSIGTT because measurements of blood glucose during the first phase of the study 
suggested that this dosage could eliminate urinary glucose spillover.  Additionally, 
administration of a lower dextrose dosage than the 300 mg/kg bwt used during the 
established FSIGTT facilitates rapid administration via the IV catheter.  Rapid infusion of 
dextrose is advantageous because the minimal model assumes that the glucose is supplied 
to the system with a pulse width of zero (personal communication; Ray Boston 2008).  
The insulin dosage used in the new FSIGTT was selected (20 mU/kg bwt) with the aim of 
facilitating glucose disposal in horses, without causing clinical hypoglycemia.  This 
insulin dosage was also recommended by other investigators after completion of a study 
involving the established FSIGTT (Treiber et al. 2005a). 
Analysis of uAUCg revealed that urinary glucose spillover was significantly 
lower during the new FSIGTT, when compared with the established FSIGTT or CGIT, 
but was not completely abolished.  Increased urine production was also detected during 
the established FSIGTT, suggesting that osmotic diuresis was occuring as a result of 
glucose spilling into the urine.  On average, more than 10 % of glucose administered 
during the established FSIGTT was lost to the urine, compared with less than 3 % for the 
new FSIGTT.  These results are in agreement with previous findings in dogs 
demonstrating that urinary glucose excretion varies directly with the size of glucose load 
(Kaneko et al. 1978).  Regression analysis of urinary glucose concentration demonstrated 
that cessation of urinary glucose spilling occurred the earliest with the new FSIGTT, and 
the latest with the established FSIGTT.  Although glucose was still apparent in the urine 
beyond the time suggested by the regression analysis, this was most likely a result of 
inadequate clearance of glucose-containing urine from the bladder.  Incomplete emptying 
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of the bladder would be expected to affect subsequent samples.  Glucose is normally 
freely filtered at the glomerulus and most of the filtered glucose is reabsorbed in the 
proximal tubules with a smaller percentage in the more distal segments of the nephron 
(Brodehl et al. 1987).  Urine typically contains only minimal amounts of glucose, 
however, it has been reported that glucosuria develops when blood glucose 
concentrations exceed 160 to 180 mg/dL in horses (Carlson 2002), which is when the 
resorptive capacity of the renal tubules is exceeded (Brodehl et al. 1987). 
Minimal model variables obtained for the new and established FSIGTT did not 
differ significantly. Mean SI values for the new and established FSIGTT were 2.02 × 10-4 
L·min-1·mU-1 and 1.64 × 10-4 L·min-1·mU-1, respectively and these values compare 
favorably with results of previous studies (Hoffman et al. 2003; Treiber et al. 2005b).  In 
these studies mean SI values of 2.1 × 10-4 L·min-1·mU-1 and 1.9 × 10-4 L·min-1·mU-1 were 
registered for 46 horses (Treiber et al. 2005b) and in 4 non-obese thoroughbred geldings 
(Hoffman et al. 2003), respectively.  However, higher (3.0 and 2.9 × 10-4 L•min-1•mU-1) 
mean SI values were detected in a previous study of sixteen mares performed by our 
group (Toth et al. 2008).  Lower mean SI values of 0.39 × 10-4 L·min-1·mU-1 and 0.08 × 
10-4 L·min-1·mU-1 were also measured in healthy ponies and in ponies with history of 
laminitis, respectively (Treiber 2005).  However, there is evidence to suggest that ponies 
have lower insulin sensitivity than horses (Rijnen and van der Kolk 2003). 
Glucose effectiveness values measured in the present study compared favorably 
with results obtained in previous studies (Hoffman et al. 2003; Toth et al. 2008; Treiber 
et al. 2005b).  Mean Sg values registered for non-obese and moderately obese 
thoroughbred geldings were 1.43 × 10-2 min-1 and 1.59 × 10-2 min-1, respectively 
(Hoffman et al. 2003). 
When the minimal model is applied, AIRg is estimated from serum insulin 
concentrations measured during the first 10 minutes following exogenous glucose 
administration (Tiley et al. 2007), therefore the high correlation between AUCi and AIRg 
recorded throughout the study was expected.  Conversely, it was surprising that AIRg 
values did not differ significantly between the new FSIGTT and established FSIGTT, 
despite the significant difference registered for AUCi when the two tests were compared.  
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This latter finding may be explained by the fact that different exogenous insulin dosages 
administered at 20 min contributed to the significant difference in AUCi between the two 
tests.  In contrast, only insulin concentrations measured during the first 10 minutes of the 
FSIGTT, prior to exogenous insulin administration, are included in the minimal model 
when AIRg is estimated.  Mean AIRg values previously detected in 16 mixed breed 
(Quarter Horse / Tennessee Walking Horse) mares (Toth et al. 2008) were 503 and 520 
mU·min·L-1 and these values are consistent with results obtained in the current study.  
However, AIRg values measured in non-obese, moderately obese, and obese 
Thoroughbred horses were 211, 221, and 408 mU·min·L-1, respectively (Hoffman et al. 
2003), which are lower than those reported here. 
The CGIT was completed in each horse without complications during the third 
phase of the study.  After its initial description by Eiler et al. (2005), the CGIT has been 
used in several studies to identify horses with IR, and to establish glucose and insulin 
dynamics (Frank et al. 2005a; Frank et al. 2006).  In the study reported here, the mean ± 
SD AUCg value registered during the CGIT was 15.7 ± 1.2 × 103 mg/dL•min, which 
compares favorably to 12.7 × 103 mg/dL•min registered in eight healthy mares (Frank et 
al. 2005a) and to the median value of 15.5 × 103 mg/dL•min reported for obese horses 
with IR (Frank et al. 2006).  In contrast the mean AUCi value of 18.3 × 103 μU/mL•min 
measured in this study was somewhat higher than the range of 10.6 – 13.2 × 103 
μU/mL•min reported for 5 nonobese horses (Frank et al. 2006) but lower than 25 × 103 
μU/mL•min demonstrated in 8 healthy mares.  Serum insulin and blood glucose 
concentrations were measured more frequently during the CGIT in this study than 
recommended in the original report (Eiler et al. 2005).  Calculation of AUCg and AUCi 
from a larger number of samples should increase accuracy, and this may explain why our 
results differed from those of previous studies. 
In conclusion, results of this study indicate that glucose dosages equal to or higher 
than 200 mg/kg bwt result in AUCg plateau, which suggests that the 300 mg/kg bwt 
dosage used in the established FSIGTT is too high.  Furthermore, profuse urinary glucose 
spilling was detected during the established FSIGTT.  Although we were unable to 
demonstrate significant difference in minimal model values between the new and 
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established FSIGTT procedures because of high variability, it is likely that urinary 
glucose loss confounds minimal model analysis results, since one assumption of the 
model is that glucose exiting the blood stream is used by peripheral tissues.  A new 
FSIGTT was developed for use in horses to minimize urinary glucose loss.  In addition, 
the smaller dextrose dosage used in the new FSIGTT facilitates more rapid 
administration, which may also improve the accuracy of minimal model analysis. 
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CHAPTER 4  
Evaluation of C-peptide dynamics and clearance in horses 




Insulin is a peptide hormone containing A and B chain that is synthesized by the 
β-cells of the pancreatic islets of Langerhans (Wahren et al. 2000; Wilcox 2005).  Upon 
translation of the insulin mRNA, pre-proinsulin is generated and this molecule is 
comprised of a signal peptide, the B chain, the connecting peptide (C-peptide) and the A 
chain (Wilcox 2005).  Proinsulin is synthesized by removal of the signal peptide from 
pre-proinsulin in the ribosomes of the rough endoplasmic reticulum of β-cells.  Proinsulin 
is then transported to the Golgi apparatus, where it forms soluble, zinc containing 
hexamers.  Enzymes acting outside the Golgi convert proinsulin to insulin by cleaving the 
C-peptide from the molecule during the formation of immature storage vesicles.  C-
peptide has an important role in insulin synthesis by linking the A and B chains of insulin 
in a manner that facilitates folding and interchain disulfide bond formation (Wahren et al. 
2000).  Proteolytic removal of C-peptide from proinsulin allows the carboxy terminal of 
the B-chain of the insulin molecule to assume a conformation which facilitates interaction 
with the insulin receptor.  Insulin and C-peptide are cosecreted in equimolar amounts 
when mature granules release their contents into the portal circulation (Wilcox 2005).   
Until recently, C-peptide was generally accepted to possess little or no biological 
activity.  Lately, however, specific binding of C-peptide to cell surfaces has been 
demonstrated, suggesting the presence of G-protein coupled membrane receptors for this 
protein (Wahren et al. 2000).  C-peptide has been shown to elicit concentration-
dependent stimulation of Na+-K+ ATPase in proximal segments of nephrons obtained 
from rats (Ohtomo et al. 1996).  Indeed, patients suffering from type I diabetes mellitus 
(DM) frequently develop glomerular hyperfiltration early in the course of their disorder, 
which can be significantly decreased by infusion of exogenous C-peptide (Johansson et 
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al. 1992).  Addition of C-peptide to the treatment regime of type I diabetic human 
subjects significantly decreased urinary albumin excretion, when compared with insulin 
treatment alone (Wahren et al. 2000).  Through its stimulatory effect on Na+-K+ ATPase, 
C-peptide has also been suggested to ameliorate nerve dysfunction in type I diabetes 
(Wahren et al. 2000). 
Compensatory hyperinsulinemia associated with insulin resistance typically 
predates the development of type II DM in human subjects (Brunton et al. 2006).  
Similarly, horses suffering from decreased insulin sensitivity triggered by endotoxemia or 
obesity exhibit an augmented pancreatic insulin response to exogenous glucose 
challenge, indicated by higher acute insulin response to glucose (AIRg) values (Hoffman 
et al. 2003; Toth et al. 2008).  In humans, overproduction of insulin by pancreatic β-cells 
eventually induces β-cell exhaustion, impaired insulin secretion, and relative insulin 
deficiency (Brunton et al. 2006).  As glucose levels rise, β-cell function further 
deteriorates, with diminishing sensitivity to glucose, ultimately resulting in the 
development of type II DM (Wilcox 2005).  Insulin-resistant horses and ponies rarely 
develop pancreatic β-cell insufficiency and usually maintain a state of compensated IR 
(Johnson et al. 2005; Treiber et al. 2005b).  Nevertheless, DM has been described in a 
Spanish Mustang in association with IR (Johnson et al. 2005) and hyperglycemia was 
also registered in 2 ponies suffering from insulin resistance, which indicates failed 
compensation (Treiber et al. 2006b).  Thus, estimation of the ability of pancreatic β-cells 
to secrete insulin is important for the accurate assessment of glucose homeostasis. 
During minimal model analysis of the frequently sampled intravenous glucose 
tolerance test (FSIGTT), serum insulin concentrations measured during the first 10 
minutes after exogenous glucose administration provide an estimate for AIRg (Tiley et 
al. 2007).  The AIRg reflects the ability of pancreatic β-cells to secrete insulin after 
glucose challenge.  However, it has been demonstrated in humans that approximately 60 
percent of insulin secreted into the portal vein is removed by the liver (Wilcox 2005), so 
serum insulin concentrations measured in peripheral blood provide only a crude estimate 
of pancreatic function (Hovorka et al. 1998; Kjems et al. 2000).  It is therefore preferable 
to measure serum C-peptide concentrations when assessing pancreatic function, because 
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this peptide is not extracted by the liver (Hovorka et al. 1998; Kjems et al. 2000).  Higher 
AIRg values have been associated with IR in horses (Hoffman et al. 2003; Toth et al. 
2008), but it has not been determined whether this occurs as a result of increased 
pancreatic insulin secretion or reduced hepatic insulin extraction.  This could be 
investigated by simultaneously measuring insulin concentrations in blood samples 
obtained from both the portal vein and hepatic vein, but the measurement of C-peptide 
concentrations from peripheral blood samples is a more practical alternative.  
A literature search revealed only one report describing C-peptide measurements in 
horses; but the authors did not state whether the test was validated for the horse (Johnson 
et al. 2005).  Characteristics of C-peptide dynamics in horses, including clearance rate 
and plasma half life have not been reported to date.  C-peptide metabolism has been 
established in dogs by blocking endogenous C-peptide secretion using a somatostatin 
infusion (Polonsky et al. 1983).  Exogenous C-peptide was then administered to 
investigate hepatic metabolism and metabolic clearance rate of C-peptide. 
The aims of the study reported here were 1) to measure C-peptide concentrations 
in equine serum using a human double antibody C-peptide radioimmunoassay (RIA), 2) 
to establish clearance rate of C-peptide, and 3) to describe C-peptide dynamics during the 
FSIGTT in horses.  We hypothesized that the human double antibody C-peptide RIA 
would be able to detect equine C-peptide and that concentrations would increase as the 
pancreas responds to exogenous glucose during the FSIGTT. 
 
4.2 Materials and Methods 
 
Horses – Six mares from the University of Tennessee teaching and research herd 
were evaluated during the study period (Oct 2006 to March 2007).  Horses were admitted 
to the teaching hospital in pairs and housed separately in 3.7-m × 3.7-m stalls.  To 
eliminate differences attributable to sex, only mares were selected.  Horses were 6 to 13 
years of age (mean age, 9.3 years; median, 9 years); breeds included Quarter horse / 
Tennessee Walking horse crossbreds (n = 3), Quarter horse (2) and Standardbred (1).  
Horses were weighed at the time of admission and weights ranged from 461 kg to 523 kg 
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(mean weight, 497 kg; median, 501 kg). Body condition score (on a scale of 1 to 9) 
ranged from 4 to 6 (Henneke et al. 1983).  Daily physical examinations were performed 
throughout the study period.  Grass hay and water were provided ad libitum, and each 
horse was acclimated to its new environment for approximately 72 h before experiments 
started.  The study protocol was approved by the University of Tennessee Institutional 
Animal Care and Use Committee. 
Experimental design – The study reported here comprises two phases performed 
three months apart.  The aim of the first phase was to evaluate C-peptide clearance in 
horses after suppression of pancreatic insulin secretion by somatostatin, while the second 
phase involved measurement of C-peptide concentrations in equine sera obtained during 
the FSIGTT in the same six horses. 
C-peptide dynamics – On the first day of the study, a 14-gauge polypropylene 
catheter1 was inserted into each jugular vein.  Patency of IV catheters was maintained by 
infusion of 5 mL of saline solution containing heparin (4 U/mL) every 6 hours.  Tests 
were performed 24 h after catheter insertion.  At –90 min relative to C-peptide infusion, 
each horse was administered a 500 μg bolus of (D-Trp8)-somatostatin-142 followed by a 
continuous rate infusion (CRI) of 500 μg/h somatostatin for 330 min through one of the 
intravenous catheters.  Blood samples were collected at –100, –95, –90, – 75, – 60, – 45, 
– 30, – 15, – 10, – 5, 0 min using an injection cap and infusion set3 (length, 30 cm; 
internal diameter, 0.014 cm) attached to the contralateral intravenous catheter.  At 0 min, 
a 50 nmol bolus of biosynthetic human C-peptide4 was administered intravenously.  
Further blood samples were collected at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24, 
25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150, 180, 210, and 240 min (n = 43 
samples).  At each time point, 3 mL of blood was withdrawn from the catheter and 
discarded.  A 4-mL blood sample was subsequently collected then the catheter was 
flushed with 5 mL of saline solution containing heparin.  Blood was transferred to a tube 
without anticoagulant.  Samples were allowed to clot at 22 oC for 1h and then serum was 
                                                 
1 Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, Ill 
2 Bachem Americas, Inc. 3132 Kashiwa Street, Torrence, CA 90505 
3 Butterfly, Abbott Laboratories, North Chicago, Ill. 
4 GenScript Co., 120 Centennial Ave., Piscataway, NJ 08854 
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harvested via low-speed (1,000 × g) centrifugation.  Serum samples were stored at –20oC 
until analyzed. 
FSIGTT procedure – This procedure was performed during the second phase of 
the study.  Each horse was weighed and a 14-gauge polypropylene catheter was inserted 
into the left jugular vein one day before the FSIGTT.  Patency of the IV catheter was 
maintained by infusion of 5 mL of saline solution containing heparin into the catheter 
every 6h.  During tests, horses were allowed access to grass hay and water ad libitum.  
An injection cap and infusion set (length, 30 cm; internal diameter, 0.014 cm) were 
attached to the catheter.  The FSIGTT procedure first described for use in horses by 
Hoffman et al. (2003) was followed.  Briefly, a 300 mg/kg bolus of 50% (wt/vol) 
dextrose5 solution was administered to each horse via the infusion line and catheter, 
followed by infusion of 20 mL saline solution containing heparin.  Blood samples were 
collected via the catheter immediately before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 
19 min after infusion of dextrose.  At 20 min, regular insulin6 (30 mU/kg) was 
administered followed by another infusion of 20 mL saline solution containing heparin.  
Blood samples were subsequently collected via the catheter at 22, 23, 24, 25, 27, 30, 35, 
40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 min after the dextrose bolus infusion.  At 
each time point, 3 mL of blood was withdrawn from the infusion line and discarded.  A 
6-mL blood sample was then collected, followed by infusion of 5 mL of saline solution 
containing heparin.  Half the volume of the blood sample was transferred to a tube 
containing sodium heparin, which was immediately cooled on ice and then refrigerated.  
The remaining blood was transferred to a tube containing no anticoagulant.  These 
samples were allowed to clot at 22 oC for 1 hour and then serum was harvested via low-
speed (1,000 × g) centrifugation.  Plasma and serum samples were stored at –20oC until 
further analyzed. 
C-peptide RIA – Serum concentrations of C-peptide were measured using a 
human, double antibody RIA kit7 previously used, but not validated in horses (Johnson et 
al. 2005).  Samples were assayed in duplicate in accordance with instructions provided 
                                                 
5 Dextrose 50% injection, Abbott Laboratories, North Chicago, Ill. 
6 Humulin R, Eli Lilly and Co, Indianapolis, Ind. 
7 Siemens Medical Solutions Diagnostics, 5210 Pacific Concourse Dr., Los Angeles, CA 90045-6900 
(formerly: Diagnostics Products Co.) 
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by the manufacturer.  The accuracy of the assay was assessed by recovery and 
parallelism.  Dilutional parallelism was evaluated by diluting three aliquots of six 
separate equine serum samples to 1:2, 1:4 and 1:8 dilutions of their initial concentration 
using sterile nanopure water.  Once the concentration for the undiluted sample was 
obtained, expected (E) concentrations were calculated according to the dilutions used.  
Observed (O) concentrations were compared with expected values and a ratio was 
calculated, which was expressed as a percentage (%O/E).  Spiking and recovery was 
assessed by adding 50 μL solutions containing 195.3, 71.2, and 21.8 ng/mL human C-
peptide to 950 μL of three aliquots of six different equine serum samples.  Expected 
values were calculated by calculating the contribution of the added human C-peptide plus 
the initial value for horse serum alone.  For each spiked sample, observed concentrations 
were compared with expected values and %O/E was calculated.  Since human antibody 
RIA was used in this study, results are expressed as human equivalents (HE) of 
immunoreactive (ir) C-peptide.  C-peptide values were converted from ng/mL to 
pmol/mL using a conversion factor of 0.333. 
Serum insulin concentrations – Insulin concentrations were determined by use 
of a radioimmunoassay8 previously validated for equine insulin (Freestone et al. 1991).  
Each sample was assayed in duplicate and intra-assay coefficients of variation of less 
than 10% were required for acceptance of assay results.  Insulin values were converted 
from μU/mL to pmol/mL using a conversion factor of 6.945 × 10–3. 
Statistical analysis – Serum C-peptide concentrations were measured and 
clearance was calculated using commercially available software.9  Statistical analysis was 
performed according to a randomized blocked design, blocked on horse.  Serum C-
peptide concentrations measured before, and during the first 90 min of the somatostatin 
CRI were averaged for each horse and compared using mixed model analysis of variance 
(one-tailed test).  Mixed model analysis of variance with repeated measures was used to 
compare C-peptide concentrations measured before and after dextrose administration 
                                                 
8 Coat-A-Count insulin, Siemens Medical Solutions Diagnostics, 5210 Pacific Concourse Dr., Los Angeles, 
CA 90045-6900 (formerly: Diagnostics Products Co.) 
9 WinNonlin 5.1, Pharsight, Mountain View, CA  
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using statistical software.10  During the FSIGTT, C-peptide-to-insulin ratios were 
averaged in each horse for the 3 baseline samples and for samples obtained between 1 
and 19 min (n = 13 samples) and subsequently compared using mixed model analysis of 
variance.  No comparisons were made after the 19 min time point because of the 
confounding effect of exogenous insulin.  Square root or log transformation was used to 





Experimental procedures remained well tolerated throughout the study with no 
abnormalities registered during daily physical examinations.  Evaluation of baseline 
insulin concentrations and insulin sensitivity (SI) values revealed that one horse included 
in the study suffered from IR.  The mean resting insulin concentration for this horse was 
58.3 μU/mL and mean SI was determined to be 0.23 × 10–4 L•min-1•mU-1.  Data from this 
horse were therefore handled separately. 
Mean ± SD percent O:E ratio for the 6 serially diluted samples was 119 ± 25% 
(Table 4.1) and parallelism was observed. Observed-to-expected spike and recovery 
ratios for 6 samples with 3 spiking concentrations ranged from 112 to 136% with a mean 
± SD of 123.09 ± 8.02% (Table 4.2). 
Due to malfunction of the intravenous fluid pump, delivery of somatostatin failed 
in one horse, so mean C-peptide clearance rate was calculated using data obtained from 
four horses.  Mean ± SD ir-C-peptide HE concentration measured before (0.23 ± 0.12 
pmol/mL) and during the first 90 min (0.11 ± 0.06 pmol/mL) of the somatostatin CRI 
differed significantly (P = 0.030; one-tailed test).  Mean ir-C-peptide HE concentration 
(2.96 ± 0.67 pmol/mL) peaked 1 min after intravenous administration of 50 nmol 
biosynthetic human C-peptide and remained significantly (P = 0.003 at 50 min) elevated 
for 50 min (Figure 4.1) relative to baseline.  Mean ± SD clearance rate of ir-C-peptide 
HE was calculated to be 1.74 ± 0.74 mL/min/kg bwt. 
                                                 
10 PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC. 
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Table 4.1 – Dilutional parallelism of human equivalents of immunoreactive C-peptide as 
measured in six different equine serum samples using a human double antibody C-








A 1 in 1 0.9 NA NA 
 1 in 2 0.41 0.45 91 % 
 1 in 4 0.26 0.23 116 % 
 1 in 8 0.11 0.11 97 % 
     
B 1 in 1 1.47 NA NA 
 1 in 2 0.71 0.73 98 % 
 1 in 4 0.47 0.37 128 % 
 1 in 8 0.11 0.18 60 % 
     
C 1 in 1 0.78 NA NA 
 1 in 2 0.42 0.39 108 % 
 1 in 4 0.30 0.19 153 % 
 1 in 8 0.14 0.10 146 % 
     
D 1 in 1 1.37 NA NA 
 1 in 2 0.75 0.69 109 % 
 1 in 4 0.45 0.34 132 % 
 1 in 8 0.24 0.17 141 % 
     
E 1 in 1 1.23 NA NA 
 1 in 2 0.69 0.61 112 % 
 1 in 4 0.34 0.31 111 % 
 1 in 8 0.17 0.15 113 % 
     
F 1 in 1 1.29 NA NA 
 1 in 2 0.77 0.65 119 % 
 1 in 4 0.45 0.32 139 % 
 1 in 8 0.25 0.16 161 % 
 
O/E = ratio of observed (O) concentration to expected (E) concentration 
NA = not applicable   
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Table 4.2 – Recovery of human equivalents of immunoreactive C-peptide as measured 
from six different equine serum samples spiked with biosynthetic human C-peptide using 











A 0 0.9 NA NA 
 195.2 14.2 10.6 134 % 
 71.2 6.0 4.4 136 % 
 21.8 2.5 2.0 128 % 
     
B 0 1.5 NA NA 
 195.2 12.6 12.0 113 % 
 71.2 5.8 5.0 117 % 
 21.8 2.8 2.5 112 % 
     
C 0 0.8 NA NA 
 195.2 13.2 10.5 125 % 
 71.2 5.6 4.3 131 % 
 21.8 2.3 1.8 124 % 
     
D 0 1.4 NA NA 
 195.2 14.0 11.1 127 % 
 71.2 6.2 4.9 128 % 
 21.8 2.7 2.4 112 % 
     
E 0 1.2 NA NA 
 195.2 12.5 10.9 114 % 
 71.2 6.00 4.7 126 % 
 21.8 2.6 2.3 114 % 
     
F 0 1.3 NA NA 
 195.2 13.0 11.0 118 % 
 71.2 6.4 4.8 133 % 
 21.8 2.9 2.3 125 % 
 
O/E = ratio of observed (O) concentration to expected (E) concentration 























Figure 4.1 – Mean ± SE concentration of human equivalents of immunoreactive C-
peptide in serum collected from horses (n = 4) after administration of 50 nmol 
biosynthetic human C-peptide at 0 min. Endogenous C-peptide secretion was suppressed 
by infusion of 500 μg biosynthetic human somatostatin at –90 min followed by 500 μg/h 
for 330 min. 
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Measurements of ir-C-peptide HE were successfully performed from blood 
samples collected during the FSIGTT from all five horses.  For 100 min after intravenous 
glucose administration, ir-C-peptide HE concentrations remained significantly elevated 
(P = 0.042 at 100 min) relative to baseline (Figure 4.2).  Mean ± SD ir-C-peptide HE-to-
insulin ratio was 3.6 ± 1.95 preceding glucose administration, and this ratio significantly 
decreased (P = 0.004) to 1.03 ± 0.18 during the first 20 min following dextrose 
administration (Figure 4.3). 
In the horse with preexisting IR, the resting concentration (0.24 pmol/mL) and 
clearance rate (1.62 mL/kg/min) of ir-C-peptide HE were both similar to those registered 
in healthy horses.  However, mean ir-C-peptide HE-to-insulin ratio values for the three 
baseline samples and those from the first 20 min of the FSIGTT appeared to be lower 




Serum C-peptide concentrations were successfully measured in equine serum, and 
the release of C-peptide and insulin from the pancreas were suppressed in horses by 
intravenously administering somatostatin.  This enabled determination of the C-peptide 
clearance rate in horses.  Administration of dextrose during the FSIGTT was associated 
with higher concentrations of ir-C-peptide HE relative to baseline and a lower C-peptide-
to-insulin ratio. 
Somatostatin is a peptide hormone that has two biologically active isoforms 
somatostatin-14 and somatostatin-28 containing 14 and 28 amino acid, respectively 
(Ludvigsen 2007).  This peptide hormone is present in the brain, and is also secreted by 
the enteroendocrine D cells and δ-cells of the pancreas.  Pancreatic somatostatin secretion 
is influenced by changes in blood glucose concentrations, and hormonal effects are 
exerted in an autocrine or paracrine fashion through binding to one of five somatostatin 
receptor subtypes (Low 2004).  In mice, somatostatin receptor subtype 5 is responsible 
for the inhibition of insulin secretion from the β-cells and somatostatin receptor subtype 

























Figure 4.2 – Mean ± SE concentrations of human equivalents of immunoreactive C-
peptide measured during the frequently sampled intravenous glucose tolerance test in 5 
horses.  Dextrose (300 mg/kg) was infused intravenously at time = 0 followed by 30 











































Figure 4.3 – Mean ± SE concentrations of human equivalents of immunoreactive C-
peptide (solid squares) and insulin (open circles) as measured from three baseline 
samples and samples collected during the first 19 min of the frequently sampled 

































Figure 4.4 – Concentrations of human equivalents of immunoreactive C-peptide (solid 
squares) and insulin (open circles) as measured from three baseline samples and samples 
collected during the first 19 min of a frequently sampled intravenous glucose tolerance 
test in a horse suffering from insulin resistance 
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humans, however, somatostatin inhibits insulin secretion by binding to somatostatin 
receptor subtype 2 (Low 2004). 
Successful suppression of C-peptide secretion in horses was evident by the 
significantly lower ir-C-peptide HE concentrations detected after initiation of the 
somatostatin CRI.  However, detection of trace amounts of ir-C-peptide HE during the 
same period suggests that suppression was incomplete.  These findings are consistent 
with previous observations in humans, as intravenous administration of somatostatin, or 
its analogue octreotide, resulted in only partial suppression of C-peptide release to 48% 
and 27% of baseline concentrations, respectively (Hwu et al. 2001).  In dogs, however, 
an intravenous bolus of 50 μg somatostatin followed by a CRI of 800 ng/kg/min, 
suppressed C-peptide concentrations below the detection limit of the assay (Polonsky et 
al. 1983).  Complications associated with somatostatin infusion such as gastrointestinal 
discomfort, diarrhea or fainting observed in human subjects (Hwu et al. 2001) were not 
detected in this study. 
The resting mean ir-C-peptide HE concentration measured in this study (0.23 ± 
0.12 pmol/mL) corresponds well with those reported previously for samples obtained 
from the femoral artery (0.24 ± 0.04 pmol/mL) and hepatic vein (0.33 ± 0.06 pmol/mL) 
of fasted dogs (Polonsky et al. 1983) or from fasted human subjects (range: 0.14 to 0.35 
pmol/mL; Faber et al. 1978).  Our results compare favorably with plasma C-peptide 
concentrations of 0.18 pmol/mL and 0.64 ± 0.17 pmol/mL registered in one diabetic 
Spanish Mustang and five healthy horses, respectively (Johnson et al. 2005). 
Mean clearance rate for ir-C-peptide HE measured in this study (1.74 ± 0.74 
mL/min/kg) was lower than the values of 4.4 mL/min/kg and 4.7 mL/min/kg detected in 
healthy and diabetic human subjects, respectively (Faber et al. 1978), and an even higher 
endogenous C-peptide metabolic clearance rate of 11.5 ± 0.8 mL/kg/min has been 
detected in dogs (Polonsky et al. 1983).  In humans, C-peptide is metabolized by the 
kidney and partially excreted into the urine (Zavaroni et al. 1987).  In the basal state, 
renal C-peptide metabolism is characterized by a high fractional extraction of 
approximately 26 % and very low urinary clearance of only 14 % (Zavaroni et al. 1987).  
These values indicate that most of the C-peptide taken up by the kidneys is metabolized 
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by renal tissues.  Differences in kidney function may therefore explain the wide variation 
in C-peptide clearance rate registered in different species. 
Concentrations of ir-C-peptide HE increased and remained significantly higher 
than baseline for 100 min during the FSIGTT.  This observation was expected because 
insulin and C-peptide are co-secreted from the pancreas in equimolar amounts, and 
increased insulin concentrations are routinely demonstrated during the FSIGTT in horses 
(Hoffman et al. 2003; Hovorka et al. 1998).  Similar observations were made in dogs 
during a 60 min intravenous glucose infusion, with elevated C-peptide and insulin 
concentrations detected (Polonsky et al. 1983).  When intravenous glucose tolerance tests 
(IVGTT) are performed in humans, higher C-peptide concentrations are detected after 
glucose infusion (Kjems et al. 2001).   
Characteristic biphasic C-peptide secretion occurs in humans following glucose 
infusion (Kjems et al. 2001), but this was not observed in this study.  The most likely 
explanation for this finding is that glucose concentrations are not sustained during the 
FSIGTT in horses, so concentrations may not remain high enough to stimulate second 
phase insulin secretion.  It has been suggested that the second phase insulin secretion 
requires the augmenting action of glucose (Henquin et al. 2002).  Indeed, prolonged 
elevation of glucose concentration during the hyperglycemic clamp facilitates clearer 
determination of the second phase insulin response than the intravenous glucose tolerance 
test (Caumo and Luzi 2004).  For this reason, the hyperglycemic clamp is considered the 
gold standard method for the assessment of biphasic insulin response in vivo (Caumo and 
Luzi 2004).  Furthermore, tolbutamide is often administered to humans during the 
IVGTT to trigger the insulin/ C-peptide response at t = 20 min (Kjems et al. 2001), 
whereas only insulin is administered during the FSIGTT performed in horses (Hoffman et 
al. 2003; Toth et al. 2008).  Tolbutamide is a first generation sulfonylurea drug that 
stimulates pancreatic insulin secretion (Krentz and Bailey 2005).  Finally, the second 
phase insulin/ C-peptide response may blend with the first phase in horses, resulting in a 
secretory pattern similar to that demonstrated in mice (Henquin et al. 2002).  In isolated 
mouse pancreatic islets, second phase insulin response to glucose is flatter and lower than 
the first phase (Henquin et al. 2002).  
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One of the most intriguing findings of this study was the significant decrease in 
C-peptide-to-insulin ratio from a baseline of 3.6 ± 1.9 to 1.0 ± 0.2 after dextrose 
administration during the FSIGTT.  Similar results have been obtained in human subjects 
as the C-peptide-to-insulin molar ratio decreased from a fasting level of 5.0 to values 
between 2.0 and 3.0 following β-cell stimulation (Faber et al. 1978).  The authors of that 
study hypothesized that the lower C-peptide-to-insulin ratio was due to the longer half-
life of C-peptide.  In dogs, the C-peptide-to-insulin molar ratio remained unchanged after 
initiation of a glucose infusion lasting 60 min (Polonsky et al. 1983).  One possible 
explanation for this change in proportions is that hepatic insulin extraction decreases 
following glucose challenge in horses, causing the peripheral blood C-peptide-to-insulin 
ratio to approach 1:1 after stimulation of pancreatic β-cells.  It is unlikely that increased 
hepatic extraction of C-peptide contributes to the shift in ratio, since very little or no 
hepatic C-peptide extraction has been demonstrated in dogs (Polonsky et al. 1983) or 
humans (Polonsky et al. 1986). Reduced hepatic insulin extraction may be a normal 
physiological response to dextrose infusion if it results in more insulin being left in 
circulation to act on insulin-sensitive tissues that store glucose.  Alternatively, renal 
clearance of C-peptide might increase in response to dextrose, which would lower serum 
concentrations and alter the C-peptide-to-insulin ratio.  In human subjects, renal uptake, 
renal clearance and fractional extraction of C-peptide markedly increased when elevated 
plasma C-peptide concentrations were induced by the consumption of amino acids 
(Zavaroni et al. 1987). 
One interesting observation from this study was that a horse suffering from 
preexisting insulin resistance exhibited a lower C-peptide-to-insulin ratio than that 
registered in healthy horses, both during the resting period and following dextrose 
administration.  This difference was attributed to higher insulin concentrations because 
C-peptide concentrations did not appear to be affected.  These findings suggest that 
higher concentrations of insulin detected in horses and ponies with IR are a consequence 
of reduced insulin clearance rather than enhanced secretion (Hoffman et al. 2003; Toth et 
al. 2008; Treiber et al. 2006b).  However, caution must be exercised when interpreting 
this result because data were only collected from a single insulin-resistant horse. 
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One of the weaknesses of the study reported here is our inability to measure 
equine specific C-peptide, due to the lack of a species-specific C-peptide RIA or 
biosynthetic equine C-peptide.  However, amino acid sequences of equine and human C-
peptide are homologous, differing only in seven residues (Wahren et al. 2000), which 
suggests a high potential for cross reactivity.  Another limiting factor of this study was 
the small number of horses evaluated, which was compounded by the exclusion of one 
horse because of pre-existing IR and malfunction of the infusion pump. Nevertheless, 
detection of statistical significance was still possible.  
Measurement of ir-C-peptide HE may provide an additional tool for the 
assessment of glucose and insulin dynamics in horses, facilitating precise reconstruction 
of the prehepatic insulin secretion profile.  Evaluation of C-peptide concentration during 
IVGTT has been used to accurately assess prehepatic insulin secretion in healthy subjects 
and people suffering from type II diabetes (Kjems et al. 2000; Kjems et al. 2001).  The 
use of the C-peptide minimal modeling of the insulin modified IVGTT was also 
demonstrated to correctly assess β-cell function in 15 healthy human subjects (Toffolo et 
al. 1999). 
Estimation of pancreatic insulin secretion is important in horses because 
decreased insulin sensitivity and hyperinsulinemia have been associated with laminitis 
(Bailey et al. 2007; Carter et al. 2009; Treiber et al. 2006b).  Insulin concentrations 
higher than 32 mU/L predict incipient pasture-associated laminitis in ponies before 
exposure to pastures rich in non-structural carbohydrates (Carter et al. 2009).  
Development of laminitis in ponies undergoing experimental induction of 
hyperinsulinemia (1,036 ± 55 μU/mL) as euglycemia was being maintained provides 
evidence that insulin plays a role in the pathogenesis of laminitis (Asplin et al. 2007b).  
Insulin resistance, established from increased insulin concentrations via the proxy 
measure, reciprocal of the square root of insulin, was one of the criteria used to identify 
ponies suffering from prelaminitic metabolic syndrome; a condition associated with a 10-
fold increase in the incidence of pasture-associated laminitis (Treiber et al. 2006b).  In 
the same study, euglycemia was registered in all but 2 horses suffering from IR, 
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indicating that increased insulin secretion managed to sustain insulin-mediated glucose 
disposal in spite of the decreased insulin sensitivity (Treiber et al. 2006b). 
Decompensation develops when increased pancreatic insulin secretion is unable 
to offset reduced insulin sensitivity and hyperglycemia develops (Treiber et al. 2006b).  
Increased expression of matrix metalloproteinases 2 and 9 has been described in horses 
suffering from laminitis (Souza et al. 2006) and in endothelial cells and macrophages 
exposed to high glucose concentrations (Death et al. 2003).  These findings suggest that a 
connection exists between the hyperglycemia associated with decompensation and 
laminitis.  Hence, accurate description of prehepatic insulin secretion based on peripheral 
C-peptide concentration will likely enhance our understanding and treatment of IR and 
comorbid conditions in horses. 
In conclusion, we demonstrated that C-peptide can be detected and quantified in 
equine serum using a double antibody human C-peptide RIA.  Changes in the proportions 
of ir-C-peptide HE and insulin were demonstrated in association with dextrose infusion 
suggesting that hepatic insulin extraction may be influenced by changes in blood glucose 
levels.  Precise quantification of C-peptide concentration from equine serum along with 
further studies investigating the relationship between serum C-peptide levels and 
pancreatic insulin release are required to facilitate accurate evaluation of β-cell function 
in horses.  More insulin-resistant horses must be evaluated in the future to confirm or 
refute our observation that higher insulin concentrations detected in one horse with IR 
were a result of reduced insulin clearance rather than enhanced pancreatic secretion.  
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CHAPTER 5  
Effects of pretreatment with dexamethasone or levothyroxine 




Insulin resistance (IR) is a state in which normal concentrations of insulin fail to 
elicit the expected physiologic response (Kahn 1978).  Development of IR in horses has 
previously been associated with endotoxemia (Toth et al. 2008; Vick et al. 2008), obesity 
(Hoffman et al. 2003), pituitary pars intermedia dysfunction (PPID; Keen et al. 2004) 
and dexamethasone administration (Tiley et al. 2007).  The importance of decreased 
insulin sensitivity (SI) is underscored by its purported role in the development of 
laminitis (Asplin et al. 2007b; Bailey et al. 2008; Treiber et al. 2006b), osteochondrosis 
(Pagan 2001) and decreased fertility (Sessions et al. 2004). 
Previous studies have demonstrated that ponies predisposed to laminitis suffer 
from decreased insulin sensitivity (Bailey et al. 2008; Treiber et al. 2006b).  Treiber et al. 
(2006b) showed that 25% of ponies with preexisting IR, but no clinical evidence of 
laminitis in March developed clinical laminitis by May.  The appearance of clinical 
laminitis in these ponies coincided with a significantly higher starch content measured 
within pasture grass in May relative to March (Treiber et al. 2006b).  Excessive 
consumption of non-structural carbohydrates including starches can lead to rapid 
fermentation within the equine hindgut causing intraluminal acidosis, Gram-negative 
bacterial death, and increased intestinal permeability (Longland and Byrd 2006; Weiss et 
al. 1998).  Studies specifically examining hindgut bacterial populations during the 
development of carbohydrate-induced laminitis revealed that proliferation of bacteria 
belonging to the Streptococcus bovis/equinus complex consistently preceded the 
development of laminitis, implicating these specific microorganisms in the pathogenesis 
of alimentary laminitis (Milinovich et al. 2007; Milinovich et al. 2006).  Horses grazing 
on pastures rich in soluble carbohydrate may therefore develop laminitis as a result of 
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intestinal events caused by carbohydrate overload, exacerbation of preexisting IR, or both 
problems occurring concurrently. 
Endotoxin is a heat stable lipopolysaccharide (LPS) found in the outer membrane 
of Gram-negative bacteria, which is released upon bacterial death and during bacterial 
multiplication (Rietschel et al. 1994).  Under physiological circumstances, only a small 
amount of endotoxin enters the bloodstream, and it is subsequently removed by the 
Kupffer cells of the liver (Hardie and Kruse-Elliott 1990a).  Clinically apparent 
endotoxemia develops when the liver is unable to clear all of the circulating endotoxin, or 
when excessive amounts of endotoxin enter the blood (Hardie and Kruse-Elliott 1990a; 
Morris 1991).  In horses, endotoxemia most commonly results from compromise of the 
gastrointestinal mucosal barrier, which allows endotoxin to move from the intestinal 
lumen to the bloodstream (Morris 1991).  Other conditions associated with endotoxemia 
include Gram-negative bacteremia, pleuropneumonia, and metritis (Morris 1991; 
Werners et al. 2005). 
Endotoxemia may contribute to the development of laminitis in horses.  Elevated 
endotoxin concentrations were detected in 85% of horses developing Obel Grade 3 
laminitis after experimental carbohydrate overload (Sprouse et al. 1987).  In a previous 
study, we demonstrated that transient IR develops after LPS administration (Toth et al. 
2008), which leads to the hypothesis that endotoxin-induced alterations in glucose and 
insulin dynamics contribute to the development of laminitis in horses.  It has also been 
recognized that hospitalized horses suffering from endotoxemia have 5 times the odds of 
developing laminitis than horses with no evidence of endotoxemia (Parsons et al. 2007).  
This finding supports the role of endotoxemia in the development of laminitis and also 
raises the question of whether stress induced by stall confinement (Harewood 2005; Mal 
1991) increases the risk of disease. 
Chronic IR in pastured ponies and stress associated with hospitalization are pre-
existing factors that may exacerbate the reduction in insulin sensitivity induced by 
endotoxemia.  If this is the case, ponies and horses affected by these conditions may 
undergo exaggerated responses to endotoxin that lower insulin sensitivity even further 
and raise the likelihood of laminitis.  This may enhance the negative impact of minor 
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intestinal events occurring in grazing ponies if endotoxemia develops in these animals.  
We therefore hypothesized that differences in resting insulin sensitivity affect the 
magnitude of changes in glucose and insulin dynamics induced by endotoxin 
administration. 
Dexamethasone (DEX) and levothyroxine sodium (L-T4) treatments were 
administered to alter resting insulin sensitivity prior to endotoxin administration in this 
study.  It has previously been demonstrated that SI decreases when DEX is administered 
to horses (Tiley et al. 2007).  Insulin sensitivity significantly decreased in healthy adult 
horses when DEX was administered orally at a dosage of 0.08 mg/kg, IV, q 48h for 21 
days (Tiley et al. 2007).  In contrast, we have previously shown that SI increases in 
healthy adult mares treated with L-T4 for 8 or 48 weeks (Frank et al. 2008; Frank et al. 
2005b).  The mechanisms responsible for this improvement in SI have not been 
determined in horses, but it may be the result of increased glucose transport through the 
cell membrane in both intra and extrahepatic sites (Haber et al. 1995; Romero et al. 2000; 
Weinstein et al. 1994).  Thyroid hormone has been shown to increase glucose transporter 
4 (GLUT4) gene expression as well as translocation of glucose transporters to cell 
membranes (Romero et al. 2000; Weinstein et al. 1994). 
 
5.2 Materials and methods 
 
Horses – Twenty-four adult mares from the University of Tennessee teaching and 
research herd were included in the study.  The study was performed over the course of 
five months between September 2007 and January 2008.  Horses were admitted to the 
University of Tennessee Veterinary Teaching Hospital in groups of four and remained 
hospitalized for 22 days.  At the conclusion of the study, horses were returned to the 
research herd.  To eliminate differences attributable to gender only mares were selected.  
Mean ± SD weight of horses upon admission was 519 ± 36 kg.  The age of horses ranged 
from 5 to 16 years (mean ± SD: 10.4 ± 3.6 years) and breeds included Quarter horse (11), 
Quarter horse / Tennessee Walking horse crossbred (10), Tennessee Walking Horse (1), 
Standardbred (1) and Thoroughbred (1).  Body condition scores (on a scale from 1 to 9) 
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ranged from 4 to 6 (Henneke et al. 1983).  The study protocol was approved by the 
University of Tennessee Institutional Animal Care and Use Committee. 
 
Experimental design – Using a completely randomized design, horses were assigned to 
one of the three treatment groups, each containing eight horses. The treatment groups 
included: 
Control group (n = 8)  horses receiving 200g of oats and no other medications  
L-T4 group (n = 8) horses receiving 48 mg of L-T4 powder1 mixed with 200g 
of oats once daily 
DEX group (n = 8) horses were administered 20 mg dexamethasone2 (2 
mg/mL solution) orally using a syringe and 200g of oats 
once daily 
Horses were weighed and physical examinations were performed on the first day (Friday) 
of the study, then each horse was housed separately in 3.7-m X 3.7-m stalls within the 
veterinary teaching hospital.  Grass hay was fed in amounts equivalent to two percent of 
body weight (bwt) and ad libitum water was provided, and each horse was acclimated to 
its new environment for approximately 72h.  On the fourth day of the study (Monday) a 
14G intravenous catheter3 was inserted into the left jugular vein and left in place for 
approximately 24h.  A baseline frequently sampled IV glucose tolerance test (FSIGTT) 
was performed on the fifth day (Tuesday) starting at 9:00 AM.  Treatments were 
administered each morning for 15 days, starting on the sixth day (Wednesday). On the 
twentieth day (Wednesday) horses were weighed, and intravenous catheters were inserted 
and left in place for approximately 48h.  The post-treatment FSIGTT procedure was 
performed on day 21 (Thursday) starting at 0900.  On this day, treatments were 
administered at 1200, after completion of the FSIGTT.  Additionally, at 1300 all horses 
received an intravenous LPS infusion, and 20h later horses underwent the post-LPS 
FSIGTT starting again at 0900 AM.  Horses in the DEX and L-T4 groups received 
                                                 
1 Thyro L, Lloyd Inc, Shenandoah, IA 
2 Dexamethasone, VetOne, Bimeda-MTC Animal Health Inc., Cambridge, ON, Canada 
3 Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, IL. 
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tapering doses of their respective treatments for another 6 days after the conclusion of the 
study. 
Lipopolysaccharide administration – Escherichia coli O55:B5 LPS4 was mixed with 
30 mL of sterile saline (0.9% NaCl) solution under a fume hood with the investigator 
wearing gloves and a respirator to minimize exposure.  The LPS solution (20 ng/kg) was 
infused via the IV catheter during a 15-minute period.  Horses were observed for signs of 
colic and physical examination variables, including rectal temperature, heart rate, 
respiratory rate, mucous membrane color, and capillary refill time were recorded every 
30 min for the first 3h, then every hour for the following 3h, and then every 2h for 6h.  
 
Complete blood count (CBC) analysis – To evaluate individual responses to endotoxin, 
CBC analyses were performed in each horse.  Blood was collected from the indwelling 
jugular catheter into tubes containing EDTA before the LPS infusion was initiated and 2h 
(ie, 1h 45 min after completing the LPS infusion).  Samples were immediately 
transported to the clinical pathology laboratory for CBC analysis.  
 
FSIGTT procedure – One day preceding the FSIGTT, a 14-gauge polypropylene 
catheter was inserted into the left jugular vein.  During tests, horses were allowed access 
to grass hay and water.  Patency of the IV catheter was maintained before the test by 
infusion of 5 mL of saline solution containing heparin (4 U/mL) into the catheter every 6 
hours.  During the FSIGTT, an injection cap and infusion set5 (length, 30 cm; internal 
diameter, 0.014 cm) were attached to the catheter.  The FSIGTT procedure first described 
by Hoffman (Hoffman et al. 2003) and modified by our research group (Chapter 3) was 
used.  Briefly, a bolus (100 mg of glucose/kg) of a 50% (wt/vol) dextrose solution6 was 
administered to each horse via the infusion line and catheter, followed by injection of 
saline solution containing heparin.  Blood samples were collected via the catheter 10, 5 
and 1 min before and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after infusion of 
                                                 
4 Sigma Chemical Co., St Louis, MO 
5 Butterfly, Abbott Laboratories, North Chicago, IL. 
6 Dextrose 50% injection, Abbott Laboratories, North Chicago, IL. 
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dextrose.  At 20 min, regular insulin7 (20 mU/kg) was administered followed by another 
infusion of saline solution containing heparin.  Blood samples were subsequently 
collected via the catheter at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 
150, and 180 min relative to the dextrose infusion.  At each time point, 3 mL of blood 
was withdrawn from the infusion line and discarded.  A 6-mL blood sample was then 
collected, followed by infusion of 5 mL of saline solution containing heparin.  Half of the 
volume of blood was transferred to a tube containing sodium heparin, which was 
immediately cooled on ice and then refrigerated.  The remaining blood was transferred to 
a tube containing no anticoagulant.  Those samples were allowed to clot at 22oC for 1h 
and then serum was harvested via low-speed (1,000 × g) centrifugation.  Plasma and 
serum samples were stored at –20oC until further analyzed.  
 
Plasma glucose and serum insulin concentrations – Plasma glucose concentrations 
were measured by use of a colorimetric assay8 on an automated discrete analyzer.9  
Serum insulin concentrations were determined by use of a radioimmunoassay10 that has 
been validated for use in horses (Freestone et al. 1991).  Each sample was assayed in 
duplicate and intra-assay coefficients of variation < 5% or < 10% were required for 
acceptance of glucose and insulin assay results, respectively.  
 
Interpretation of FSIGTT data by use of the minimal model – Values of SI, glucose 
effectiveness (Sg), acute insulin response to glucose (AIRg), and disposition index (DI) 
were calculated for each FSIGTT in accordance with the minimal model (Bergman et al. 
1981) by use of commercially available software11,12 and previously described methods 
(Hoffman et al. 2003).  Disposition index was calculated via multiplication of AIRg by 
SI.  
 
                                                 
7 Humulin R, Eli Lilly and Co, Indianapolis, IN. 
8 Glucose, Roche Diagnostic Systems Inc, Somerville, NJ. 
9 Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ. 
10 Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, CA. 
11 MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA. 
12 Stata 9.2, Stata Corporation, College Station, TX. 
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Statistical analysis – To evaluate the effects of LPS administration on physical 
parameters and white blood cell (WBC) count, measurements obtained before and after 
endotoxin administration were compared using mixed model analysis of variance.  In 
each horse, area under the curve for glucose (AUCg) and for insulin (AUCi) were 
calculated for all three FSIGTT procedures (baseline, post-treatment and post-LPS) from 
the glucose and insulin concentrations measured during the FSIGTT, by use of the 
trapezoidal method and commercially available computer software.13  To determine the 
effects of treatments and time (baseline, post-treatment and post-LPS) on Sg, SI, AIRg, 
DI, AUCi and AUCg mixed model analysis of variance was used.  If data was non-
normally distributed or unequal variance was encountered, square root or log 
transformation was applied.  When a significant treatment × time effect was detected, 
protected Least Significant Difference mean separation method was used.  Significance 




Mean ± SD body weight of horses receiving L-T4 (n = 8) decreased significantly 
(P < 0.001) relative to baseline (528.9 ± 25.3 kg) by the end of the 15-day pretreatment 
period (511 ± 28 kg), whereas mean body weight remained unchanged in the DEX and 
control groups. 
Mean ± SE baseline SI values did not differ significantly (P = 0.942) between 
groups (Table 5.1), but one horse within the L-T4 group had a low baseline SI value 
(0.59 ×10–4 L•min-1•mU-1) at the beginning of the study that was judged to be an outlier 
(studentized residual of 2.14), so data from this animal were excluded from the analysis 
of treatment and time effects on glucose and insulin dynamics.  Insulin sensitivity 
significantly decreased (P < 0.001) over time in all groups across the 15-day pretreatment 
period.  Mean SI values decreased by 47%, 52%, and 78% relative to baseline for control, 
L-T4 and DEX groups, respectively.  A significant (P = 0.021) treatment × time effect 
was detected; mean SI for the DEX group was significantly (P = 0.032) lower than 
                                                 
13 PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC 
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control group by the end of the pretreatment period.  Significant treatment × time effects 
were also detected for AUCg (P = 0.001) and AUCi (P < 0.001).  Mean AUCg 
significantly increased (P < 0.001) over time in the DEX group, but did not change in the 
control (P = 0.626) and L-T4 (P = 0.878) groups relative to baseline.  Mean AUCi 
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Table 5.1 – Mean ± SD minimal model variables and AUCi and AUCg registered in 
horses undergoing 15 days of control, levothyroxine sodium (L-T4) or dexamethasone 
treatment followed by intravenous administration of 20 ng/kg LPS.  Measurements were 
taken on day 5 (after acclimation; baseline), before LPS administration (pre LPS) and 20h 
after LPS infusion (post LPS).  Respective treatments (control/L-T4/dexamethasone) were 
also administered on day 21 preceding the LPS administration. 
 Treatment  
 Control 
(n = 8) 
L-T4  
(n = 7) 
Dexamethasone 
(n = 8) 
Trt × time
P 
baseline 3.24 ± 1.7 a 3.48 ± 1.35a 3.34 ± 1.82a 




Post LPS 0.63 ± 0.59d,e 1.48 ± 1.2b,c,d 0.21 ± 0.23e 
 0.021 
baseline 2.02 ± 0.99 2.29 ± 1.36 2.68 ± 1.31 




Post LPS 2.29 ± 1.7 1.41 ± 1.06 1.53 ± 0.98 
 0.288 
baseline 516 ± 263 434 ± 162 416 ± 221 
Pre LPS 664 ± 428 545 ± 191 884 ± 263 AIRg (mU•min•L-1) 
Post LPS 1190 ± 1150 712 ± 108 1635 ± 741 
0.099 
baseline 14.9 ± 9 14.6 ± 7.4 11.7 ± 4.1 
Pre LPS 8.8 ± 4.1 7.9 ± 6 6.9 ± 6.9 DI × 10-2 
Post LPS 5.5 ± 5.4 9.6 ± 6.7 2.4 ± 3.1 
0.103 
baseline 5.12 ± 1.33a,b 5.81 ± 2.3a,b,c 4.85 ± 1.85a 
Pre LPS 10.2 ± 4.91c 9.1 ± 7.49a,b,c 23.23 ± 20.74d AUCi (mU/mL•min) 
Post LPS 26.9 ± 33.32d 9.61 ± 4.5b,c 57.25 ± 47.35e 
< 0.001 
baseline 17.27 ± 0.94a,b,c 16.65 ± 1.52a 15.83 ± 1.02a 
Pre LPS 16.92 ± 1.27a,b 16.77 ± 2.72a 19.57 ± 2.39c,d AUCg (g/dL•min) 
Post LPS 19.87 ± 3.52d 18.67 ± 2.63b,c,d 22.43 ± 3.38e 
0.001 
a-c For variables with significant (P < 0.05) treatment × time effects, mean values with 
different superscripts differ significantly, as determined by repeated measures ANOVA 
and comparison of least squares means using Least Significant Difference adjustment. 
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increased over this 15-day period in the control (P = 0.001) and DEX (P < 0.001) groups, 
but remained unchanged in the L-T4 group (P = 0.153).  No significant changes in Sg, 
AIRg, or DI were detected. 
All horses included in this study responded to LPS by exhibiting colic signs, and 
leukopenia defined by a WBC count < 5.4 × 103 WBCs/µL (Smith 2002) that was 
detected 2h after LPS administration (Table 5.2).  One horse had a baseline WBC count 
of 5.1 × 103 cells/µL which further decreased to 2.4 × 103 cells/µL following endotoxin 
administration.  Heart rate, respiratory rate and rectal temperature increased (P < 0.001) 
and WBC count decreased (P < 0.001) in all treatment groups following LPS 
administration.  Horses in the DEX group had significantly higher maximal heart rates 
after LPS administration than L-T4 (P < 0.001) and control (P = 0.006) group animals, 
and maximal respiratory rates were higher in DEX group, compared with the control 
group during the same period (P = 0.006).  
Insulin sensitivity significantly decreased after LPS administration in control (P = 
0.002) and DEX (P = 0.015) groups, but remained unaffected (P = 0.695) in the L-T4 
group.  Additionally, mean AUCi (P < 0.001) and AUCg (P < 0.001) values were 
significantly higher in the DEX and control groups after LPS administration, compared 
with values obtained beforehand (Figure 5.1 and 5.2).  Mean AUCg increased (P = 
0.016) over time in the L-T4 group, but AUCi remained unchanged (P = 0.329) relative to 
values obtained before LPS administration.  Mean SI measured 20h after LPS 
administration was significantly (P = 0.002) higher in the L-T4 group than the DEX 
group, and there was a trend (P = 0.075) towards higher SI values in the L-T4 group 
relative to control group.  No significant treatment × time effects were detected for Sg, 




In the present study, SI decreased significantly across the 15-day pretreatment 
period in all treatment groups, which was an unexpected finding.  Possible explanations 
for this finding include stress associated with hospitalization, changes in exercise, or
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Table 5.2 – Mean ± SD maximal heart rate (HR), maximal respiratory rate (RR), 
maximal rectal temperature (T) and white blood cell (WBC) count measured in horses 
undergoing 15 days of control, levothyroxine sodium (L-T4) or dexamethasone treatment, 
followed by intravenous administration of 20 ng/kg LPS.  Measurements of WBC were 
performed on day 20 immediately before LPS administration (Pre LPS) and 2h after the 
initiation of the LPS infusion (Post LPS).  Physical examinations were performed on day 
20 before LPS administration (Pre LPS) and within 12h after the initiation of the LPS 
infusion (Post LPS).  Respective treatments (control/L-T4/dexamethasone) were also 
administered on day 20 preceding the LPS administration. 
 Treatment  
 Control 
(n = 8) 
L-T4 
(n = 8) 
Dexamethasone 
(n = 8) 
Pre LPS 32.6 ± 7 a 38.8 ± 5.1 a 39.3 ± 5.2 a HR 
bpm Post LPS 64.3 ± 16.4 b 55 ± 6.8 b 79.8 ± 16.1 c 
Pre LPS 17.6 ± 5.9 a 17.3  ± 3.5 a 17.5 ± 6.7 a RR 
b/min Post LPS 38 ± 7.1 b 53.3 ± 20.4 c,b 59.8 ± 16.2 c 
Pre LPS 37.3 ± 0.3 a 37.4 ± 0.3 a 37.3 ± 0.3 a T 
ºC Post LPS 38.6 ± 0.3 b 38.9 ± 0.4 b 39.2 ± 0.6 b 
Pre LPS 7.26 ± 1.35 a 6.94 ± 0.71 a 7.38 ± 0.82 a WBC 
×103/μL Post LPS 3.04 ± 0.89 b 3.03 ± 0.86 b 2.94 ± 0.90 b 
a-c For variables with significant (P < 0.05) treatment × time effects, mean values with 
different superscripts differ significantly, as determined by ANOVA for repeated 
measures and comparison of least squares mean values by use of a Least Significant 
Difference adjustment. 
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Figure 5.1 – Mean ± SE plasma glucose concentration during the FSIGTT in horses 
undergoing 15 days of control (panel A), L-T4 (panel B) or dexamethasone (panel C) 
treatment followed by intravenous administration of 20 ng/kg LPS.  Testing was 
performed on day 5 at baseline (solid squares), day 21 before LPS administration (empty 























































Figure 5.2 – Mean ± SE serum insulin concentration, during the FSIGTT in horses 
undergoing 15 days of control (panel A), L-T4 (panel B) or dexamethasone (panel C) 
treatment followed by intravenous administration of 20 ng/kg LPS.  Testing was 
performed on day 5 at baseline (solid squares), day 21 before LPS administration (open 




















































alterations in diet.  At the end of the pretreatment period, the lowest mean SI value was 
detected in the DEX group.  Administration of LPS exacerbated IR causing an additional 
71.2 % and 63.4 % decrease in SI in the DEX and control groups, respectively.  
However, the degree of change did not differ between these groups, so our hypothesis 
that resting insulin sensitivity influences the magnitude of endotoxin-induced IR was not 
supported.  Nevertheless, mean SI after LPS administration was less than 0.5 × 10–4 
L•min-1•mU-1 in the DEX group, indicating an additive effect. In contrast to our 
expectations, pretreatment with L-T4 did not increase SI, but did prevent endotoxin-
induced exacerbation of IR.  After endotoxin infusion, horses receiving L-T4 treatment 
had significantly higher SI values than horses undergoing dexamethasone treatment, and 
there was a trend towards higher insulin sensitivity in the L-T4 group, when compared 
with control results.   
Two methods were used to evaluate glucose and insulin dynamics and estimate 
insulin sensitivity.  One of these methods was minimal model analysis, which partitions 
glucose disposal into glucose- and insulin-mediated parts by fitting a nonlinear model to 
data obtained from the FSIGTT (Kronfeld et al. 2005a).  Although the repeatability of 
this method was shown to be lower than the euglycemic-hyperinsulinemic clamp (EHC) 
in one study (Pratt et al. 2005), this technique is preferred because it is technically 
simpler and provides estimates of Sg, AIRg and DI as well as SI.  The second method 
involved calculation of area under the curve values for glucose and insulin concentrations 
during the FSIGTT.  It has previously been demonstrated that horses suffering from IR 
have significantly higher AUCi and AUCg than their healthy counterparts (Frank et al. 
2006). 
Dexamethasone and L-T4 treatments alter insulin sensitivity in horses (Frank et al. 
2008; Frank et al. 2005b; Tiley et al. 2007).  In a previous study, insulin sensitivity 
significantly increased when horses were treated with L-T4 for 8 weeks.  These changes 
were paralleled by significant decreases in plasma triglyceride, total cholesterol and very 
low density lipoprotein concentrations (Frank et al. 2005b).  When the duration of L-T4 
treatment was extended to 48 weeks, increased insulin sensitivity persisted throughout the 
study and was accompanied by significant weight loss (Frank et al. 2008).  It is 
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speculated that SI improves in response to L-T4 treatment because weight loss in induced, 
but thyroid hormones may also exert direct effects on glucose uptake (Frank et al. 2008).  
However, SI did not increase across the 15-day pretreatment period in the study reported 
here.  On the contrary, insulin sensitivity was significantly lower by the end of the 15d 
pretreatment period.  Since identical changes were noted in the control group, it was 
assumed that insulin sensitivity decreased because of factors common to all treatment 
groups. 
Before enrollment in the study, horses were kept on pasture without additional 
feed provided.  During the study however, horses were moved into stalls, exercise was 
restricted, and only grass hay was fed.  It has previously been demonstrated that short-
term exercise training increases SI in both obese and lean horses (Powell et al. 2002), and 
skeletal muscle GLUT4 content increases 2- to 3-fold after 6 weeks of exercise 
(McCutcheon et al. 2002).  Sedentary behavior is often implicated in the development of 
IR in humans (Muoio and Newgard 2008), so this is one possible explanation for the 
reduction in SI across the pretreatment period.  Alternatively, stress associated with stall 
confinement during hospitalization (Harewood 2005; Mal 1991) may have contributed to 
the decrease in SI.  It has been previously demonstrated that minor perturbations in 
housing conditions, such as removal of a horse from its accustomed environment, are 
sufficient to alter the normal circadian rhythm of cortisol concentrations, which would 
raise total cortisol secretion across a 24-hour period (Irvine and Alexander 1994). 
Mean insulin sensitivity significantly decreased to 0.73 ± 0.63 × 10–4 L•min-1•mU-1 
in horses that received dexamethasone for 15d relative to baseline, which compares 
favorably with the mean value of 0.53 ± 0.13 × 10–4 L•min-1•mU-1 detected in horses that 
received 0.08 mg/kg bwt dexamethasone intravenously every other day for 21 days (Tiley 
et al. 2007).  Dexamethasone induces IR by altering insulin signaling pathways in 
adipocytes (Kawai et al. 2002) and skeletal muscle (Ruzzin et al. 2005) and liver (Saad et 
al. 1993) tissues.  Phosphorylation of phosphoinositol-3-kinase, a central molecule in 
insulin signal transduction, significantly decreased in rat liver following dexamethasone 
treatment (Saad et al. 1993).  In skeletal muscle, glucocorticoid-induced IR is 
accompanied by reduced insulin-mediated phosphorylation of protein kinase B, which in 
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turn leaves the enzyme glycogen synthase kinase-3 in its unphosphorylated active form.  
Active glycogen synthase kinase-3 phosphorylates and thereby inactivates glycogen 
synthase, which inhibits glycogen synthesis and contributes to the development of IR 
(Ruzzin et al. 2005).  Protein kinase Cβ appears to play an important role in 
glucocorticoid-induced IR in adipocytes (Kawai et al. 2002).  In horses, treatment with 
dexamethasone for 21 days impairs insulin-mediated phosphorylation of glycogen 
synthase kinase-3 in skeletal muscle but does not alter the expression of GLUT4 or protein 
kinase B, or affect insulin-stimulated phosphorylation of protein kinase B (Tiley et al. 
2008). 
All horses included in the study exhibited characteristic signs of endotoxemia after 
LPS administration, including leukopenia, elevated rectal temperature, heart rate and 
respiratory rate.  These findings are in agreement with previous observations of 
endotoxemic horses (Barton et al. 2004; MacKay et al. 1999).  It was surprising however, 
that clinical signs of endotoxemia were not ameliorated by dexamethasone treatment.  On 
the contrary, horses in the DEX group had significantly higher heart and respiratory rates 
than horses in the control group.  It has previously been demonstrated that dexamethasone 
pretreatment suppresses LPS-induced interleukin-1β and interleukin-6 responses in rats 
(O'Connor et al. 2003).  These mediators play a central role in the development of the 
LPS-induced inflammatory reaction (Morris 1991).  Nevertheless, the same study also 
showed that exposure to an acute stressor preceding dexamethasone administration 
eliminates the inhibitory effect of this drug on proinflammatory cytokine production and 
release (O'Connor et al. 2003).  In ponies, dexamethasone administration 5 min 3, 9 and 
24h after endotoxin infusion did not prevent the endotoxin-induced reduction in WBC 
count (Ewert et al. 1985). 
In the study reported here, SI was lower twenty hours after LPS administration in 
horses undergoing control and dexamethasone treatments, but remained unaffected in the 
L-T4 group.  Results of two independently conducted studies, including one performed by 
our research group, have established that SI decreases in response to LPS infusion in 
horses (Toth et al. 2008; Vick et al. 2008).  In humans, assessment of glucose and insulin 
dynamics in response to LPS revealed a biphasic response with an initial increase in 
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glucose utilization followed by a progressive decrease in SI (Agwunobi et al. 2000).  
Endotoxin-mediated IR involves hepatic, skeletal muscle and adipose tissues (McCowen et 
al. 2001; Song et al. 2006).  Lipopolysaccharide-induced activation of Toll-like receptor 4 
in 3T3-L1 adipocytes stimulated the expression of inflammatory cytokines and provoked 
IR (Song et al. 2006).  In rats, sustained endotoxemia adversely affected the early steps of 
the insulin signaling pathway by inhibiting tyrosine phosphorylation of the insulin receptor 
substrate-1 molecule in skeletal muscle and hepatocytes (McCowen et al. 2001). 
Both SI and AUCi remained unchanged 20h following LPS infusion in horses 
receiving L-T4.  This finding was attributed to the effects of thyroid hormone on glucose 
transport at both hepatic and extrahepatic sites (Haber et al. 1995; Romero et al. 2000; 
Weinstein et al. 1994).  In 3T3-L1 adipocytes, treatment with tri-iodothyronine (T3) was 
shown to increase GLUT1 and GLUT4 content and favor partitioning to plasma 
membranes, which would facilitate transmembrane glucose transport into cells (Romero et 
al. 2000).  These changes were observed in both the presence and absence of insulin 
(Romero et al. 2000).  An in vivo study performed in rats treated with L-thyroxine yielded 
similar results, demonstrating that insulin-stimulated glucose transport increased in 
association with higher GLUT1 and GLUT4 content and functional activity (Matthaei et 
al. 1995).  Thyroid supplementation has been shown to increase both basal and insulin-
stimulated glucose uptake in skeletal muscle, with the change being proportional to the 
increase in GLUT4 content (Weinstein et al. 1994).  In liver-derived ARL-15 cells, T3 
stimulates glucose transport by increasing GLUT1 content and enhancing its partition to 
the cell surface (Haber et al. 1995). 
In conclusion, results of this study indicate that thyroid supplementation protects 
against endotoxin-induced IR when administered to horses for 15 days beforehand.  It was 
also demonstrated that horses receiving dexamethasone treatment developed exacerbated 
IR following LPS administration, which may explain why hospitalized horses with 
endotoxemia are more likely to develop laminitis.  These animals may have higher cortisol 
concentrations as a result of stress and confinement.  Insulin sensitivity may also be lower 
in these animals because exercise is restricted during hospitalization.  It can also be 
hypothesized that chronically insulin-resistant horses grazing on pasture experience minor 
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intestinal events resulting in endotoxemia that exacerbates IR and contributes to the 
development of laminitis.  Although the single endotoxin dose used in this study was 
sufficient to exacerbate IR, none of the treated horses developed laminitis.  However, a 
bolus infusion is only a crude approximation of the clinical condition because 
endotoxemia is more severe and persists for longer in affected animals.  Further studies are 
required to explain why L-T4 treatment failed to prevent the decrease in SI that occurred 
across the pretreatment period, yet protected horses against endotoxin-induced IR. 
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CHAPTER 6  
Effects of endotoxemia on the development of laminitis and 




Endotoxemia, carbohydrate overload, and insulin resistance (IR) are important 
risk factors for laminitis in horses and these conditions can occur concurrently (Garner et 
al. 1975; Parsons et al. 2007; Treiber et al. 2006b; van Eps and Pollitt 2006).  An 
association between carbohydrate overload, endotoxemia, and laminitis was first 
described by Sprouse et al. in 1987 (Sprouse et al. 1987).  This group detected elevated 
plasma endotoxin concentrations in 85% of horses that developed laminitis following 
carbohydrate overload (Sprouse et al. 1987).  Alterations in the mucosal barrier, 
occurring after carbohydrate overload may enable endotoxin absorption during the 
prodromal stages of laminitis (Weiss et al. 1998).  An association between endotoxemia 
and IR has recently been established, based upon results of two independently conducted 
studies in which endotoxemia was experimentally induced in healthy horses (Toth et al. 
2008; Vick et al. 2008).  Insulin sensitivity significantly decreased 24 h after intravenous 
administration of exogenous endotoxin to healthy horses in both reports, suggesting that 
this disturbance is a component of the systemic inflammatory response induced by 
endotoxemia.  Results of these studies suggest that intestinal carbohydrate overload leads 
to endotoxemia, which induces IR.  However, no studies have been performed to date to 
determine whether pre-existing endotoxemia increases the likelihood or severity of 
experimentally-induced laminitis in horses. 
Endotoxemia frequently develops in horses suffering from gastrointestinal 
disturbances, metritis, pleuropneumonia or Gram-negative sepsis (Morris 1991; Werners 
et al. 2005).  The absorption of lipopolysaccharide (LPS) into circulation is a prolonged 
process in most clinical cases of endotoxemia, yet most experimental models involve the 
administration of a single bolus infusion of LPS with dosages ranging from 0.02 μg/kg to 
200 μg/kg (Barton et al. 2004; Bottoms et al. 1981; Doherty et al. 2003; Toth et al. 
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2008).  There are only few reports describing the administration of exogenous endotoxin 
to horses as a continuous rate infusion (CRI) (Duncan et al. 1985; Kindahl et al. 1991; 
MacKay et al. 1991).  Infusion rates ranged from 0.03 μg/kg/h to 1 μg/kg/h in these 
studies, resulting in cumulative doses that exceed the amount administered as a bolus 
infusion in other studies.  In humans, however, 100 times lower dosages of 0.75 ng/kg/h 
LPS have been used to model low-grade inflammation (Taudorf et al. 2007).  Lower LPS 
dosages may therefore represent a model for endotoxemia associated with minor 
intestinal events if they occur when horses and ponies are grazing on pasture grass rich in 
soluble carbohydrate. 
The association between pasture-associated laminitis and IR is supported by 
results of a study by Treiber et al. (2006b).  This group demonstrated that ponies 
suffering from prelaminitic metabolic syndrome, a condition characterized by lower 
resting insulin sensitivity, have an odds ratio of 10 to develop clinical laminitis.  
Laminitis became apparent in these ponies in the month of May when pasture grass 
contained significantly more starch than in March (Treiber et al. 2006b).  When starches 
are abundant, the digestive capacity of the equine small intestine is exceeded and this 
carbohydrate enters the hindgut and undergoes rapid bacterial fermentation, resulting in 
the proliferation of lactic acid-producing bacteria, and a concomitant decrease in Gram-
negative bacteria (Garner et al. 1978; Longland and Byrd 2006).  Analysis of hindgut 
bacterial populations during the development of carbohydrate-induced laminitis revealed 
that bacteria belonging to the Streptococcus bovis/equinus complex, predominantly 
Streptococcus lutetiensis (formerly known Streptococcus infantarius ssp. coli) proliferate 
(Milinovich et al. 2007; Milinovich et al. 2006).  This alteration precedes the 
development of lameness, which implicates these specific microorganisms in the 
pathogenesis of alimentary laminitis.  Additionally, damage to the intestinal mucosa, 
triggered by high intraluminal levels of lactic acid and endotoxin, may compromise the 
mucosal barrier, and thereby facilitate absorption of endotoxin (Garner et al. 1978).  If 
these intestinal events occur at a minor level, subclinical endotoxemia may contribute to 
the development of clinical laminitis in horses and ponies grazing on pasture.  This could 
occur through exacerbation of preexisting IR or as a result of sustained inflammatory 
 136
reaction (Toth et al. 2008).  The significance of endotoxemia in the development of 
laminitis has been further emphasized by the work of Parsons et al. (2007).  This group 
demonstrated that hospitalized horses suffering from clinical endotoxemia have 5-fold 
higher odds of developing laminitis than horses without endotoxemia. 
One method for experimentally inducing laminitis in horses involves the 
administration of oligofructose (OF) at dosages ranging from 5 g/kg to 12.5 g/kg (French 
and Pollitt 2004b; Kalck et al. in press; van Eps and Pollitt 2006).  In this model, higher 
OF dosages are associated with more severe laminitis and greater loss of 
hemidesmosomes between the lamina densa of the basement membrane and the 
epidermal basal cells (French and Pollitt 2004b).  Development of laminitis in the OF 
model is also associated with altered glucose and insulin dynamics (Kalck et al. in press; 
van Eps and Pollitt 2006) as well as clinical signs suggestive of a systemic inflammatory 
response (van Eps and Pollitt 2006). 
It was therefore hypothesized that the IR associated with alimentary carbohydrate 
overload would be significantly greater in horses pretreated with endotoxin, and that the 
severity of laminitis would increase when endotoxin and OF treatments were combined.  
Specific aims of this study were (1) to use low-dose endotoxin CRI as an experimental 
model for minor intestinal events occurring in horses grazing on pasture, (2) to determine 
whether LPS infusion alone induced IR and/or laminitis, and (3) to investigate whether 
pre-treatment with LPS would accentuate IR and/or laminitis induced by intestinal 
carbohydrate overload.  An OF dosage of 5g/kg bwt was selected for this study because 
our research group has recently determined that this dosage induces mild laminitis that 
horses can successfully recover from (Kalck et al. in press) 
 
6.2 Materials and methods 
 
Horses – Twenty-four adult mares from the University of Tennessee research and 
teaching herd were included in the study.  Mean ± SD bodyweight (bwt) was 495 ± 43 kg 
(range from 403 – 559 kg) with the body condition score ranging from 4 to 6 (Henneke et 
al. 1983).  Mean ± SD age of the horses were 11.2 ± 3.8 (range: 6 – 16); breeds included 
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Quarter Horse/Tennessee Walking horse crossbred (n = 8), Quarter Horse (n = 11), 
Tennessee Walking Horse (n = 4), and Thoroughbred (n = 1). 
 
Experimental design – Procedures were performed between the months of January and 
June 2008.  Three treatments were compared using a completely randomized design with  
eight repetitions (horses) per treatment.  Treatment groups consisted of: 
LPS group (n = 8)  Endotoxin CRI for 8h followed by administration of 4L 
water via nasogastric intubation 
OF group (n = 8) Saline (0.9% NaCl) CRI for 8h followed by 5g/kg bwt OF 
dissolved in 4L water 
LPS/OF group (n = 8) Endotoxin CRI followed by 5g/kg bwt OF dissolved in 4L 
water.  
Horses were brought into the teaching hospital in groups of three and one horse was 
assigned to each treatment group.  Each horse was individually housed in a 3.7-m ×3.7-m 
stall and fed grass hay in amounts equivalent to 2% of bwt and ad libitum water.   
Upon admission (Friday), horses were weighed and physical examinations were 
performed.  An intravenous catheter was inserted into the jugular vein 24h prior to the 
baseline frequently sampled intravenous glucose tolerance test (FSIGTT).  The baseline 
FSIGTT was then performed at 0800 on day four (Monday).  A CRI of either LPS or 
0.9% NaCl solution was initiated at 0800 on day five (Tuesday) and continued until 1600.  
At 0800 on day six (Wednesday; 16h after completion of the CRI), each horse received 
either 5 g/kg OF dissolved in 4L of water or 4L water alone via nasogastric intubation.  A 
post-treatment FSIGTT was performed 24h later, starting at 0800 on day seven 
(Thursday).  Horses were evaluated for the presence of laminitis for 48h after the 
administration of water or OF using the Obel grading system (Taylor et al. 2002).  Horses 
that developed laminitis remained hospitalized and were treated with phenylbutazone 
until clinical signs of laminitis resolved or euthanasia was performed.  The study protocol 




Lipopolysaccharide administration – Escherichia coli O55:B5 LPS1 was mixed with 
1L 0.9% NaCl with the investigator wearing protective attire.  Lipopolysaccharide 
solution was infused intravenously at a dosage of 7.5 ng/kg/h for 8h using an infusion 
pump set at a rate of 100 mL/h.  Horses enrolled in the OF group received 800 mL 0.9% 
NaCl intravenously at the same rate.  Horses were observed for signs of colic and 
physical examination parameters were monitored, including rectal temperature, heart rate 
and respiratory rate, for 72h after the initiation of the CRI.  Data were recorded hourly 
during the 8-hour CRI, then every 2h for 8h, and finally every 4h for 56h. 
 
Oligofructose administration – Oligofructose2 was administered to horses at a dosage 
of 5 g/kg bwt.  Powder was mixed with 4L warm water until dissolved and then 
administered via nasogastric intubation.  Horses in the LPS group received 4L water 
alone by the same route. 
 
Complete blood count (CBC) analysis – To evaluate the individual response to 
endotoxin, CBC analysis was performed in each horse on three occasions.  Blood was 
collected from the indwelling jugular catheter into tubes containing EDTA before the 
CRI was initiated, 2 hours after initiation of the CRI, and finally at the end of the 8-hour 
infusion.  Samples were immediately transported to the clinical pathology laboratory 
within the teaching hospital for CBC analysis.  
 
FSIGTT procedure – A 14-gauge polypropylene catheter3 was inserted into the left 
jugular vein the day before procedures were initiated and an injection cap and infusion 
set4 (length, 30 cm; internal diameter, 0.014 cm) were attached to the catheter during 
each test.  The FSIGTT first described by Hoffman (Hoffman et al. 2003) and further 
refined by our research group (Chapter 4) was used.  Briefly, a rapid (< 1 min) bolus 
infusion (100 mg of glucose/kg) of 50% (wt/vol) dextrose solution5 was administered to 
                                                 
1 Sigma Chemical Co., St Louis, MO, 
2 Orafti P95 BENEO-Orafti Inc. 2740 Route 10 West, Morris Plains, NJ 07950 
3 Abbocath-T 14G X 140mm, Abbott Laboratories, North Chicago, IL. 
4 Butterfly, Abbott Laboratories, North Chicago, IL. 
5 Dextrose 50% injection, Abbott Laboratories, North Chicago, IL. 
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each horse via the infusion line and catheter, followed by 20 mL infusion of saline 
solution containing heparin (4 U/mL).  Blood samples were then collected via the 
catheter 10, 5, and 1 min prior to, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, and 19 min after 
infusion of dextrose.  At 20 min, regular insulin6 (20 mU/kg) was infused, followed by 
another infusion of 20 mL saline solution containing heparin.  Blood samples were 
subsequently collected via the catheter at 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 
100, 120, 150, and 180 min relative to the dextrose bolus infusion.  At each time point, 3 
mL of blood was withdrawn from the infusion line and discarded.  A 6 mL blood sample 
was then collected, followed by infusion of 5 mL of saline solution containing heparin.  
Half of the volume of blood was transferred to a tube containing sodium heparin, which 
was immediately cooled on ice and then refrigerated.  The remaining blood was 
transferred to a tube containing no anticoagulant.  These samples were allowed to clot at 
22oC for 1h and then serum was harvested via low-speed (1,000 × g) centrifugation.  
Plasma and serum samples were stored at –20oC until further analyzed.  
 
Laminitis scoring – Obel grading was performed as previously described (Taylor et al. 
2002) and horses were assessed before LPS or saline was infused intravenously on day 
four.  Obel grades were also determined every 4h for 56h after OF or water was 
administered.  Horses that developed laminitis were subsequently monitored every 12h 
until lameness resolved (n = 6) or euthanasia was performed (n = 1). 
 
Phenylbutazone administration – Treatment for laminitis was initiated as soon as Obel 
grade ≥ 2 laminitis was detected.  Phenylbutazone7 was administered at an initial dosage 
of 4.4 mg/kg IV or PO q12h.  The dosage was then gradually reduced over time, 
according to the response shown by each individual horse. 
 
Plasma glucose and serum insulin concentrations – Plasma glucose concentrations 
were measured by use of a colorimetric assay8 on an automated discrete analyzer9.  
                                                 
6 Humulin R, Eli Lilly and Co, Indianapolis, IN. 
7 Equi-Phar, Vedco, Inc., St. Joseph, MO. 
8 Glucose, Roche Diagnostic Systems Inc, Somerville, NJ. 
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Serum insulin concentrations were determined by use of a radioimmunoassay10 that has 
previously been validated for use in horses (Freestone et al. 1991). Each sample was 
assayed in duplicate and intra-assay coefficients of variation < 5% or < 10% were 
required for acceptance of glucose and insulin assay results, respectively. 
 
Interpretation of FSIGTT data by use of the minimal model – Values of insulin 
sensitivity (SI), glucose effectiveness (Sg), acute insulin response to glucose (AIRg), and 
disposition index (DI) were calculated for each FSIGTT in accordance with the minimal 
model (Bergman et al. 1981) by use of commercially available software11,12 and 
previously described methods (Hoffman et al. 2003).  Disposition index was calculated 
via multiplication of AIRg by SI. 
 
Statistical analysis – White blood cell, neutrophil and lymphocyte counts obtained at 0, 
2h, and 8h relative to the initiation of the LPS infusion were compared between horses 
receiving endotoxin (LPS and LPS/OF) versus saline control (OF group) using a mixed 
model analysis of variance with repeated measures.  Heart rate, respiratory rate and rectal 
temperature measurements were compared among treatment groups using mixed model 
analysis of variance with repeated measures.  Fisher’s Exact Test was used to evaluate 
the relationship between development of laminitis and treatment groups.  In each horse, 
area under the curve for glucose (AUCg) and for insulin (AUCi) were calculated for both 
FSIGTT procedures (baseline, post-treatment) from the glucose and insulin 
concentrations measured, by use of the trapezoidal method, using commercially available 
computer software.13  To determine the effects of treatments and time (baseline, post-
treatment) on Sg, SI, AIRg, DI, AUCi and AUCg mixed model analysis of variance with 
repeated measures was used.  Two outliers, an SI value with a studentized residual of 
4.79 and an AIRg value with a studentized residual of 3.22, were eliminated from the 
final analysis.  When a significant treatment × time effect was detected, protected Least 
                                                                                                                                                 
9 Cobas Mira, Roche Diagnostic Systems Inc, Somerville, NJ. 
10 Coat-A-Count insulin, Diagnostic Products Corp, Los Angeles, CA. 
11 MinMod Millenium, version 6.10, Raymond Boston, University of Pennsylvania, Kennet Square, PA. 
12 Stata 9.2, Stata Corporation, College Station, TX. 
13 PROC MIXED, SAS, version 9.1, SAS Institute Inc, Cary, NC 
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Significant Difference mean separation method was used to compare groups at different 




Horses that received LPS exhibited signs of abdominal pain, including pawing, 
stretching and occasional attempts to roll during the first 4h of the LPS infusion.  
Transient diarrhea was noted 16 to 24h following OF administration when horses 
received this treatment.  At the initiation of the study, none of the horses exhibited signs 
of laminitis (Obel grade 0).  Laminitis developed in 7 horses 28 to 36h following OF 
administration and all affected animals recovered after treatment with phenylbutazone, 
with one exception.  This horse from the LPS/OF group developed Obel grade 4 laminitis 
and remained lame despite treatment with phenylbutazone.  Euthanasia was performed 
and pathological examination revealed marked rotation of the third phalanx in all four 
feet, compatible with severe laminitis. 
Significant time × treatment effects (P < 0.001) were registered for WBC, 
neutrophil, and lymphocyte counts (Table 6.1 and Figure 6.1).  Two hours following the 
initiation of the LPS infusion, neutrophil, WBC and lymphocyte counts significantly 
decreased in LPS and LPS/OF groups relative to baseline values, and compared to horses 
receiving 0.9 % NaCl treatment (OF group).  Neutrophil and WBC counts significantly 
increased whereas lymphocyte counts further decreased 8 h following the commencement 
of the LPS infusion in LPS and LPS/OF groups, relative to baseline or control (OF group) 
values. 
With respect to physical examination findings, significant treatment × time effects 
were registered for rectal temperature (P < 0.001), heart rate (P < 0.001) and respiratory 
rate (P = 0.004).  A biphasic response for rectal temperature and heart rate was observed 
in horses from the LPS/OF group, with peaks apparent approximately 2 to 8h after 
commencement of the LPS infusion and again 24h after nasogastric intubation with OF.  
Single peaks were observed approximately 2 to 8h after the initiation of the LPS infusion 
and at 24 h after OF administration in the LPS and OF groups, respectively (Figure 6.2). 
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 Table 6.1 – Mean ± SD white blood cell, neutrophil, and lymphocyte counts registered 
at 0, 2 and 8 h relative to the initiation of an 8-hour lipopolysaccharide (LPS and LPS/OF 
groups) or saline (OF group) continuous rate infusion. 
Treatment 
 LPS and LPS/OF   
(n = 16) 
OF               




0 h 7.32 ± 1.35 a 6.98 ± 1.60 a 
2 h 3.05 ±1.18 b 7.28 ± 1.81 a WBC 
(× 103/µL) 
8 h 8.81 ± 2.30 c 7.20 ± 1.48 a 
< 0.001 
0 h 4.24 ± 1.26 a 4.02 ± 1.01 a 
2 h 1.54 ± 1.00 b 4.17 ± 1.41 a 
Neutrophils 
(× 103/µL) 
8 h 7.89 ± 2.34 c 4.09 ± 1.07 a 
< 0.001 
0 h 2.68 ± 0.59 a 2.50 ± 0.84 a 
2 h 1.39 ± 0.36 b 2.63 ± 0.87 a 
Lymphocytes 
(× 103/µL) 
8 h 0.80 ± 0.39 c 2.66 ± 0.78 a 
< 0.001 
a-c For variables with significant (P < 0.05) treatment × time effects, mean values with 
different superscripts differ significantly, as determined by ANOVA for repeated 
















































































Figure 6.1 – Mean ± SE white blood cell (panel A), neutrophil (panel B), and 
lymphocyte (panel C) counts registered at 0, 2 and 8 h relative to initiation of the LPS 
(open columns; LPS and LPS/OF groups) or saline (solid columns; OF group) continuous 









































































Figure 6.2 – Mean rectal temperature (panel A), heart rate (panel B) and respiratory rate 
(panel C) registered in horses receiving lipopolysaccharide (LPS; solid squares), 
oligofructose (OF; open circles), or LPS followed by OF (open triangles). 
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Mean ± SD Obel laminitis grade was zero, 0.4 ± 0.7, and 1.7 ± 1.5 for LPS, OF 
and LPS/OF groups, respectively.  Laminitis was not observed in the LPS group.  Two 
horses in the OF group developed Obel grade 1 (n = 1) or 2 (n = 1) laminitis and five 
horses in the LPS/OF group developed Obel grade 2 (n = 2), 2.5 (n = 1), 3 (n = 1), and 4 
(n = 1) laminitis.  The Fisher’s exact test revealed a significant (P = 0.021) association 
between treatment groups and development of Obel grade > 2 laminitis with 0, 12.5 and 
62.5 % of horses developing Obel grade > 2 laminitis of in LPS, OF and LPS/OF groups, 
respectively.  Individual comparisons between treatment groups using the Fisher’s exact 
test demonstrated that horses in the LPS/OF group were significantly (P = 0.013; one-
tailed test) more likely to develop laminitis of Obel grade > 2 than horses in the LPS 
group.  A trend (P = 0.060; one-tailed test) towards increased likelihood of developing 
laminitis of Obel grade > 2 in horses receiving both LPS and OF versus OF alone was 
also detected.  It was noted that 4 of 5 cases of laminitis registered in the LPS/OF group 
occurred during the months of February and March, when horses were kept on pasture 
and fed primarily hay in round bales. 
Although post-treatment SI was significantly decreased over time compared to 
baseline in LPS (P = 0.006), OF (P < 0.001), and LPS/OF (P = 0.018) groups, the 
treatment × time effect was not statistically significant (P = 0.224; Table 6.2).  
Conversely, a significant treatment × time effect (P = 0.037) was detected for AIRg, as 
the pancreatic insulin response increased significantly over time in the LPS (P = 0.005) 
and LPS/OF (P < 0.001) groups, but remained unchanged (P = 0.104) in the OF group.  
Disposition index remained unchanged over time for LPS (P = 0.293) and LPS/OF (P = 
0.160) groups, but significantly decreased after OF (P = 0.011) administration, which 
resulted in a significant treatment × time effect (P = 0.022).  No significant alterations in 
Sg were registered. 
Mean post-treatment AUCg and AUCi were significantly higher than pre-
treatment baseline values in all three groups. A significant treatment × time effect was 
registered for AUCg (P < 0.001), but not AUCi (P = 0.093). 
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Table 6.2 – Mean ± SD glucose and insulin variables values registered before (pre) and 
after (post) treatment in horses from lipopolysaccharide (LPS), oligofructose (OF), and 












Post 1.21 ± 0.93 c 1.31 ± 0.71 c 1.85 ± 2.15 b,c 
0.224 




Post 2.09 ± 1.75 2.85 ± 1.45 2.85 ± 1.09 
0.320 
Pre 469 ± 316 a 490 ± 386 a,b 346 ± 114 a AIRg 
(mU•min•L-1) 
 Post 861 ± 456 
b,c 702 ± 449 a,b,c 1046 ± 602 c 
0.038 
Pre 13.5 ± 4.8 a,b,c 18.6 ± 5.9 a,b 15.4 ± 9.8 a,b,c DI 
× 10-2 
 Post 9.6 ± 7.0 
b,c 8.2 ± 6.0 c 20.8 ± 18.2 a 
0.023 
Pre 6.29 ± 3.01 a,b,c 5.66 ± 2.64 a,b 4.46 ± 1.43 a AUCi 
(mU/mL•min) 
 Post 12.18 ± 3.80 
d 8.04 ±3.08 c 8.11 ± 3.52 b,c 
0.093 
Pre 16.00 ± 1.41 a 16.43 ± 1.40 a,b 16.18 ± 1.14 a AUCg 
(g/dL•min) 
 Post 18.25 ± 2.64 b,c 23.36 ± 2.67 d 19.92 ± 1.67 c 
< 0.001 
a-c For variables with significant (P < 0.05) treatment × time effects, mean values with 
different superscripts differ significantly, as determined by ANOVA for repeated 





Administration of LPS, OF, or both treatments lowered insulin sensitivity, but the 
magnitude of change did not differ between groups, so our hypothesis that pretreatment 
with LPS would exacerbate the insulin resistance induced by OF was not supported.  
Nevertheless, significant association between treatments and the incidence of Obel grade 
> 2 laminitis was demonstrated, with the highest incidence of laminitis observed in the 
LPS/OF group.  Results suggest that endotoxemia is an important determinant of 
laminitis severity in the OF experimental model, but lipopolysaccharide does not induce 
the condition when administered alone for 8h.  Furthermore, physical examination and 
complete blood count results indicate that continuous infusion of LPS at a rate of 7.5 
ng/kg/h is sufficient to induce a systemic inflammatory response.  This provides an 
experimental model for systemic inflammation and results help to explain why 
endotoxemia is an important risk factor for laminitis in horses. 
Alterations in WBC, neutrophil, and lymphocyte counts were induced by 
endotoxemia in this study.  Previous studies investigating the effects of endotoxemia on 
blood leukocytes in horses have yielded variable results (Kelmer et al. 2008; MacKay et 
al. 1999; Morris et al. 1990).  Intravenous administration of 30 ng/kg Escherichia coli 
O55:B5 endotoxin significantly decreased the WBC count between 60 and 300 min after 
endotoxin infusion (MacKay et al. 1999).  Morris et al. (1990) used the same endotoxin 
dosage and detected a significantly lower WBC count 1.5 and 2 h following endotoxin 
infusion, with counts returning to baseline 2.5 to 8h after LPS administration.  In the 
study reported here, the initial leukopenia registered at 2 h was followed by a rebound 
leukocytosis recorded at 8 h, with the WBC count significantly higher than baseline.  The 
rebound leukocytosis was most likely due to the significant increase in neutrophil count 
registered 8 h after initiation of the LPS infusion.  This latter finding is consistent with 
results reported by Kelmer et al. (2008).  This group detected a significantly higher mean 
polymorphonuclear cell count 6h after 0.2 μg/kg LPS was administered intravenously to 
horses.  The higher neutrophil count detected 8h after initiation of the endotoxin CRI in 
our study is likely to be a consequence of enhanced granulocyte production and release 
from the bone marrow (Morris 1991).  This was likely to have been triggered by 
 148
endotoxin-induced secretion of granulocyte colony stimulating factor, keratinocyte-
derived chemokine, and macrophage inflammatory protein-2 (Morris 1991; Zhang et al. 
2005).  Elevated plasma cortisol concentrations have been detected in humans following 
endotoxin administration and this would provide an explanation for the progressive 
lymphopenia registered during the endotoxin CRI if the same alteration occurs in horses 
(Richardson et al. 1989).  Unfortunately, blood cortisol concentrations were not measured 
in this study. 
Alterations in physical examination parameters have previously been associated 
with exogenous endotoxin administration in horses (Barton et al. 2004; Clark and Moore 
1989; Kelmer et al. 2008; Moore et al. 2007).  Administration of LPS to horses at 
different dosages (20 to 200 ng/kg) significantly increased heart rate and rectal 
temperature with peak values registered between 60 – 120 min and 120 – 180 min after 
bolus infusion, respectively (Barton et al. 2004; Kelmer et al. 2008; Morris et al. 1990).  
In horses, physical examination findings have also been significantly altered by OF 
administration (Kalck et al. in press; van Eps and Pollitt 2006).  Administration of 10g 
OF/kg bwt significantly increased rectal temperature and heart rate, with the highest 
values demonstrated at 20 and 32 h relative to OF administration (van Eps and Pollitt 
2006).  These findings correspond well with the alterations in physical examination 
parameters detected in this study, and provide an explanation for the biphasic response 
observed in horses receiving OF sixteen hours after completion of the LPS infusion 
(LPS/OF group). 
Endotoxemia has previously been shown to influence glucose and insulin 
dynamics in horses.  Our research group demonstrated that intravenous administration of 
20 ng/kg Escherichia coli O55:B5 lipopolysaccharide significantly lowered SI and DI, 
and raised AIRg when administered to healthy horses (Toth et al. 2008).  Endotoxemia-
induced IR has also been detected in horses by Vick et al. (2008).  This group used the 
euglycemic hyperinsulinemic clamp and showed that insulin sensitivity significantly 
decreased 24h after the administration of 0.045 μg/kg LPS.  These findings correspond 
well with results of the current study, which also show that SI significantly decreased 
from the baseline mean value of 3.59 × 10–4 L•min-1•mU-1 to the post-treatment value of 
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1.21 × 10–4 L•min-1•mU-1 in horses receiving LPS.  Additionally, the significantly higher 
AUCg and AUCi detected in horses treated with LPS provides further evidence of 
reduced insulin sensitivity.  
It has previously been shown that administration of 7.5 to 12.5 mg/kg OF via 
nasogastric intubation alters blood glucose and insulin concentrations in horses (van Eps 
and Pollitt 2006).  Nasogastric intubation with 10 g/kg OF significantly increased plasma 
glucose concentrations from 12 to 48 h after its administration, relative to saline treated 
controls.  A similar trend was noted for serum insulin concentrations as well, although 
significant differences were only registered at 12, 40, and 44h (van Eps and Pollitt 2006).  
Results of a recent study performed by our research group indicate that intestinal 
carbohydrate overload induced by OF significantly alters glucose dynamics in horses.  
Higher AUCg values for the FSIGTT were detected 24 and 48 h after administration of 5 
g OF/kg bwt, when compared with controls (Kalck et al. in press).  Minimal model 
analysis results from the same study indicated lower insulin sensitivity 24 and 48 h after 
OF administration relative to controls, but this difference was not statistically significant 
because of wide variability in results between and within horses.   
In the study reported here, horses in the LPS, OF and LPS/OF groups 
demonstrated a significant decrease in SI, accompanied by significant increases in AUCg 
and AUCi.  Changes in AUCg were greatest in horses receiving the OF treatment alone, 
indicated by the significant time × treatment interaction.  Consistent with these findings 
Kalck et al (in press) also demonstrated that AUCg values increased 34 and 32% when 
measured 24 and 48h, respectively after oral administration of 5g/kg OF to horses.  
Higher AUCg values registered following OF administration are more likely to be a 
consequence of decreased insulin sensitivity than fructan absorption from the small 
intestine, because only a small amount of this carbohydrate is absorbed in the proximal 
gastrointestinal tract of the horse (Bailey et al. 2007).  Administration of LPS followed 
by OF had no additive effect on SI or AUCi in this study and AUCg was more 
profoundly affected when OF was administered alone.  This suggests that prior exposure 
to endotoxin reduces the effect of intestinal carbohydrate on glucose metabolism.  
Development of early endotoxin tolerance, characteristic of repeated endotoxin exposure, 
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may explain the absence of an additive effect of LPS/OF treatment on glucose and insulin 
dynamics.  Higher maximum TNFα concentrations and earlier, more sustained serum 
TNFα activity was detected following the first infusion when two endotoxin infusions 
were administered to horses 24h apart (Allen et al. 1996), indicating that early phase 
endotoxin tolerance develops in horses.  Nevertheless, the biphasic response detected for 
physical examination variables is not consistent with endotoxin tolerance.  Alternatively, 
LPS infusion alone may have maximally lowered SI in the LPS/OF group. 
Increased AIRg successfully compensated for lower SI in horses receiving LPS 
and LPS/OF treatments, as demonstrated by DI values being statistically the same before 
and after treatment in these groups.  It is thought that pancreatic insulin secretion 
increases to sustain insulin-mediated glucose disposal when insulin sensitivity decreases, 
and this represents an efficient compensatory mechanism in the horse (Treiber et al. 
2006b).  In contrast, humans with IR more commonly develop pancreatic exhaustion in 
association with type II diabetes mellitus (Brunton et al. 2006; Kaiser et al. 2003).  
Equine pancreatic β-cells maintain high basal insulin concentrations and euglycemia, 
which makes type II DM a rare condition in the horse (Treiber et al. 2005b).  
Nevertheless, excessive compensation characterized by elevated circulating insulin 
concentrations may be a precursor of metabolic disorders, such as laminitis (Treiber et al. 
2005a).  Horses in the OF group, however, suffered from uncompensated IR, as indicated 
by the lower post-treatment mean DI value.  Decompensation develops when increased 
insulin secretion can no longer be sustained. Decompensated insulin resistance 
characterized by hyperglycemia has been described in horses suffering from laminitis 
(Treiber et al. 2006b). 
In the study reported here, a significant association existed between treatment and 
the incidence of laminitis, with 0 of 8, 1 of 8, and 5 of 8 horses developing Obel grade > 
2 laminitis in the LPS, OF and LPS/OF groups, respectively.  The highest incidence of 
laminitis occurred in the LPS/OF group and this indicates that endotoxemia plays an 
important role in the development of this condition.  This finding is supported by the 
previous observation that hospitalized horses suffering from clinical endotoxemia have an 
odds ratio of five to develop laminitis (Parsons et al. 2007).  Endotoxemia may contribute 
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to the development of laminitis by inducing digital vasoconstriction mediated by 5-
hydroxytryptamine and thromboxane B2 (Menzies-Gow et al. 2004).  Alternatively, 
endotoxemia may enhance cyclooxygenase-2 mRNA expression in vascular smooth 
muscle cells (Rodgerson et al. 2001) or activate the coagulation cascade (Pernerstorfer et 
al. 1999; Weiss et al. 1994).  It has recently been shown that horses exhibit a strong 
innate immune response during the developmental stages of laminitis, and a mixture of 
innate and adaptive immune responses at the onset of lameness, which suggests that 
lamellar inflammation plays an important role in laminitis (Belknap et al. 2007). 
Although measurements of inflammatory cytokines were not performed in the study 
reported here, clinical examination and CBC findings were suggestive of a systemic 
inflammatory response following the lipopolysaccharide CRI and again after 
administration of OF.  These inflammatory responses provide a plausible explanation for 
the high incidence of laminitis in horses that received LPS followed by OF.  
Although endotoxemia has long been suspected to contribute to the development 
of laminitis (Elliott and Bailey 2006) and LPS has been demonstrated in the blood of 
horses subjected to carbohydrate overload to induce laminitis (Sprouse et al. 1987), 
convincing evidence connecting these two conditions has been lacking.  Therefore, the 
ability of endotoxin pretreatment to increase the incidence of Obel grade ≥ 2 laminitis, 
demonstrated in this study, is of great clinical importance.  Our findings indicate that 
endotoxemia associated with colitis, strangulating intestinal obstruction, metritis or 
pleuropneumonia (MacKay 2001; Morris 1991) requires aggressive treatment in order to 
prevent laminitis.  Furthermore, if minor intestinal events occur in horses grazing on 
pasture (Longland and Byrd 2006), they may result in subclinical endotoxemia that could 
trigger laminitis.  Ponies suffering from IR are predisposed to pasture-associated laminitis 
(Carter et al. 2009; Treiber et al. 2006b), so endotoxin-mediated exacerbation of 
preexisting IR may be an important trigger for laminitis when susceptible horses and 
ponies are grazing on pasture.  Lower insulin sensitivity associated with endotoxemia 
(Toth et al. 2008; Vick et al. 2008) may contribute to the development of laminitis 
through the induction of vasoconstriction (Kim et al. 2006) or activation of matrix 
metalloproteinases (Treiber 2005). 
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At the same time, it is important to note that none of the horses receiving the LPS 
infusion as the only treatment (LPS group) developed laminitis.  This finding is in 
agreement with results of previous studies in which laminitis failed to develop after 
experimental administration of endotoxin alone (Barton et al. 2004; Kelmer et al. 2008; 
MacKay et al. 1999).  Only one study reports the development of clinical signs consistent 
with laminitis in 6 of 7 horses following endotoxin administration (Duncan et al. 1985).  
This study by Duncan et al. (1985) involved 24-hour infusion of endotoxin into the portal 
vein at a rate of 1 μg/kg/h. 
Laminitis of Obel grade 1 or 2 developed in two horses from the OF group that 
did not receive LPS beforehand.  Nasogastric intubation with OF, using dosages ranging 
from 5.0 to 12.5 g/kg has been successfully used to induce laminitis in previous studies 
(Croser and Pollitt 2006; French and Pollitt 2004b; Kalck et al. in press; van Eps and 
Pollitt 2006).  Kalck et al. (in press) recently demonstrated that administration of 5 g/kg 
OF induced clinically apparent laminitis in 3 of 8 horses, which corresponds well with 
our findings.  A temporal progression of histopathologic changes consistent with 
laminitis has previously been demonstrated when hoof biopsy samples were collected 
every 6h for 36h following administration of 10 g/kg OF (Croser and Pollitt 2006).  
Histopathologic examination of lamellar basal cells harvested from horses 48 h after 
nasogastric intubation with 7.5, 10, and 12.5 g/kg OF revealed that the severity of 
pathologic changes, including loss of hemidesmosomes, rounding of basal cell nuclei and 
failure of the cytoskeleton, positively correlated with the OF dosage used (French and 
Pollitt 2004b).  The authors hypothesized that OF administration induces laminitis 
through activation of matrix metalloproteinases and glucose deprivation of basal cells 
found within secondary epidermal lamellae (French and Pollitt 2004b).  Nasogastric 
intubation with 10 g/kg OF also induces profound changes in the hindgut bacterial 
population by causing a shift from the predominantly Gram-negative flora to one 
dominated by Gram-positive bacteria (Milinovich et al. 2006).  Initial overgrowth of 
bacteria belonging to the Streptococcus bovis/equinus complex, predominantly 
Streptococcus lutetiensis followed by a rapid population decline were consistently 
observed in horses developing laminitis after OF administration.  These findings suggest 
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the involvement of streptococci in the development of laminitis induced by OF overload 
(Milinovich et al. 2007; Milinovich et al. 2006).  
In this study, the incidence of laminitis decreased during the months of April and 
May when pastures were growing rapidly.  It has been shown that the storage 
carbohydrate content of pasture grass is highest during late spring (Longland and Byrd 
2006; Treiber et al. 2006b), therefore adaptation of the intestinal flora to this higher 
carbohydrate load may have prevented acute digestive disturbances associated with OF 
administration.  Our results therefore indicate that horses are at greatest risk for 
developing carbohydrate overload and laminitis when they are suddenly turned out on 
pasture, instead of being gradually introduced to the new environment.  Further studies 
are required to determine whether adaptation to a high soluble carbohydrate diet helps 
prevent laminitis induced by carbohydrate overload.  For the purpose of the experimental 
model, horses should be removed from pasture and fed grass hay for 4 weeks in order to 
prevent adaptation. 
In conclusion, findings of the study reported here indicate that endotoxemia is an 
important determinant of laminitis severity.  Laminitis developed in a greater number of 
horses and was more severe when LPS was administered before induction of intestinal 
carbohydrate overload.  Results suggest that endotoxemia should be intensively managed 
in horses suffering from colitis or strangulating obstructions to prevent the development 
of laminitis.  Minor intestinal events associated with grazing on pasture may also result in 
endotoxemia, which would be expected to raise the risk of laminitis in pastured horses 
and ponies. 
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CHAPTER 7  
General Summary and Future Directions 
 
Studies reported here aimed to investigate glucose and insulin dynamics in horses 
and their relationship to endotoxemia and laminitis. 
Our results provide substantial evidence of an association between endotoxemia 
and insulin resistance (IR) in horses.  However, the specific alterations in insulin signal 
transduction induced by endotoxemia must still be elucidated in the horse.  Accurate 
characterization of mediators involved in the development of endotoxin-mediated IR may 
provide new targets for pharmacological interventions aimed to restore normal insulin 
sensitivity.  Results of our study examining the effects of resting insulin sensitivity on the 
magnitude of IR induced by endotoxemia suggest that pretreatment with levothyroxine 
sodium days prevents the reduction in insulin sensitivity triggered by endotoxemia.  
Studies must be performed in the future to determine the minimal duration of treatment 
required to achieve this protection and investigate the exact mechanisms responsible for 
this protective effect.  This work may lead to the development of new drugs for 
preventing or treating IR. 
Our observation that endotoxemia predisposes horses to laminitis corresponds 
well with clinical experience, and confirms findings previously reported in a retrospective 
study (Parsons et al. 2007).  Nevertheless, the pathophysiological mechanism by which 
endotoxemia facilitates the development of laminitis must still be identified.  The 
systemic inflammatory response triggered by endotoxemia and IR are likely to play 
important roles in the development of laminitis (Belknap 2007; Treiber et al. 2006a).  
Induction of IR using a model other than endotoxemia, such as lipid infusion (Sessions et 
al. 2004) or dexamethasone administration (Tiley et al. 2007), followed by challenge 
with 5 g/kg oligofructose would provide a practical method for assessing the role of 
altered insulin sensitivity in the development of laminitis.  If a higher incidence of 
laminitis were demonstrated in horses with experimentally-induced IR, it would suggest 
that reduced insulin sensitivity is an independent risk factor for laminitis in horses.  
Furthermore, mitigation of endotoxin-induced IR by pretreatment of horses with 
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levothyroxine sodium preceding oligofructose administration would be an alternative 
method to evaluate the role of endotoxin-induced IR in laminitis development.  Temporal 
measurements of inflammatory mediators in lamellar tissues harvested from horses 
suffering from clinical endotoxemia with and without laminitis and comparison of these 
results with healthy horses would help to determine the role of the endotoxin-induced 
inflammatory response in the development of laminitis. 
Minimal model analysis has been used throughout these studies to interpret 
frequently sampled intravenous glucose tolerance test (FSIGTT) data and to assess 
glucose and insulin homeostasis.  This procedure was selected because it not only 
estimates insulin sensitivity (SI), but also acute insulin response to glucose (AIRg), 
glucose effectiveness (Sg) and disposition index (DI).  Technical difficulties associated 
with the euglycemic hyperinsulinemic clamp (EHC) also contributed to the selection of 
the FSIGTT method.  However, our studies also showed that minimal model analysis 
increased variance, which reduced the likelihood of attaining statistical significance.  
Thus, to further characterize glucose and insulin dynamics, area under the glucose 
(AUCg) and insulin (AUCi) curves were calculated in two studies included in this thesis, 
and between-horse variability was lower for these values.  A study should be performed 
in the future to investigate the relationship between area under the curve values and 
minimal model analysis estimates using the statistical method of regression.  Area under 
the curve values alone or AUCg-to-AUCi ratios may provide an alternative method for 
estimating insulin sensitivity in the future. 
C-peptide-to-insulin ratios in horses undergoing the FSIGTT suggest that hepatic 
insulin extraction decreases following dextrose challenge.  Furthermore, the basal C-
peptide-to-insulin ratio appeared to be lower in a horse with IR, when compared with 
horses with normal insulin sensitivity, and this ratio further decreased following dextrose 
administration during the FSIGTT.  This lower C-peptide-to-insulin ratio may indicate 
that elevated resting insulin concentrations and higher AIRg values registered in horses 
with IR are a result of reduced hepatic insulin extraction.  Further studies are required to 
compare C-peptide-to-insulin ratios in horses with IR to healthy control animals.  
Comparing insulin and C-peptide concentrations in blood collected from the portal and 
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jugular vein in normal and insulin resistant horses would also allow hepatic insulin 
clearance to be quantified.  Development and validation of an equine specific C-peptide 
radioimmunoassay kit would provide more accurate measurement of C-peptide 
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